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Abstract 
The placebo effect has become recognized as an excellent example of mind-body 
interaction and as a mechanism of therapeutic action in its own right.  Theoretical and 
empirical work has shown that one‟s expectations of treatment are important mediators of 
the placebo effect, as well as treatment outcomes in diverse areas of health care.  Modern 
theorists agree that situational and individual factors both contribute to the formation of 
positive treatment expectancies; however, only the former has received adequate study.  
The current research was designed to investigate the individual psychosocial variables 
that are associated with positive treatment expectations, using irritable bowel syndrome 
(IBS) as an illness model.  People with IBS (n = 289) were recruited online to complete a 
survey study.  Participants read hypothetical vignettes about state-of-the-art treatments 
for IBS and were asked to rate their expectations to benefit from treatment on a 
continuous scale.  They then completed a series of questionnaires measuring various 
individual difference factors, health belief variables and context-specific psychosocial 
variables, all identified from the literature as potentially relevant correlates of levels of 
expectation.  Correlation and regression analyses revealed that several of these variables 
were associated with participants‟ ratings of expected treatment benefits, in particular, 
perceived somatic focus of treatment and beliefs of personal control over symptoms, as 
well as higher levels of optimism and self-focused attention.  Weaker relationships were 
identified for acute health status, coping self-efficacy, catastrophizing and patient-
provider relationship; whereas no relationships were found for trait anxiety, motivational 
factors and other health belief variables.  Among those with past experience with similar 
treatments, previous treatment satisfaction was a strong predictor of current expectations.  
 v 
Supplemental analyses revealed that among a sub-sample having previous treatment 
experience, along with higher levels of self-focused attention, significant relationships 
between treatment expectancies and independent psychosocial variables were more 
numerous and more robust.  Results are discussed in light of contributions to theory, 
directions for future research as well as potential clinical applications.    
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 Chapter 1 
INTRODUCTION 
I. Overview 
The ultimate goal of this project is to increase the effectiveness of medical 
interventions through identifying the psychosocial factors that contribute to an 
individual‟s ability to benefit from treatment.  There has been an increasing interest in the 
role of psychosocial factors in medicine and health due to the rise of a holistic, non-
dualistic approach to conceptualizing the human organism, its illness and its healing.  
There is one well-known phenomenon in medicine that for years has highlighted the 
importance of psychological factors in healing, namely, the placebo effect.  Simply, the 
placebo effect refers to the situation where an individual shows an improvement in their 
symptoms as a result of receiving a secretly inert intervention that the individual believes 
to be therapeutic.  Many consider the placebo effect as a scientifically validated 
phenomenon of „belief becoming biology‟ (Cousins, 1989), and have come to agree that 
the belief system of the patient is critically important (Moerman & Jonas, 2000; Ray, 
2004).  Placebo effects are considered some of the best examples of mind-body 
interaction (Ray, 2004; Mayer, 2003), and are now recognized as contributing to 
treatment outcome in any therapeutic situation (Benedetti, 2007).  Exploring the placebo 
effect is thus a useful model within which to begin to explore the contribution of 
psychosocial factors to a patient‟s ability to benefit from treatment (Colloca & Benedetti, 
2005; Moerman & Harrington, 2005).  In this chapter it will be shown that a patient‟s 
positive expectancy of treatment outcome is one of the key mediators of the placebo 
 2 
effect.  On this basis, this project will seek to examine the individual psychosocial factors 
that are associated with the magnitude of these integral 'positive outcome expectancies.‟  
II. Introduction to the Placebo Effect 
Throughout the history of medicine, the first psychosocial factor recognized to 
contribute to health outcomes was the individual‟s beliefs about the effectiveness of a 
treatment intervention or provider.  Galen, one of the forefathers of modern medicine, 
said,  “He cures most successfully in whom the people have the most confidence.”  
Medical scholars agree that most early medicine was predicated on the power of 
individuals‟ belief in treatment, which came to be known as the placebo effect (Shapiro 
& Shapiro, 1997). 
Before the rise of the biopsychosocial model (Engel, 1977) and the birth of the 
field of health psychology, the field of medicine had already identified the importance of 
the elusive placebo effect in contributing to health outcomes.  Although the term placebo 
comes from the Latin phrase „I shall please,‟ the word placebo has had medical 
connotations for the last 200 years.  An archetypal placebo is a sugar pill given to a 
patient with instructions that it is an active substance.  Any resulting improvement in the 
patient‟s condition is termed the „placebo effect.‟  In practice, a placebo can take almost 
any form.  Some have suggested that placebos are likely the oldest treatment, as with 
very few exceptions, we know that ancient treatments had no intrinsic healing power 
(Shapiro, 1960).  When successful, what these treatments had in common was that the 
person receiving them, and usually the healer himself, believed they might do some good 
(Thompson, 2005).   
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Early dictionaries (1785) defined a placebo as „a commonplace method of 
medicine,‟ and for many years from the early 1800s to the late 1900s, the word placebo 
was defined as an inert substance used to „placate‟ a patient‟s need for treatment.  With 
the rise of the medical model after World War II, the placebo effect came to be 
considered a nuisance variable that had to be controlled for in order to ascertain the 
genuine effects of supposedly active therapeutic interventions.  The „placebo controlled 
clinical trial‟ became the gold standard for testing the efficacy of new interventions 
(Kaptchuk, 2001), and the definition of the placebo expanded to include „a control 
treatment in a clinical trial.‟   
As recently as 1999, placebo was defined as an „ineffective substance that may 
relieve a condition because a patient has faith in its powers‟ (Oxford Concise Medical 
Dictionary).  This definition highlights that the patient‟s beliefs play an important role in 
the generation of the placebo effect.  Current definitions of placebo by scholars in the 
field of placebo research remain mum on the mechanisms of the effect (Stewart-Williams 
& Podd, 2004).  These current definitions state: 
A placebo is a substance or procedure that has no inherent power to produce an 
effect that is sought or expected. 
A placebo effect is a genuine psychological or physiological effect, in a human or 
another animal, which is attributable to receiving a substance or undergoing a 
procedure, but is not due to the inherent powers of that substance or procedure.  
Earnest research into the placebo effect itself has increased over the last half-
century.   Although much of the placebo research has been conducted in the area of pain 
and analgesia (see Colloca & Benedetti, 2005; Hoffman, Harrington & Fields, 2005 for 
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reviews), it has been demonstrated that the placebo effect is a genuine phenomenon that 
has been reported for a variety of health problems, across objective and subjective 
parameters (Stewart-Williams & Podd, 2004).  Placebos have demonstrated effectiveness 
in the treatment of physical symptoms in a variety of medical conditions.  Among the 
functional disorders and conditions, placebos have produced significant treatment effects 
in sexual dysfunction (Cranston-Cuebas, Barlow, Mitchell, & Athanasiou, 1993), 
insomnia (Bootzin & Herman, 1976; Kellog & Baron, 1975; Storms & Nisbett, 1970), 
hunger states (Heatherton, Polivy, & Herman, 1989), environmental disease (Grandjean, 
Guldager, Laresen, Jorgensen, & Holmstrup, 1997), asthma (Joyce, Jackevicius, 
Chapman, McIvor & Kesten, 2000), premenstrual syndrome (Freeman & Rickels, 1999), 
irritable bowel syndrome (Patel et al., 2005), chronic fatigue syndrome (Cho, Hotopf, & 
Wessely, 2005) and nausea (Levine, Stern, & Koch, 2006).  There are also substantial 
placebo effects reported in the psychiatric literature (see Khan, et al., 2005; Kirsch, 
Moore, Scoboria & Nicholls, 2002, as examples).  Furthermore, placebo treatment of 
medical conditions such as ulcerative colitis (Ilnyckyj, Shanahan, Anton, Cheang, & N., 
1997), hypertension (Hunyor et al., 1997), post-operative swelling (Ho, Hashish, Salmon, 
Freeman, & Harvey, 1998), post-operative pain (Levine, Gordon, & Fields, 1978, 1979), 
Parkinson's disease (de la Fuente-Fernandez, 2004; Shetty, Friedman, Kieburtz, Marshall, 
& Oakes, 1999), infertility (Dunphy, Kay, Robinson, & Cooke, 1990; Garcia et al., 
1985), duodenal ulcer (de Craen et al., 1999), functional dyspepsia (Mearin, Balboa, 
Zarate, Cucala, & Malagelada, 1999), inflammatory bowel disease (Hershfield, 1997), 
headaches (Roberts, 1994), migraines (Jhee et al., 1997), and warts (Spanos, Sternstrom, 
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& Johnston, 1988), has resulted in significant physiological changes and/or amelioration 
of symptomology. 
Despite these findings, there has still been considerable debate regarding the 
veracity of the placebo effect in conditions other than pain (see Hrobjartsson & Gøtzsche, 
2001; Wampold, Minami, Tiernery, Baskin, & Bhati, 2005, Wickramasekera, 2001). 
Genuine placebo effects have been differentiated from other non-specific effects of 
treatment, such as regression to the mean and the natural course of an illness, which are 
controlled for in placebo research through the use of a no-treatment control group (Fields 
& Levine, 1984; Kirsch, 1997; Stewart-Williams, 2004).  Experimental research has also 
been instrumental in ruling out artifactual alternatives to genuine placebo responses, such 
as sampling biases, reporting biases or demand characteristics (Wager & Nitschke, 2005).  
Currently, most researchers agree that placebo effects are partially responsible for 
treatment outcomes in almost every area of medicine (Benedetti, 2007; Di Blasi et al., 
2001; Thompson, 2005).  Thus, understanding the mechanisms of the placebo 
phenomenon has become a crucial scientific endeavor (Crow, Gage, Hampson, Hart, 
Kimber & Thomas, 1999; Haour, 2005; Sarinopoulos et al., 2006).  From the perspective 
of the medical model, the placebo effect was seen as a nuisance variable that can 
confound clinical trials.  From the more modern biopsychosocial model of health, which 
acknowledges that biological, social and psychological factors will each contribute to 
health and illness, the placebo effect is viewed as something that might be harnessed to 
maximize current levels of clinical efficacy (Chaput de Saintonge & Herxmeimer, 1994; 
Hauprich, 1996; Thompson, 2005). 
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Early efforts to understand the placebo effect sought to identify individual traits 
that may make someone more likely to „succumb‟ to placebo effects, so that these people 
could be identified and excluded from controlled clinical trials.  Today, the identification 
of individuals who respond to placebos seems appealing as it may allow for safer and 
more economical health care delivery for those who can benefit from inert treatments.  
Unfortunately these early attempts (Beecher, 1955) and those since (e.g., Lasagna, 
Mostellar, von Felsinger & Beecher, 1954; Moertel, Taylor, Roth & Tyce, 1976; Shapiro 
& Shapiro, 1997) failed to identify people who consistently respond to placebos.  
Alternatively, researchers turned to the more fruitful pursuit of studying the situational 
factors that may be involved in the placebo effect.  These lines of research have 
uncovered several interesting situational factors that appear to be related to placebo 
effects (Harrington, 1997).  For example, placebos have been known to mimic active 
agents by producing undesirable side effects.  They also commonly follow dose-response 
curves, wherein two pills are more effective than one, larger capsules produce stronger 
effects than smaller ones, and injections produce greater effects than placebo capsules or 
pills (see reviews in Stewart-Williams, 2004 or Kirsch, 2005).  However, such research 
has not been able to isolate the ideal placebo situation, just as research could not isolate 
individuals who consistently respond to placebos.   
The placebo effect is certainly a complex phenomenon that eludes simplistic 
explanations.  Despite its complexity, researchers are still driven to understand the 
precursors and mechanisms of placebo effects, due to the recognition that placebo effects 
represent a means for therapeutic gain over an above the beneficial effects of an active 
intervention, along with the recognition that every therapeutic situation contains the 
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potential for placebo responding.  This drive has led to some testable models that attempt 
to explain the role of situational and personal factors in an individual‟s response to 
treatment.  It is important to remember that the placebo is by definition „inert,‟ and any 
changes occurring within the patient must be due to the interaction of the patient and his 
environment (Thompson, 2005).  
III. Early Models of the Placebo Effect 
A. Biological Model 
Our earliest understanding of the placebo effect was that a patient‟s and/or service 
provider‟s belief or expectation of outcome was the key element that contributed to 
placebo effects (Kupers & Marchand, 2005; Morris, 1997).  Early formal models of the 
placebo effect, however, focused on biological and conditioning models to explain this 
effect.  In the late 1970s, researchers discovered that at least some forms of placebo 
analgesia were mediated by the brain‟s natural painkillers, i.e., endogenous opioids 
(Levine, Gordon & Fields, 1978).   This proved an exciting development that spurred 
much research into placebo analgesia.   Meta-analyses of placebo effects in controlled 
clinical trials have now found that placebo analgesia is one of the most common and 
potent instances of the placebo effect (Morris, 1997, Hrobjartsson & Gøtzsche, 2001).  
Pain research has consistently found that placebo effects account for an average 35% of 
any reported therapeutic benefit in relation to pain control (Wall, 1993), over and above 
the benefit provided by the active treatment.  Although fascinating, these findings offer 
an incomplete account of the mechanisms of the placebo effect.  For instance, there is no 
strictly biological account of how taking a placebo could activate the endogenous opioid 
system.  Investigators have also discovered that not all placebo analgesia is mediated by 
 8 
endogenous opioid systems (Amanzio & Benedetti, 1999; Gracely et al., 1983). 
Furthermore, as reviewed above, placebo effects have been demonstrated in numerous 
conditions other than pain (Colloca, Lopiano, Benedetti & Lanotte, 2005; Morris, 1997).      
B. Conditioning Model 
An early prominent model of the placebo effect is the classical conditioning 
model, which posits that in standard treatments, the physical characteristics of the 
environment, provider or treatment (conditioned stimulus) become paired with the active 
ingredients of the treatment (e.g., morphine, unconditioned stimulus) to elicit 
physiological effects (e.g., analgesia, unconditioned response).  After „learning‟ that such 
characteristics signal physiological changes in the body, a placebo with the same 
characteristics (conditioned stimulus) could then elicit the same changes in the organism 
(conditioned response) without the presence of the active treatment.  This model was 
inspired primarily by Ader and colleagues who discovered that they could condition 
placebo-induced immunosuppression in rats (Ader & Cohen, 1975).  Support for this 
model of placebo effects has been demonstrated several times in humans (e.g., Goebel et 
al., 2002; Voudouris, Peck & Coleman, 1985, 1989, 1990).  A conditioning model 
cannot, however, account for all reported aspects of the placebo effect in humans.  For 
example, this theory cannot explain placebo effects in patients that have never been 
exposed to the specific active treatment (Haour, 2005), nor why placebo effects are 
resistant to extinction, which is normally seen in classically conditioned learning 
(Montgomery & Kirsch, 1997). 
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C. Response Expectancy Model  
Irving Kirsch‟s (1985) response expectancy model of placebo effects was 
considered a main competitor to the conditioning model of the placebo effect.  Response 
expectancies are anticipations of the occurrence of nonvolitional responses (such as pain, 
analgesia, sadness, joy, intoxication, vomiting, alertness, etc) that arise when, in the case 
of the placebo effect, an individual is presented with an intervention (Kirsch, 1997a).  In 
a general treatment scenario where there is a suggestion that a specific treatment would 
lead to amelioration in one‟s symptoms, response expectancies (or treatment 
expectancies) would refer to one‟s expectation to benefit from that treatment.  The 
concept of response expectancy was introduced as an extension to social learning theory.  
Expectancy was already a central concept in a number of influential theories of learning 
and behaviour.  Bolles (1972) classified expectancies into two categories.  Response-
stimulus expectancies are beliefs about the relation between behaviour and environmental 
consequences.  Stimulus-stimulus expectancies are beliefs that certain stimulus events 
predict other stimulus events.  In Rotter‟s (1954) social learning theory, which builds on 
Tolman's (1932) expectancy model of reinforcement learning, expectancies are 
„perceived probabilities that reinforcement will follow behaviour.‟  Behaviour is thus 
considered a function of the expectancy that behaviour will bring reinforcement, together 
with the perceived value of the reinforcement (an expectancy-value framework).  In 
Bandura‟s (1977) social learning theory, behaviour is also guided by self-efficacy 
expectancies, expectancies regarding one‟s ability to execute behaviour that 
reinforcement is contingent upon.  In each of these theories, expectancies involve the 
occurrence of a voluntary behaviour.  Response expectancy theory, on the other hand, 
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refers to expectancies about non-volitional responses, i.e., responses that occur 
automatically (Kirsch, 1985).  These are the types of expectancies that Kirsch considers 
to mediate the placebo effect.       
Response expectancies are considered unmediated; this means that no additional 
psychological, situational or behavioural factors need be evoked to explain the influence 
of response expectancies on placebo responding.  They are also considered self-
confirming; for example, if you expect morphine to reduce pain, and you believe you are 
taking morphine, then you will experience reduced pain as expected.  Early support for 
the response expectancy model has been demonstrated in various ways.  First, there are 
studies wherein the placebo responses are more strongly related to a substance‟s expected 
effects than to the substance‟s actual effects.  For example, responses to placebo alcohol 
have been found to be more closely related to a culture‟s beliefs about the effects of 
alcohol rather than its actual physiological effects (MacAndrew & Edgerton, 1969). 
Similarly, effects of placebo caffeine often follow individuals‟ beliefs about caffeine‟s 
effects (Kirsch & Weixel, 1988; Fillmore et al., 1994).   
Second, Montgomery and Kirsch (1997) demonstrated that manipulating subjects‟ 
conscious expectancies could actually eliminate the effect of conditioned analgesia.  In 
this important study, Montgomery and Kirsch first employed an established conditioning 
paradigm to elicit a placebo analgesia response (Voudouris et al., 1985, 1990).  In this 
paradigm, subjects are first stimulated on several trials with an electric current to the arm, 
in order to determine what intensity of current is subjectively experienced as moderate 
pain and low pain for each individual, using a pain intensity scale of 0 (no pain) to 10 
(intolerable pain).  During a pre-test phase when no placebo intervention is administered, 
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subjects are stimulated at a level to generate moderate pain.  A placebo „analgesia cream‟ 
is then applied to certain areas of a subject‟s arm.  Then subjects undergo a series of 
manipulation trials where stimulus intensity is surreptitiously lowered during placebo 
trials so that it generates only „low pain,‟ and kept at a higher level during no-placebo 
trials.  In the original studies using this paradigm (Voudouris et al., 1985, 1990), these 
conditioning manipulations resulted in lower pain reports during placebo trials vs. no-
placebo trials in a post-test phase (where the current is kept at the higher level), 
demonstrating that placebo responses can be conditioned.  To test the contribution of 
verbal information to the conditioning of this placebo response, some subjects in 
Montgomery & Kirsch‟s study were randomly assigned to an „informed pairing‟ group, 
where they were explicitly informed that stimulus intensities were being reduced during 
placebo trials in the manipulation phase.  As usual, subjects assigned to the „uninformed 
pairing‟ group showed a placebo response during post-test, indicating that the 
conditioning trials had been successful in eliciting analgesia.  In contrast, those subjects 
in the „informed pairing‟ group did not show greater placebo responses in the post-test 
phase, indicating that the verbal information had eliminated the effect of conditioning.  
Montgomery and Kirsch conclude that subjects in the „informed‟ group no longer 
expected the placebo cream to produce analgesia.      
D. Resolution of the Conditioning – Expectancy Debate 
For several years, the conditioning and response expectancy models were 
considered opposing models of the placebo effect.  However, as evidence accumulated, it 
became clear that these models are not mutually exclusive (see Haour, 2005; Kirsch, 
2005; Stewart-Williams & Podd, 2004, for reviews).  Advances in theories of 
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conditioning have aided this shift in conceptualization.  It has been recognized that at 
least in humans, conditioning involves conscious learning, where the individual comes to 
associate or expect certain consequences (the association of the conditioned stimulus with 
the unconditioned response, Rescorla, 1988).   
There is now almost universal agreement that conditioning involves the 
production of expectancies (Benedetti, et al., 2003; Kirsch, Lynn, Vigorito & Miller, 
2004).  Most contemporary theorists of the placebo effect agree that the majority of 
placebo effects are mediated by response expectancies (i.e., expectations to see specific 
changes as a result of the intervention; Benedetti et al., 2003; Colloca & Benedetti, 2005; 
Kirsch, 2005; Pollo et al., 2001; Vase et al., 2002), although there is evidence that some 
placebo effects are mediated by conditioning alone (Benedetti, Pollo, Lopiano, Lanotte, 
Vighetti & Rainero, 2003; Pacheco-Lopez, Engler, Niemi & Schedlowski, 2006; Enck, 
Benedetti & Schedlowski, 2008).  Although expectancies have been shown to be induced 
via conditioning procedures, as discussed further later they also can be formed via other 
information, such as prior experience, verbal suggestion, observation learning, etc 
(Kirsch, 1990, 1997, 2005). 
The centrality of expectancies in influencing therapeutic outcomes is a central 
assumption of this proposed research.  At this point we have reviewed the ubiquity of 
placebo effects in the treatment situation, as well as the theory that such placebo effects 
are mediated by one‟s expectation to see specific changes as a result of that treatment.   
At this point, it will be pertinent to outline the impressive evidence that supports this 
theory.  First to be presented is the support for response expectancy-mediated outcomes 
arising from the placebo literature.  This will be followed by evidence in non-placebo 
 13 
research that demonstrates the fundamental role of expectations in influencing subjective 
and objective health outcomes. Throughout this review and the description of research to 
follow, the term „treatment expectancies‟ will be used interchangeably with „response 
expectancies,‟ and „treatment expectations.‟  Although an individual could have several 
different types of expectations regarding a therapeutic situation or a treatment, herein 
„treatment expectancies‟ is used to refer to one‟s expectation to see benefit from 
treatment. 
IV. Support for the Role of Expectancies 
A. Placebo Literature Support  
There are several studies from the field of experimental placebo research that 
support, either directly or indirectly, the contribution of expectancies to a placebo 
response.  Indirect support is often demonstrated in studies where explicit expectancies 
are not measured, but are either assumed to be induced via verbal suggestion or are 
assumed to be present due to experimental procedures.  
In an early study of experimental placebo analgesia, Montgomery & Kirsch 
(1996) demonstrated that the application of an inert cream accompanied by a verbal 
suggestion that the cream was a powerful topical analgesic produced a reduction in pain 
(induced via controlled mechanical pain stimuli) at the body site where the placebo was 
administered but not at a control body site.  Although expectations of analgesia were not 
measured, the researchers assumed that verbal suggestion had produced such 
expectations.   
Similarly, in a study examining the role of conditioning and verbal suggestion in 
one clinical condition (motor performance in Parkinson‟s patients) as well as three 
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experimental conditions (placebo analgesia and placebo stimulation of growth hormone 
and cortisol release), it was found that verbal suggestion had no effect on hormonal 
secretions, whereas it did affect pain reports and motor performance.  Verbal suggestions 
were also shown to override conditioning procedures to influence pain and motor 
performance; however hormonal placebo responses were only responsive to conditioning 
(Benedetti, et al., 2003). 
In a study of post-operative pain in patients who underwent thoracic surgery for 
lung cancer, it was found that different verbal instructions about the certainty of receiving 
a painkiller produced different reported analgesic effects, and led to significant 
differences in the intake of opioids for pain (Pollo et al., 2001).   Following surgery, 
every patient received a starting dose of an opioid painkiller, and over the following three 
days all patients received intravenous saline, and were treated with the active painkiller 
upon request.  Patients were randomly assigned to three experimental conditions that 
received different verbal instructions about the saline solution that they were receiving.  
Those in the „double-blind‟ condition were told that they had a 50% chance of receiving a 
placebo or the active painkiller, as in traditional double-blind placebo-controlled trials.   
Subjects in the „deceptive‟ condition were deceptively informed that they were receiving 
the active painkiller (100% certainty of receiving „active‟ treatment), and those in the 
„natural history‟ condition were told that they were simply receiving a rehydrating 
solution.  The number of doses and total dosage of active painkiller requested by each 
group served as the dependent variable.  The double-blind group requested a significant 
20.8% fewer painkillers than did the natural history group, and the deceptive 
administration group requested 33.8% less painkiller.  This indicates that a strong placebo 
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effect occurred and that it was significantly larger in the deceptive group (those who were 
„certain‟ that they were receiving an active painkiller).  It is important to note that there 
was no difference in the pain intensity ratings of the three groups upon request for 
painkiller, further indicating that those who thought that they were receiving a painkiller 
were, in fact, experiencing analgesia.  The authors highlight that the different placebo 
analgesic responses were due to the different verbal instructions, which presumably 
induced different expectations for pain relief.   
Verbally induced variations in the „certainty‟ of receiving an active treatment 
have also been shown to influence the magnitude of placebo responses on a larger scale.  
Vase and colleagues (2002) conducted a meta-analysis comparing the magnitude of 
placebo analgesia effects in controlled clinical trials (where subjects are informed that 
there is a 50% chance of receiving a placebo) versus in placebo analgesia studies (where 
subjects are deceptively told that they are certainly receiving an active analgesia).  This 
study found that placebo effect sizes were modest in clinical trials (d = .15, range = -.95 - 
+ .57), but were significantly more robust in placebo studies (d = .95, range = -.64 - 2.29; 
p < 01).  The authors argue that the main difference between these sets of studies is the 
strength of the suggestion for pain relief, and thus presumably the strength of subject‟s 
expectations for relief. 
Serendipitous support for the powerful role of patients‟ expectations has surfaced 
in placebo-controlled trials of acupuncture for post-surgical and chronic pain (Bausell, 
Lao, Bergman, Lee, & Berman, 2005; Linde et al., 2007, respectively).  In the first study, 
investigators preformed a blinding check to ascertain whether subjects thought that they 
had been assigned to the active acupuncture group or to the sham acupuncture group 
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(Bausell et al., 2005).  Although there were no differences in pain reports amongst those 
receiving active or placebo treatment, those who believed they were in the active 
treatment group reported less pain than those who believed they were receiving the 
placebo treatment.  In the second study, subjects randomly assigned to active or sham 
acupuncture were asked before, and mid-way through several weeks of treatment, 
whether they expected to personally benefit from the treatment.  At treatment completion, 
regardless of group assignment, those who reported high expectations to benefit from 
treatment had greater odds of having responded to the treatment.  The results of these 
studies truly highlight the importance of patients‟ beliefs and expectations about 
treatment (Benedetti, 2005, 2007). 
Support that is more direct is indicated in several studies where expectations of 
treatment outcome are measured directly and found to be positively associated with 
actual treatment outcome.  Montgomery and Kirsch (1997) first demonstrated a direct 
correlation between expected and actual treatment responses in the study that was 
described in part above.  An additional aspect of this study involved the measurement of 
expected pain after conditioning trials and prior to post-test trials using an analogue scale 
identical to the one used to measure pain ratings (i.e., „0‟ = no expected pain to „10‟ = 
intolerable pain expected).  Conditioning trials in the uninformed pairing group altered 
participant‟s placebo response expectancies (calculated by subtracting placebo trial 
expected pain ratings from no-placebo trial expected pain ratings), as well as their post-
test pain reports.  Regression analyses found that expected pain levels accounted for 49% 
of the variance in reported pain levels.  In this study, although conditioning did lead to 
placebo analgesia, it appeared to be mediated by expectancies.   
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Price and colleagues (1999) conducted a similar experiment of conditioned 
placebo analgesia using painful thermal stimulation and a modified within-subjects 
design.  In this study, separate areas of participant‟s arms were treated with different 
„doses‟ of a placebo analgesic, versus a control solution.  During conditioning trials, 
stimulus intensities at a personal level of 2/10 were delivered to the area treated with a 
„strong‟ analgesic.  On the area of the „weak‟ analgesic, subjects received stimulation at 
an intensity of 5/ 10 and at the „control‟ site intensities were set at 6/ 10.  After 
manipulation trials, subjects indicated their expected pain intensity and expected pain 
unpleasantness on a visual analogue scale (VAS).  Placebo effects, manifested both 
within sensory and affective dimensions of pain, were shown by reliable reductions in 
pain ratings after conditioning trials.  Expected levels of pain intensity and 
unpleasantness contributed to a large proportion of the variance in sensory and affective 
pain ratings within the areas treated with placebo cream, providing further evidence that 
the conditioning effect (and the placebo effect) is mediated by expectancy (Price, Milling, 
Kirsch, Duff, Montgomery & Nicholls, 1999).  
Similar robust associations between expected and concurrent pain intensity and 
unpleasantness levels have been demonstrated in other studies of experimental placebo 
analgesia, both in clinical (Vase, Robinson, Verne & Price, 2003) and non-clinical 
populations (de Jong, van Baast, Arntz & Merckelbach, 1996; De Pascalis, Chiaradia & 
Carotenuto, 2002).  Together these studies of experimental placebo analgesia support the 
expectancy model by indicating that a significant amount of variance in actual pain relief 
following placebo treatment can be accounted for by expected pain relief.  The proportion 
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of variance attributed to expectancies has been reported to vary from 25 to 49% (Vase et 
al., 2003).      
B. Health Psychology Literature Support  
 Fascinating studies supporting the role of expectancies in health outcomes have 
been reported by an Italian research group, comprising of Benedetti, Amanzio, Pollo and 
colleagues, who have been studying the contribution of conscious expectations to 
treatment outcomes.  For example, Pollo et al., (2002) reported remarkable results 
regarding the moderating effect of positive expectations on the motor performance of 
Parkinson‟s patients receiving deep brain stimulation via electrodes implanted in 
subthalamic nuclei.  They found that expectations of good motor performance, induced 
by verbal suggestion, actually led to significantly faster hand movements.   
This group of researchers have also been studying the contribution of expectations 
to health outcomes by using an „open vs. hidden administration‟ paradigm.  Here, clinical 
patients all receive the active treatment.  The „open administration‟ subgroup is made 
explicitly aware, through verbal information and observable procedures, that they are 
receiving the active treatment.  The „hidden administration‟ subgroup receives the active 
treatment without their knowledge (e.g., in their intravenous saline).  Using this 
paradigm, these investigators have been able to truly distinguish the effects of an active 
treatment while controlling for the effects of a patient‟s expectations of treatment, and 
have contributed valuable support for the role of expectations in the therapeutic context.   
This paradigm was first used in the 1980s to study placebo analgesia.  In a study 
of postoperative pain following oral surgery, it was found that a hidden injection of 6-8 
mg of morphine was equivalent to an open injection of placebo morphine (saline).  In 
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other words, telling a patient that a painkiller is being administered is as potent as 6 –8 
mg of morphine (Colloca & Benedetti, 2005)!  Benedetti et al., (2003a) reported a study 
of the open vs. hidden administration of treatment in three clinical conditions 
(postoperative pain, postoperative anxiety, and subthalamic stimulation in Parkinson‟s 
patients) and two experimental conditions in healthy subjects (administration of a beta-
blocker and a muscarinic antagonist).  In each of these conditions it was found that the 
open administration was significantly more effective than the hidden administration.  
These results show clearly that a person‟s knowledge about an intervention affects their 
response to the intervention.  
Several other independent studies where expectations have been measured also 
lend support to the central role of expectancies in contributing to various health outcomes 
(Mondloch, Cole & Frank, 2001).  Briefly, it has been reported that positive treatment 
expectancies predict substantial amounts of variance in nurses‟ reports of physical health 
status following heart transplants (Leedham et al., 1995), expectations regarding 
symptoms have been found to predict symptom severity after oral surgery (McCarthy, 
Lyons, Weinman, Talbot & Purnell, 2003), depressed patients with high expectations of 
benefit show a greater response to antidepressant medication (Krell, Leuchter, Morgan, 
Cook, & Abrams, 2004), and positive outcome expectancies predict several outcome 
measures at post-treatment after cognitive-behavioural treatment for chronic fatigue 
syndrome (Goosens, Vlaeyen, Hidding, Kole-Snijders, & Evers, 2005).  Patient 
expectations of the likelihood of experiencing severe nausea during chemotherapy have 
been found to be a strong predictor of actual nausea (Montgomery et al., 1998; Roscoe et 
al., 2004).  Furthermore, negative expectations regarding the course of one‟s illness have 
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been found to predict poor outcome for chronic fatigue symptoms in a controlled clinical 
trial (Chadler, Godfrey, Ridsdale, King, & Wessely, 2003).   
Additional evidence that expectancies play a role in physical symptomotology can 
be found in experiments where symptoms have been reduced by manipulating patient 
expectancies, usually via suggestion.  Such experiments have found that enhancing 
expectations for a positive outcome can increase gastrointestinal motility in patients 
undergoing abdominal surgery (Disbrow, Bennet & Owings, 1993), reduce blood loss 
during elective spinal surgery (Bennett, Benson, & Kuiken, 1986), modulate cellular 
immune dysregulation (Kiecolt-Glaser, Marucha, Atkinson & Glaser, 2001), enhance 
immune reactions to an injection of tuberculin (Smith & McDaniel, 1983), and potentiate 
release of endogenous dopamine (Fuente-Fernandez et al., 2001).   
V. How Expectancies Lead to Placebo Effects 
This review has clearly revealed that across a wide range of different therapeutic 
contexts, one‟s expectations about their symptoms, their illness and the outcome of their 
treatment can have a notable impact on one‟s response to treatment.  Having established 
the association between a person‟s expectations and their response to interventions (see 
also Crow et al., 1999), we are left with the difficult question of how expectancies 
influence therapeutic outcomes.  Despite Kirsch‟s position that response expectancies are 
directly self-confirming, there are several factors that have been proposed to mediate this 
relationship, including behavioural change, cognitive-attentional biases, emotional 
change and neurobiological change.  Although a clear understanding of the mechanisms 
by which expectations influence outcome is not integral to the proposed research, they 
will be summarized here to satisfy the potential curiosity of the reader and strengthen our 
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key assumption that positive treatment expectancies contribute to positive intervention 
outcomes. 
A. Behavioural Change 
Some contend that positive expectations of treatment outcome contribute to better 
outcomes via changes in a patient‟s behaviours, such as improved adherence to treatment, 
greater activity levels or increased seeking of social support (Stewart-Williams, 2004).  
There are at least two studies that have shown that positive expectations are related to 
behaviour change.  It has been demonstrated that positive expectations are related to 
better self-care in chronic disease patients (De Ridder et al., 2004), and that higher pre-
operative expectations predict later adherence to a complex medical regimen (Leedham, 
Meyerowitz, Muirhead, & Frist, 1995).  Although there may be a role for behaviour 
change, this proposed mediator of expectations cannot account for many instances of 
expectation-mediated placebo responding.  For example, it is difficult to argue that 
behavior change is responsible for the significant placebo analgesia effects demonstrated 
using the open versus hidden paradigm for post-operative pain (Colloca & Benedetti, 
2005). 
B. Cognitive- Attentional Biases 
It is suggested that expectations about the effects of a treatment may contribute to 
subjective changes through the creation of cognitive-attentional biases (Caspi & Bootzin, 
2002).  Stewart-Williams (2004) suggests that expectations may induce schematic 
processing changes, wherein there is an increased likelihood that subjects may perceive 
and recall an effect when none has occurred, or when changes are small.  Alternatively, 
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subjects with greater expectations may overlook ambiguous or disconfirming symptoms 
in post-treatment reports.  As discussed by Stewart-Williams (2004), the activation of 
these cognitive schemas (e.g., “I will experience analgesia”) may serve to direct one‟s 
attention inward towards sensations indicative of analgesia.  He notes that there is 
evidence that attending to internal experiences such as sensations and emotions can 
amplify these experiences (Franzoi, 1996).  Some potential support for this theory is 
found in a study where individuals with greater expectations of the benefit of elective 
surgery reported more perceived improvement in their symptoms, but not fewer 
symptoms or better health post-surgically than individuals with lower expectations 
(Flood, et al., 1993).  These investigators suggest that perhaps those with greater 
expectations place more importance on any mild symptom improvements that they 
experience. 
Further support for the idea that expectations may influence outcomes via 
cognitive-attentional biases comes from cases where a reverse placebo effect is found.  
An example of a reverse placebo effect is when subjects are given a placebo together 
with the suggestion that is a relaxant, yet some subjects report increased arousal relative 
to baseline (Duncan & Laird, 1980).  It has been suggested that individuals who have a 
tendency to attend to internal stimuli, as opposed to external stimuli (e.g., verbal 
suggestion), may selectively attend to and notice sensations associated with arousal as 
opposed to relaxation, which then produces a reverse placebo effect (Sirois, 2001, 2009).  
It could be argued that selectively attending to and reporting disconfirming symptoms 
may interact reciprocally with the contingent activation and confirmation of expectations 
for arousal.  Overall, at this time there is neither strong support nor refutation for the 
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account that cognitive-attentional biases mediate the expectancy-outcome relationship.  
However, as discussed later, such attentional biases likely modulate the strength of 
situationally induced expectations (Sirois, 2001, 2009).    
C. Emotional Change  
It has been suggested that positive expectations may induce emotional changes, 
which then contribute to better health.  For example, there is a strong health psychology 
literature that shows that lower levels of anxiety, depression or demoralization contribute 
to better psychological and physical health, via reduced stress hormone levels, improved 
sleep, greater activity, etc. (Stewart-Williams, 2004).  There is certainly some evidence 
that suggests that expectations may influence subjective health via changes in affective 
states.  For instance, one study found that positive outcome expectancies (measured on a 
general optimism scale) were related to decreased symptom reports in patients with 
diabetes, and that this relationship was mediated by decreased negative affectivity 
(DeRidder, Fournier, & Bensing, 2004).  Another study found that both reduced 
expectation of pain and reduced fear of pain contributed to placebo analgesia (de Jong, 
van Baast, Arntz, & Merckelbach, 1996), yet here a mediation model was not tested.  At 
this time, there have been no empirical studies directly testing the role of emotional 
change in mediating the relationship between expectations and outcome.  There is reason 
to believe that this model of mediation is insufficient.  Specifically, placebo analgesia 
research demonstrating the link between expectation and analgesia (Montgomery & 
Kirsch, 1996; Price et al., 1999) has also shown that placebo effects can be found in 
specific body zones but not others simultaneously, suggesting that these effects are not 
mediated by global mechanisms such as anxiety reduction.  
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D. Neurobiological Change 
In Kirsch‟s (1985) response expectancy model of placebo effects, he posits that 
expectancies lead to placebo effects directly, (i.e., they are not mediated by other 
psychological or behavioural factors).  This model implies that expectations induce 
neurophysiological events that manifest as placebo effects.  This indeed is the „black box‟ 
of this field of study, yet a lot of headway has been made in the last few years.  Research 
has shown that placebos can produce changes in the brain similar to those of the drugs 
they are „mimicking‟ (Lieberman et al., 2004), and brain imaging studies have shown that 
placebo effects are associated with specific and localized changes in brain functioning 
(Haour, 2005).  For example, placebo dopamine administration is associated with the 
release of endogenous dopamine and binding to the corresponding receptors (De la 
Fuente-Fernandez, et al., 2001; De la Fuente-Fernandez & Stoessl, 2002).  A similar 
effect has been shown for caffeine; placebo caffeine seems to stimulate the same 
neurochemical actions as does the ingestion of real caffeine (Kaasinen, Aalto, Nagren & 
Rinne, 2004).  
Considerable progress has been made in our understanding of the neurobiological 
mechanisms of the placebo effect, and most of our knowledge originates from the field of 
pain and analgesia (see Colloca & Benedetti, 2005 for a review).  Petrovic and colleagues 
(2002) demonstrated that placebo and opioid analgesia share a neuronal network.  It has 
also been shown that placebo analgesia operates through both opioid and non-opioid 
mechanisms (Gracely et al., 1983; Amanzio & Benedetti, 1999) and researchers have 
begun to discuss the distinction between bottom-up pain pathways and top-down 
„expectation‟ pathways of drug analgesia (Colloca & Benedetti, 2005).  Functional neural 
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imaging studies (fMRI) have found that placebo analgesia is related to decreased activity 
in pain-sensitive brain regions (Kong et al., 2006; Wager et al., 2004), and it has been 
shown that expectations of analgesia correlate with opioid release in some of these areas 
(Zubieta, Yau, Scott, & Stohler, 2005).   At this time there have been at least two theories 
proposed to understand the neural circuitry of expectation-induced analgesia (see Enck, 
Benedetti & Schedlowski, 2008; Lieberman et al., 2004; Ploghaus, Becerra, Borras, & 
Borsook, 2003).   
Research has also begun to uncover the neurophysiological correlates of the 
placebo or expectation response in conditions other than pain, such as Parkinson‟s, 
depression, immunological and hormonal responses and cardiovascular responses (for 
reviews see Colloca, Lopiano, Benedetti & Lanotte, 2005; Pacheco-Lopez, Engler, Niemi 
& Schedlowski, 2006).  For example, endogenous neurotransmitters released within the 
cortex and brain stem in response to expected pharmacologic effects have been shown to 
modulate immunologic and end organ function through distinct efferent neural pathways.  
Three of these pathways that have been extensively studied are the neocortical-
sympathetic-immune axis, the brain stem-vagus-cholinergic pathway, and the 
hypothalamus-pituitary-adrenal immune axis, which modulate effects through the release 
of norephinephrine, acetylcholine, and adrenocorticotropic hormone, respectively 
(Pacheco-Lopez et al., 2006).  Additionally, brain-imaging studies have discovered some 
of the neural correlates of placebo-induced reductions in taste aversion (Nitschke et al., 
2006; Sarinopoulos, Dixon, Short, Davidson & Nitschke, 2006), and visually induced 
anxiety (Petrovic et al., 2005).  Advances in understanding the neural circuitry involved 
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in expectation-induced autonomic responses are thought to be relevant towards the 
understanding of how expectations affect the immune system (Lanotte et al., 2005).   
E. Summary 
There have been several accounts about how response expectancies may come to 
generate objective and subjective changes in people.   A fair amount of recent research 
has focused on the neurobiological changes that accompany placebo administration.  
Despite this recent focus, it is conceivable that in the near future we will see the 
integration of cognitive-attentional, affective and neurobiological factors into a dynamic 
and reciprocal model of how response expectancies induce therapeutic changes.  
VI. Inducing Expectancies 
As discussed above, modern models of placebo effects recognize that response 
expectancies are central (Stewart-William, 2004), and it has come to be accepted that 
expectations can play a role in influencing outcome in any treatment scenario.  The 
„expectation effect‟ account does not rule out the influence of the therapeutic 
relationship, the provider‟s expectations, or sociocultural factors; instead it is thought that 
the effects of such factors come through their influence on the recipient‟s expectancies 
(Stewart-Williams & Podd, 2004).  Those who write about the expectation account of 
placebo responding agree that people may acquire expectancies in various ways, for 
example through conditioning, observational learning, direct personal experience, or 
verbal suggestion (Kirsch et al., 2004; Stewart-Williams, 2004; Vase, Robinson, Verne & 
Price, 2003).  Other than this general agreement, there has not been much discussion or 
investigation regarding the genesis or the correlates of these important response 
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expectancies.  As outlined above, the focus of work in this area has been on testing the 
role and influence of response expectancies, as well as their mechanisms of action.  This 
line of research is crucial and intellectually interesting, and support for the role of 
expectancies and research into their mechanisms of action are certainly accumulating.  
However, it is felt that at this point, it can also be clinically relevant to examine the 
psychosocial factors that contribute to the magnitude of expectancies (Janzen, Silvius, 
Jacobs, Slaughter, Dalzial, & Drummond, 2006).  Since we know that expectations 
regarding treatment contribute to significant amounts of variance in treatment outcome, 
from a clinical point of view it is important that we now begin to understand what factors 
contribute to these expectations.  This remains an area of study that has not yet been 
sufficiently explored, and is the focus of the current research.  In order to proceed, we 
will first explore theoretical accounts of expectancy formation. 
A. Theories of Expectancy Formation 
 On a basic level, expectancies are defined as beliefs about a future state of affairs.  
They are subjective probabilities linking the future with an outcome at some level of 
probability ranging from merely possible to virtually certain (Olson, Roese & Zanna, 
1996).  It is thought that expectancies have evolutionary significance, as one of the 
fundamental purposes of the brain is to anticipate the future (Dennett, 1991).  The 
capacity for memory has survival value in that it allows for the learning of contingencies 
between two stimuli/responses; contingencies that can be used to anticipate the future 
relationships between these stimuli and responses so that the organism can minimize 
punishment and maximize reward.  Thus, it follows that evolution must have favoured 
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organisms that managed to construct predictions about future contingencies (i.e., 
expectancies). 
As noted above, expectancies are considered one type of belief, namely, beliefs 
about the future.  Not all beliefs are expectancies, but all beliefs imply expectancies (i.e., 
it is possible to derive an expectancy from any belief).  For example, „Fire is hot‟ is a 
belief, „If I touch fire I will be burned‟ is an expectancy derived from the belief.  „Fire is 
hot‟ is not an expectancy itself, but a belief about the world.  As expectancies are beliefs 
about the future, the question of how expectancies form is really a question of how 
beliefs are formed (Olson et al., 1996).   
Beliefs themselves can be classified in an innumerable number of ways (e.g., 
beliefs about cats, beliefs about what people do in the spring, etc).  As such, it is 
sometimes considered more productive to classify the sources from which beliefs are 
developed (Olson et al., 1996).  Olson et al. outline that beliefs come from three major 
sources; namely, a) direct personal experience, b) indirect experience (vicarious learning, 
communication from others), and c) other beliefs.  Moreover, „other beliefs‟ are 
acknowledged to have formed from either direct experience or third-party 
communications, and often can be conveniently categorized as beliefs about the self, 
beliefs about others and beliefs about the world.  Note the similarity here between the 
sources of belief development and the sources of response expectancy development 
mentioned above.  Specifically, in both cases it is agreed that beliefs (and thus 
expectancies) can be induced via direct or indirect experience with the world.  Although 
Kirsch (1985) comments briefly that attributional processes may also be a source of 
response expectancies, he doesn‟t elaborate about how „other beliefs‟ may be an 
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important source for expectancy development.   Luckily, general expectancy theory does 
elaborate how other beliefs may also be a source of specific beliefs (and thus 
expectancies).  For example, causal attributions may be a source of beliefs: if something 
is attributed to stable causes, similar outcomes will be expected in the future.  
Furthermore, logical inferences are made to derive situation-specific beliefs from other 
existing beliefs (e.g., nice doctors are effective doctors, thus the treatment received from 
this nice doctor will be effective).  
Expectancies are thought to vary on certain dimensions, most notably in level of 
certainty, or strength/ magnitude.  The source of the belief/ expectancy development is 
thought to be one of the determinants of the level of certainty of a particular expectancy.  
For instance, if the expectancy was formed based on direct personal experience, it is 
thought to be held with more certainty than if developed from indirect experience (Fazio 
& Zanna, 1981; Stewart-Williams, 2004).  What is harder to predict is the relative level 
of certainty for expectancies derived from beliefs that are derived from other beliefs 
(Olson et al., 1996).  Furthermore, in the general expectancy literature, there seems to be 
little theoretical or empirical work focused on how various relevant pieces of information 
are integrated to determine the level of certainty of a specific expectation.  Since the 
strength of treatment outcome expectancy has been found to correlate substantially with 
subjective and objective outcome parameters, it may be clinically relevant to begin to 
develop an integration model.       
Fortunately, there has been some initial work in this direction among placebo 
researchers and theorists.  For instance, most researchers agree that both situational and 
individual factors interact to contribute to the magnitude of a placebo effect (Enck & 
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Klosterhalfen, 2005; Geers, Helfer, Kosbab, Weiland & Landry, 2005; Montgomery, 
David, DiLorenzo & Erblich, 2003; Patel et al., 2005), and most agree that the placebo 
effect is mediated by expectancies.  As such, there has been some effort to discuss how 
different sources of information are used in the determination of response expectancy and 
placebo effects.  The Belief-Activation Model, proposed by Sirois (2001, 2009), is a 
useful contribution to this discussion.   
B. Belief-Activation Model 
The Belief-Activation Model (BAM) is the first model of placebo responding to 
really integrate the contribution of situational and individual factors to the strength and 
direction of treatment expectancies.  This model highlights the interaction of contextual 
and individual differences in the formation of positive or negative placebo effects.  
Contextual differences are considered „placebo-salient cues,‟ which include differences in 
the physical, informational, and interactive aspects of the intervention context, including 
verbal suggestions.  Such placebo-salient cues are thought to activate expectations about 
the specific treatment and its context.  Presumably, certain aspects of the environment 
will activate „other beliefs‟ about what to expect in „this type‟ of environment, beliefs 
that were formed previously based on direct or indirect experiences.  Sirois‟ Belief-
Activation Model acknowledges that expectancies can also be reflections of more 
inclusive beliefs about healing outcomes; beliefs that are influenced both by personal 
experiences and culturally specific beliefs.  This model is unique in that it highlights the 
importance of individual difference variables in the generation of a placebo response.  In 
particular, it is posited that certain individual difference variables can either enhance or 
attenuate the strength of the treatment expectancies that are activated by placebo-salient 
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cues.  This model is useful in that it can explain why there is variability in treatment 
expectancies and placebo responses across individuals even when contextual factors 
remain constant.  It acknowledges that each individual will come to the treatment setting 
with a unique set of beliefs about illness and healing (e.g., „I have a weak immune 
system‟), as well as unique psychological characteristics (e.g., low levels of self-focused 
attention) that can modulate the personal salience of situational cues.     
VII. Purpose of Current Research 
The current research was inspired by the placebo literature, which has highlighted 
the importance of treatment expectancies in the generation of treatment outcomes, both in 
experimental and clinical contexts.  Given that such treatment expectancies have been 
shown to play a central role in the placebo effect, as well as in the outcome of active 
treatments, it is thought that anything that helps activate and maintain these positive 
expectations may facilitate overall improved treatment outcomes across a variety of 
settings and conditions.  Understanding the development of such expectancies is thus an 
important endeavor, one that has not received much empirical attention (Olson et al., 
1996; Janzen et al., 2006).  As noted earlier, the contextual factors that contribute to the 
strength of positive treatment expectancies have been well studied in the placebo 
literature (Harrington, 1997).  However, much less empirical work has examined the 
contribution of personal factors.  Theoretically, there has been some effort to identify 
those person-specific factors that will contribute to the formation of treatment 
expectancies.  Kirsch‟s Response Expectancy Model of the placebo proposes that both 
verbal suggestion and prior learning (via conditioning, observation or direct experience) 
will influence the magnitude of one‟s expectations of outcome.  Second, the general 
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expectancy literature adds that expectancies are derived from beliefs, and that beliefs are 
formed based on information garnered through direct experience, third-party 
communication, or derived from other beliefs.  The Belief-Activation Model of the 
placebo acknowledges the influence of contextual factors but also highlights a role for 
both individual difference factors and health beliefs in the generation of a placebo 
response.  The goal of this project was to combine these models of placebo responding 
and expectancy formation, to hold the contextual variables constant, and to really focus 
on identifying the psychosocial variables that contribute to treatment expectancies.  It is 
important to note that this research was not designed to test these models, but to 
synthesize and extend them by identifying and testing the types of health beliefs, the 
range of individual difference factors and the specific context-dependent psychosocial 
variables that contribute to one‟s level of expectation to benefit from treatment. 
In order to identify potential psychosocial variables that may influence the 
magnitude of expectancies, several literatures are reviewed herein.  First, the placebo and 
health psychology literatures are reviewed to identify individual difference factors that 
have been found to contribute either to treatment expectancies, placebo responses or to 
health outcomes.  This will be followed by a similar review identifying important health 
belief factors.  Following this, a review will be made of the psychosocial correlates of 
symptom report in people with irritable bowel syndrome (IBS), the clinical population 
that has been chosen to be a model for this investigation.   
VIII. Identifying Individual Difference Variables 
In the placebo literature, there have been many individual factors suggested to 
contribute to placebo effects in general and outcome expectancies in particular.  One‟s 
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level of faith, optimism, trust, anxiety, and suggestibility are all concepts associated with 
placebo reactivity (Chaput de Saintonge & Herxheimer, 1994; Vase et al., 2003).  
However, few of these variables have been tested or verified empirically.  Sirois (2001, 
2009) reviewed several individual difference factors that have been suggested, over the 
years, to influence placebo responding.  It was found that factors such as demographics, 
hypnotizability, religiosity and acquiescence have not been reliably associated with 
placebo responsiveness.   
A. Self-Focused Attention 
One individual difference factor found to influence placebo responding is self-
focused attention, conceptualized as a predisposition to focus on and be aware of internal 
states and sensations.  Sirois (2001, 2009) reviewed the empirical support for the 
influence of self-focused attention on placebo effects and incorporated this factor into the 
Belief-Activation Model.  Briefly, it has been found that individuals with higher levels of 
self-focused attention (either naturally or via induction) are less responsive to placebo 
suggestions (Gibbons & Gaeddert, 1984) and sometimes display a reverse placebo 
response (Duncan & Laird, 1980; Gibbons, Carver, Scheier, & Hormuth, 1979).  The 
Belief-Activation Model provides an explanatory framework for understanding how self-
focused attention alters placebo responsiveness.  Sirois notes that attention is a limited 
resource; the more focus directed toward internal stimuli, the less attention is paid to 
external information (Carver & Scheier, 1981).  Thus, although placebo-salient cues (e.g., 
verbal suggestion) may induce expectations for certain physiological responses, focus on 
internal cues may detract from, or contradict, these externally activated expectations.  In 
order to resolve this belief conflict, it is posited that the individual combines these beliefs 
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into a more inclusive expectancy, for example, that „Although the treatment is normally 
effective, I will not necessarily benefit from this treatment.‟   
In contrast to the findings presented above, recent research suggests that greater 
self-focused attention can also increase placebo responding.  In particular, Geers and 
colleagues (Geers, Helfer, Weiland, & Kosbab, 2006) describe a study wherein self-
focused attention was manipulated by having half the participants tally their negative 
internal sensations after ingesting a (placebo) drug “known” to produce negative 
sensations as a side effect.  Participants were also randomly assigned to conditions 
differing in their level of placebo suggestion.  The „unconditional expectation‟ group was 
told that they were receiving the active drug; whereas the „conditional expectation‟ group 
was told that there was a 50:50 chance of receiving the „active‟ drug or a placebo, and a 
control group was given no placebo suggestion.  Placebo responding (increased negative 
sensation reporting) was only observed among those in the unconditional expectation 
group who received the manipulation designed to increase self-focus.  These results 
suggest that increased self-focused attention led to increased placebo responding because 
participants with stronger expectations directed more of their attention to internal 
sensations that confirmed these expectations.  Findings such as these are consistent with 
the Belief-Activation Model, which posits that an individual‟s predisposition to be 
internally focused represents one individual difference factor that moderates the 
magnitude of one‟s expectations of treatment outcome.  An adaptation to the model that 
is suggested by these findings is that self-focused attention seems to be able to either 
increase or decrease placebo responding according to whether internal cues either 
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confirm or contradict one‟s initial expectations induced via external cues (verbal placebo 
suggestions).  
An important point to mention is that the Belief-Activation Model proposes that 
the level of self-focused attention may alter the strength of the expectation activated by 
external information, at a point in time after a placebo has been administered.  For 
instance, after receiving an intervention accompanied by information that it will result in 
relaxation, a highly self-focused individual would be particularly attentive to internal 
sensations.  This intense internally focused attention may bring to awareness sensations 
that either contradict or confirm the initial expectation for relaxation, thus altering the 
strength of the expectation that the intervention will lead to relaxation.  What remains 
unclear is which factors influence a person‟s tendency to attend to internal stimuli that 
confirm vs. contradict the initial expectations.  The results of the Geers et al., (2006) 
study suggest that the strength of the initial expectations may be a factor that influences 
the attention to confirmatory or contradictory internal stimuli.  This suggestion is based 
on their findings that increased self-focused attention was only related to increased 
placebo responding among those participants who were „certain‟ that they were receiving 
an active drug with negative side effects, whereas there was no effect of increased self-
focused attention among those told that they had a 50% chance of receiving the active 
drug.   
There is evidence from the self-focused attention literature that suggests that this 
individual difference variable can indeed influence expectancies.  In particular, it has 
been found that self-focus increases access to self-knowledge.  According to expectancy 
theorists, accessibility is one of the determinants of the strength of a belief and its 
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corresponding expectancy (Olson et al., 1996).  Furthermore, research has shown that 
increased self-focus (both trait and state) leads to perseverance of beliefs about self 
(Davies, 1982, 1993, 1994).  With this in mind, it seems reasonable to suggest that 
personal health beliefs may be stronger predictors of treatment outcome beliefs (and 
expectancies) among individuals with higher levels of self-focus relative to individuals 
with lower levels of self-focus.   
B. Anxiety 
 In relation to health and treatment outcomes, the health psychology literature is 
replete with studies indicating that anxiety is negatively related to general health and 
recovery from illness (Rozanski, Blumenhal & Kaplan, 1999; Salaffi, Cavalieri, Nolli & 
Ferraccioli, 1991; see also Taylor, Kemeny, Reed, Bower & Grunewald, 2000).  For 
example, anxiety has been found to exacerbate pain (Staats, Hekmat, & Staats, 1998), and 
to impair the immune system (Lundh, 2000).  Anxiety has also been shown to influence 
placebo responsiveness.  Studies have found that mild to moderate levels of pre-treatment 
state anxiety are predictive of an enhanced placebo response (Coryell & Noyes, 1988; 
Rickels, Baumm, Raab, Taylor & Moore, 1965; Rickels & Downing, 1967; Shipman et 
al., 1974; Zuckerman, 1974).  On the other hand, high levels of trait anxiety have been 
found to reduce or eliminate the placebo response (Coryell & Noyes, 1988; Pollack et al., 
1994; Uhlenhuth et al., 1998; Zuckerman, 1974), or contribute to a reverse placebo 
response (Loebel, Hyde & Dunner, 1986; Rickels & Downing, 1967; Uhlenhuth et al., 
1998).   Sirois (2001, 2009) has incorporated this individual difference variable into the 
Belief-Activation Model, specifying that levels of anxiety also act to moderate the 
strength of one‟s contextually-cued treatment expectancies.  The role of anxiety is 
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explained in part by incorporating the well-established relationship between anxiety and 
self-focused attention.   For example, it has been demonstrated that the state of anxiety is 
accompanied by attentional biases; individuals high in anxiety tend to selectively attend 
to threatening stimuli (Owens, Asmundson, Hadjistavropoulos & Owens, 2004; Mathers, 
May & Eysenck, 1990).  Furthermore, it is noted that anxiety is thought to act in concert 
with self-focused attention, with the two being mutually enhancing.  For example, 
Gibbons (1991) has suggested that self-focused attention is a necessary and integral part 
of the experience of anxiety, and self-attention promotes anxiety by enhancing awareness 
of this emotional state.  Empirically, it has been demonstrated that anxiety and self-
focused attention do co-occur (Mor & Winquist, 2002) and contribute to increased 
negative symptom reporting in medical and student populations (Ahles, Cassens, & 
Stalling, 1987; Martin, Ahles & Jeffery, 1991). The Belief-Activation Model proposes 
that the attentional deficits and biases involved with high levels of anxiety diminish an 
individual‟s ability to attend to placebo-salient cues, and thus diminish the establishment 
and/or maintenance of positive treatment expectancies.   
 Although there seems to be a reliable association between anxiety and health, and 
anxiety and placebo outcome (Sirois, 2001, 2009), at this time there are mixed results 
regarding the association of anxiety to outcome expectancies.  One study found no 
relationship between state and trait anxiety and pre-intervention outcome expectancies for 
people undergoing oral surgery (McCarthy, et al., 2003); another reported no relationship 
between trait anxiety and expectations of nausea during chemotherapy treatment 
(Montgomery et al., 1998).  On the other hand, fear (of re-injury) has been shown to be 
inversely related to expectations of treatment efficacy in a chronic pain sample (Goosens 
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et al., 2005).  Furthermore, in a study of experimental placebo analgesia in an IBS 
sample, it was reported that levels of anxiety regarding upcoming pain was positively 
correlated with both expected and actual pain (Vase, Robinson, Verne & Price, 2005).  
Although the relationship between anxiety and treatment expectancies has not been 
clearly established, the empirically grounded Belief-Activation Model provides good 
theoretical support for this relationship.  
C. Optimism/ Pessimism 
 In the general health psychology literature, optimism has been identified as an 
individual difference variable that pertains to relatively stable expectations that good 
things will happen, whereas pessimism pertains to expectations that bad things will 
happen (Steed, 2002).  Research has verified that dispositional optimism consists of these 
two separate but often negatively correlated dimensions (Bryant & Cvengros, 2004).  
Behavioral medicine studies that have examined these dimensions independently, 
frequently report that optimism and pessimism show differential relationships to various 
measures of health in both clinical and non-clinical samples (Mroczek, Spiro, Aldwin, 
Ozer & Bosse, 1993; Robinson-Whelen, Kim, MacCallum & Kiecolt-Glaser, 1997; 
Räikkönen & Matthews, 2008).  In general, greater optimism has been linked to more 
favourable health indicators and outcomes, for example: stronger immune functioning 
(Segerstrom, Taylor, Kemeny, & Fahey, 1998), improved survival rates for cancer and 
heart disease patients (Allison, Guichard, Fung & Gilain, 2003; Buchanan & Seligman, 
1995, respectively); and lower risk of overall mortality in a 30-year study (Maruta, 
Colligan, Malinchoc, & Offord, 2000).  Perhaps not surprisingly, greater pessimism has 
been found to be associated with less favourable health indicators and outcomes, for 
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example: weaker immune functioning (O‟Donovan, et al., 2008), more pain and lower 
functionality in post-surgical heart disease patients (Mahler & Kulik, 2000) and increased 
mortality rates among cancer patients (Schulz, Bookwala, Knapp, Scheier & Williamson, 
1996). 
In the placebo literature, optimism and pessimism are two of the individual 
difference variables whose influence on placebo responding have been studied directly.  
As the personality literature suggests that pessimists are more likely to be influenced by 
negatively-toned information, Geers and colleagues (2005) decided to test individuals 
identified as optimistic or pessimistic on their responsiveness to a negative placebo 
(suggestion of unpleasant sensations).  This study reported that although optimists in the 
placebo group did not report more unpleasant symptoms than the control group, 
individuals identified as pessimistic did show a placebo response (Geers, Helfer, et al., 
2005).  To explore the possible interaction of self-focused attention, half of the 
participants were encouraged to signal whenever they experienced a change in their level 
of unpleasant sensations.  It was reported that this manipulation did not affect negative 
symptom reporting, suggesting that the influence of pessimism is not just a function of 
attentional biases.  Geers and his research group (Geers, Kosbab, Helfer, Weiland & 
Wellman, 2007) subsequently looked at the relationship of optimism/ pessimism to 
placebo responding in a study where the placebo suggestion was positively toned (a 
writing task improves sleep quality).  Here, it was found that greater levels of optimism 
were associated with improved sleep quality, yet only in the placebo group.  In two non-
placebo control groups (one completing the writing task without suggestion for sleep 
improvement, one with no writing task), optimism was not associated with improved 
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sleep quality, suggesting that in this sample, optimism was related to outcome only when 
there was a positive placebo suggestion.  Although in both of these studies participants‟ 
expectations were not directly measured, it is likely that optimism/pessimism contributed 
to placebo responding by moderating the extent to which participants believed the 
experimenter‟s suggestions. 
In another study, the relationship between optimism/pessimism and the strength 
of expectancies for non-volition responses was studied directly (Montgomery, David, 
DiLorenzo & Erblich, 2003).  In this study, participants were asked how much they 
expected certain non-volitional outcomes (both positive and negative) to occur.  For 
example, they were asked to rate how much alertness they expected to experience after 
drinking coffee (positive) or how much pain they expected to experience after undergoing 
surgery (negative).  Here again, degree of dispositional pessimism was correlated with 
expectancies for negative non-volition occurrences, whereas optimism was not related to 
levels of expectancy.   
   One study has demonstrated that optimism positively influences expectations of 
benefit from clinical treatment.  Weinfurt and colleagues (2003) conducted an interesting 
study examining patient characteristics that were associated with expectations of benefit 
from Phase I clinical trials for cancer treatment.  Participants indicated their expectations 
of benefit on a visual analogue scale, and completed several survey measures regarding 
their health beliefs and personal characteristics.  The authors reported a moderate positive 
correlation (r = .28) between expectation of benefit and a single-item measure of general 
dispositional optimism.   This suggests that individuals with higher levels of dispositional 
optimism also report higher expectations that they will benefit from treatment.   
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D. Hope  
 The predominant conceptualization of dispositional hope is that it is a “cognitive 
set that is based on a reciprocally derived sense of successful (a) agency (goal-directed 
determination) and (b) pathways (planning of ways to meet goals)” (Snyder et al., 1991, 
p. 571).  Dispositional hope is a variable that has also been implicated as relevant in 
contributing to health outcomes (Scioli et al., 1997; Snyder, 2002; Snyder, Sympson, 
Michael & Cheavens, 2001), and has been suggested to play a role in the placebo 
response (Yahne & Miller, 1999).  Hope is a construct similar to optimism, although 
recent research has indicated that hope and optimism are distinct constructs (Bryant & 
Cvengros, 2004).  In particular, hope has been distinguished from optimism as it 
considered more of an affective state, used in situations where outcomes are deemed 
more important, less likely and under less personal control (Bruininks & Malle, 2005). 
Similarly, expectancies and hope have been shown to be independent but related 
constructs, and it has been shown that hope contributes to response expectancies for non-
volitional responses (Montgomery et al., 2003).  In a recent qualitative study examining 
expectations of benefit in randomized clinical trials, hope was mentioned by almost all 
participants as a factor that contributes to their positive treatment expectancies (Stone, 
Kerr, Jacobson, Conboy, & Kaptchuk, 2005).  Based on the empirical and theoretical 
support for the contribution of hope to health, placebo responding, response expectancies 
and positive treatment expectancies, this individual difference variable is thought to 
warrant further study.    
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IX. Identifying Health Belief Variables 
The general literature on expectancy formation specifies that an individual‟s 
preexisting beliefs can be an important source of information in the generation of specific 
current beliefs and thus, expectancies.  Furthermore, the Belief-Activation Model 
specifies that external cues will interact, either synergistically or competitively, with an 
individual‟s personal health beliefs to influence the strength of treatment expectancies.  
One of the purposes of the proposed research is to further extend and refine our 
understanding of the contribution of these various „health beliefs‟ to the strength of 
positive outcome expectancies.  As stated above, the placebo, health psychology and IBS 
literatures will be reviewed in order to identify additional personal health belief variables 
that may contribute to the strength of one‟s outcome expectancies. 
A. Perceptions of Health 
Subjective perception of one‟s current health is known to be a powerful predictor 
of one‟s future health (Idler & Kasl, 1991; Kaplan & Camacho, 1983; Whittaker, Kemp 
& House, 2007), and has even been reported to be a better predictor than current 
objective health status (Mossey & Shapiro, 1982).  In two similar studies, „health-related 
quality of life‟ has been identified as a variable correlated with individuals‟ expectations 
of benefit in Phase I clinical trials (Cheng et al., 2000; Weinfurt et al., 2003).  In both 
these studies, the Medical Outcome Study – Short Form 36, which assesses a patient‟s 
overall perception of their health and physical functioning, was used to measure health-
related quality of life.  One of these studies also reported that expectations of benefit were 
positively correlated with „relative health stock‟ (Weinfurt et al., 2003).  This variable 
was considered an index of an individual‟s current perceived health, including their 
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expected longevity and quality of life.  It seems clear from these studies that a person‟s 
general perception of how healthy they are exerts an influence on expectations of 
treatment efficacy.  It is argued here that perceptions of current health can be considered 
one aspect of the greater umbrella concept of „personal health beliefs.‟  As such, this 
variable will be included in the proposed research in order to ascertain its relative 
contribution to positive treatment expectancies.  
B. Control beliefs 
One‟s belief about their level of control over their illness and healing is another 
variable that has been found relevant to health outcomes.  Such „control beliefs‟ have 
been studied extensively over the years, usually in one of two ways.  One popular way is 
to measure the level of control attributed to three different sources (Levenson, 1973): 
internal (e.g., “I am in control of my health”), external/ powerful others (e.g., “My doctor 
is in control of my health), and chance (e.g., “My health status is mostly dependent on 
luck”).  Other researchers have assessed the relative presence of a sense of perceived 
control over one‟s symptoms and illness.  Overall, it appears that a greater sense of 
personal control over one‟s symptoms and illness contributes to more favourable mental 
and physical health outcomes and more favourable symptom reports in chronic illnesses 
(Affleck, Tennen, Pfeiffer, & Fifield, 1987; Marshall, 1991; Taylor, Kemeny, Reed, 
Bower & Grunewald, 2000; Tennen, et al., 1992).  Furthermore, it has been noted that 
better outcomes are associated with weaker „powerful others‟ control beliefs (external 
locus of control; Härkäpää, et al., 1996; Shelley & Pakenham, 2004; So, 1998).   
Here it is suggested that control beliefs are another form of belief that will 
influence current expectancies about treatment efficacy.  This suggestion is made based 
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on the idea that control beliefs constitute a form of attribution, specifically attributions of 
therapeutic change mechanisms with regard to one‟s symptoms or illness.  In particular, 
Olson et al., (1996) predict that if positive changes are attributed to internal, stable causes 
(e.g., „I am in control of my symptom improvement), then future positive changes will be 
expected.  On the other hand, if changes are attributed to external (and perhaps unstable) 
causes, then expectations of benefit may be less certain.     
Some preliminary evidence to support the relationship between personal control 
beliefs and beliefs about treatment effectiveness has been demonstrated in studies using 
the Illness Perception Questionnaire –Revised (Moss-Morris, Weinman, Petrie, Horne, 
Cameron & Buick, 2002).  This scale contains several subscales, one of which, labeled 
„treatment control‟ could be considered as a measure of treatment expectancies.  Three of 
the five items that load on this subscale refer to beliefs about the ability of one‟s current 
treatment to control aspects of one‟s illness (e.g., “My treatment can control my illness” 
and “The negative effects of my illness can be prevented (avoided) by my treatment”).  
Two other items that load less strongly refer more to feeling of lack of control (e.g., 
“There is little that can be done to improve my illness”).  When this scale was validated 
using a large sample of mixed illness groups, it was found that the „personal control‟ 
subscale, which contains six items pertaining to beliefs of personal control over one‟s 
illness and symptoms, was strongly positively correlated with the treatment control 
subscale.    
C. Self-Efficacy 
 In Bandura‟s (1977) social learning theory (now called social cognitive theory), 
he introduced the concept of self-efficacy as an additional type of expectancy that 
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contributes to guiding behaviour, in conjunction with the expectancies that a behaviour 
will lead to reinforcement and that the reinforcement is valuable (Rotter, 1954).  Self-
efficacy expectancies reflect one‟s confidence regarding one‟s ability to execute 
behaviour that reinforcement is contingent upon.  The utility of the concept of self-
efficacy in understanding health behaviours has been wide-ranging (O‟Leary, 1992), so 
much so that self-efficacy has been adopted into most theories of health behaviour. 
Various types of perceived health-related self-efficacy have been found to predict 
adjustment to illness (Aarnold et al., 2005; Lev, Paul & Owen, 1999; Shelley & 
Pakenham, 2004), better self-care in the context of illness (de Ridder et al., 2004), as well 
as better physical health and well-being (Marshall, 1991; Schwarzer & Fuchs, 1995).  In 
one impressive study of self-management education for arthritis sufferers, it was 
demonstrated that over four years, participants enjoyed an increase in their arthritis self-
efficacy, which correlated with decreased pain reports and fewer visits to their physicians 
(Lorig, Mazonson & Holman, 1993).  „Health self-efficacy‟ in particular refers to the 
extent to which one feels confident and capable of doing what is necessary to control 
one‟s health in general (Sirois, 2003), and has been found to predict health behaviours 
among individuals with chronic illness (Sirois, 2008). 
Another type of self-efficacy that is relevant in the context of health outcomes is 
coping self-efficacy, which refers to beliefs about one‟s ability to cope with the day-to-
day aspects of their symptoms.  This health belief variable has been found to be 
associated with improved health outcomes in illness groups, primarily through its 
relationship with treatment adherence.  For example, coping self-efficacy is correlated 
with self-care in diabetics (Williams & Bond, 2002), as well as adherence to 
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cardiovascular health-promoting behaviors (Ewart, 2002).  Although the relationships 
between treatment expectancies and health self-efficacy or coping self-efficacy have not 
been examined directly, the reported link to health outcomes and health-related variables 
flag both these variables as relevant targets of study for the research proposed herein.  
Furthermore, Olson et al (1996) note that high self-efficacy implies that success is 
expected and that success reflects personal capacities (Bandura, 1977); thus, individuals 
with high self-efficacy will attribute positive changes to internal controllable factors and 
will expect future positive changes.      
X. Context-dependent Psychosocial Variables 
Imagine a situation where an allopathic physician prescribes a pharmacological 
intervention to treat fibromyalgia, along with the suggestion that this intervention will 
address the generalized aches and pains (myalgia) associated with this condition.  The 
ability of this specific intervention to elicit strong positive expectations of outcome may 
depend on a variety of personal factors that become relevant only in this specific context 
(a specific treatment administered by a specific physician); for example, whether an 
individual has a previous negative experience with this type of intervention or physician, 
or perhaps whether he/she agrees that the pain is best treated through pharmacology.  
These types of variables are intrinsic to the individual, but may only become relevant in a 
specific context.  The potential relevance of several of such context-dependent 
psychosocial variables is explored in this section.  
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A. Past Experiences with Treatment 
An individual‟s previous experience with a specific type of treatment is assumed 
to exert a strong influence on their current expectations of treatment (Montgomery & 
Bovbjerg, 2000) and on their responsiveness to placebos (Enck & Klosterhalfen, 2005; 
Chaput de Saintonge & Herxheimer, 1994).  In fact, in the expectancy literature, previous 
experiences are considered to be more effective in shaping expectancies than any 
informative factors such as verbal suggestion (Olson et al., 1996; Stewart- Williams, 
2004).  Some research has directly linked previous experience with current expectancies, 
both in laboratory and clinical settings.  For example, past experiences with non-
volitional responses have been shown to correlate with current expectancies for non-
volitional responses (Montgomery et al., 2003), and in the qualitative study mentioned 
above, past experiences with treatment was mentioned by all participants when 
discussing their expectation of benefit in a Phase I clinical trial for cancer treatment 
(Stone et al., 2005).   
Strong support for the role of previous experience has also been found in studies 
of placebo analgesia.  In one study, some subjects were randomly assigned to receive a 
surreptitious lowering of the painful stimuli after receiving what they were told 
(deceptively) was an analgesic treatment, in order to make them believe that the treatment 
was effective (Colloca & Benedetti, 2006).  When later given the same placebo treatment 
and exposed to the original higher intensity painful stimuli, a strong placebo effect was 
demonstrated.  This effect was demonstrated after minutes and also lasted from four to 
seven days.  In some subjects who did not receive the lowering of the pain stimulus, a 
placebo effect was still demonstrated, even days later, but the effect was much smaller.  
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Thus, small and large placebo responses were obtained, depending primarily on the 
previous negative or positive experience with the analgesic treatment.  They emphasize 
that in this study, verbally induced expectancies of analgesia alone resulted in either 
significant placebo responses, or no response at all, depending on the previous positive or 
negative experience of the participant.  The authors are not definitive regarding whether 
the influence of previous experience in this study was mediated through conditioning or 
expectancies, but they suggest that the conditioning procedure they used produced 
increased expectations of benefit.  
B. Illness Attributions 
 In general, expectancy theorists view causal attributions as a potential source of 
situational expectancies (Kirsch, 1985; Olson et al., 1996).  One‟s attributions about the 
cause(s) of their symptoms and/or illness are often referred to as illness attributions, 
although it is recognized that attributions for one‟s illness may be distinct from 
attributions for one‟s symptoms (Robbins & Kirmayer, 1991).  Although such 
attributions could feasibly be stable over time, they can be considered as context-
dependent as their relevance to one‟s current expectancies may vary as a function of the 
specific intervention being presented.  Such attributions are often categorized as somatic, 
psychological, some combination of both, or normalizing (Robbins & Kirmayer, 1991).  
A recent meta-analysis has implicated illness attributions as a personal variable that may 
influence placebo responding among individuals with chronic fatigue syndrome (CFS; 
Cho, Hotopf, & Wessely, 2005).  Knowing that there are often strong somatic illness 
attributions in patients with CFS, and that these attributions are associated with poorer 
health reports over time (Schmaling, Fiedelak, Katon, Bader & Buchwald, 2003) these 
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authors speculated that illness attributions (physical, psychological, or both) may 
influence patients‟ expectancies of treatment outcome (and thus their placebo 
responsiveness) across different types of intervention.  Their analyses were designed to 
estimate the average placebo response in clinical trials of CFS and to determine whether 
intervention type influenced the magnitude of the placebo response.  They report a pooled 
placebo response of 19.6%, and found that intervention type contributed to the 
heterogeneity of placebo responses, with psychological interventions eliciting a lower 
placebo response.  The authors suggest that these differences across intervention type are 
a function of the influence of illness attributions on treatment expectancies.  A 
complementary, but somewhat distinct explanation for these results can be proffered, 
based on the argument that one‟s attributions regarding the cause of their symptoms 
(somatic/ psychological) do not necessarily lead directly to one‟s attributions for 
symptom change (e.g., via a somatically-focused treatment vs. a psychologically-focused 
treatment).  For instance, one could attribute symptoms to psychological factors, yet still 
prefer a pharmacological treatment to manage one‟s symptoms (e.g., a stress headache 
treated with ibuprofen).  With this in mind, the results presented by Cho et al (2005) 
could indicate that individuals with CFS hold lower expectations for outcome (and show 
smaller placebo responses) when offered treatments that focus on psychological targets. 
 Another study involving participants with CFS demonstrated more directly that 
illness attributions were linked with treatment outcomes.  In a randomized controlled trial 
of cognitive-behavioural therapy for CFS, greater somatic attributions predicted poorer 
outcome at follow-up (Chadler et al., 2003).  This study seems to provide support for the 
idea that one‟s attributions can interfere with verbal suggestions provided by the 
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treatment provider.  Specifically, individuals who attributed their illness to a physical 
problem were less able to benefit from this psychological intervention.  These studies 
suggest that it is reasonable to hypothesize that illness attributions (for either the cause of 
symptoms or the management of symptoms) can alter the magnitude of positive treatment 
expectancies.   
C. Motivation 
Motivational factors, such as desire for relief or desire to please the experimenter 
or physician, can also be considered as context-dependent psychosocial variables as they 
may fluctuate from one temporal or spatial context to another.  In placebo literature in 
particular, motivational factors have been of interest as they have been proposed as a 
potential mediator of placebo responses.  Some authors posit that motivation is a factor 
that contributes to placebo responding independently of outcome expectations  (Vase et 
al., 2003), while others incorporate the two by suggesting that one‟s motivation 
(conscious or subconscious) to respond in the suggested direction will moderate the 
strength of the outcome expectancy (Geers, Weiland, Kosbab, Landry & Helfer, 2005).  
The results of various studies examining the contribution of motivational factors have 
been mixed. 
A study by Price and colleagues (1999) separately examined the correlations 
between desire for pain relief, expectations of pain relief and actual placebo analgesia.  
Part of their rationale for examining motivation factors included findings from the 
placebo analgesia literature showing that placebo responses in experimental pain increase 
as a function of the duration and severity of pain (Jospe, 1978).  In the Price et al study, it 
was found that desire for pain relief was not related to the magnitude of placebo 
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responding.  The authors suggest that despite the range of desire ratings reported, this 
variable may not be as potent in experimental studies of pain among healthy participants 
subjected to brief pain stimuli, compared to its role among populations who report 
clinical pain.   
Addressing this issue, Vase and colleagues (2003) conducted a placebo analgesia 
study using evoked rectal distention in patients with irritable bowel syndrome.  After 
baseline exposure to the noxious stimuli and treatment with a „powerful analgesic‟ 
placebo, they asked patients to rate both their desire for pain relief as well as their 
expectations of pain relief.  These authors report that together, desire for relief and 
expectations of pain accounted for over 70% of the variance in actual pain ratings 
(although expectancy had the only significant beta weight in a simultaneous regression).  
The data from this study was later reanalyzed to examine the contribution of expectancies 
and desire to placebo effects (not just pain ratings) by calculating change scores from 
baseline measurement to post-placebo measurement (Price, Chung & Robinson, 2005).  
Here, the interaction of desire and expectancy was a significant predictor of placebo 
effects.  Unfortunately, the authors do not offer a description of this interaction; therefore, 
it is unclear whether motivation (desire for relief) predicts placebo analgesia 
independently of one‟s expectations, or whether motivation contributes to placebo 
responding in part by strengthening one‟s expectations for relief.     
Others have presented a more elaborated model of how motivation can strengthen 
or attenuate the magnitude of one‟s expectations of treatment, and subsequently one‟s 
response to a placebo intervention.  Specifically, Geers, Weiland and colleagues (2005) 
speculate that the placebo effect is most likely to occur when individuals have a goal that 
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can be fulfilled by confirmation of the placebo expectation.  Their „goal-activation‟ 
model posits that although situational cues may induce expectations of treatment, if a 
person‟s goal for treatment (conscious or subconscious motivation) is incompatible with 
the placebo expectations, expectation will be attenuated and have less influence on one‟s 
somatic experience.  They further speculate that a placebo-compatible goal directs 
cognitive processing and behaviour towards the confirmation of placebo expectation.  
These authors tested their model in five separate experiments where some subjects were 
primed to have a particular goal with respect to the placebo treatment.  Overall, they 
report that larger placebo effects were found when individuals were primed to have 
placebo-compatible goals.  As expectations were never directly measured in these 
studies, it is difficult to distinguish whether goals to cooperate with the placebo 
suggestions enhanced expectancies and thus placebo responding, or whether goals to 
cooperate independently influenced placebo responding.  Nevertheless, this series of 
studies provides support for the importance of motivation factors in the generation of 
placebo effects, and furthermore indicates that a closer examination of the influence of 
motivations on expectancies is warranted.    
D. Patient-Provider Relationship 
 There is an additional context-dependent psychosocial factor whose contribution 
to outcome expectancies will be examined in the proposed research.  It is a relational 
factor, specifically, the quality of the patient-provider relationship.  It has been suggested 
in the placebo literature that „common factors in therapy‟ (i.e., the therapeutic alliance) 
are additional factors that can shape treatment expectancies (Di Blasi et al., 2001; 
Pacheco-Lopez, Engler, Miemi & Schedlowski, 2006; Stewart-Williams, 2004; Turner, 
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Deyo, Loeser, Von Korff & Fordyce, 1994).  Specific aspects of the patient-provider 
interaction that have been researched and found to be related to placebo responding 
include the provider‟s interpersonal skills (Oh, 1991), persuasive influence (Shapiro, 
1971) and the time spent with the patient (Kaptchuk et al., 2006; Solomon, 2002).  In the 
expectancy literature it has been noted that positive views about another person are found 
to be associated with the acceptance of that person‟s ideas (Harris & Rosenthal, 1985).  
Empirically, one study reported that more a positive perception of the patient-provider 
relationship contributed to greater expectations of benefiting from treatment (Beach, 
Keruly & Moore 2006).  With this in mind, it is reasonable to hypothesize that positive 
beliefs about a provider would influence the degree to which a patient accepts their 
information (i.e., suggestions of treatment efficacy).   
In the field of mental health, it is well-known that the therapeutic alliance is a 
strong predictor of treatment outcome (Lambert & Barley, 2002).  Although this variable 
has not been as well studied in field of medical health, there are some reports that the 
quality of the patient-provider relationship is related to health outcomes (Beach et al., 
2006; Sans-Corrales, et al., 2006).  In the IBS literature, there have also been studies that 
indicate that dissatisfaction with one‟s provider is not uncommon and tends to contribute 
to negative attitudes regarding treatment (Chang et al., 2006; Dixon-Woods, & Crtichley, 
2000; Dhaliwal & Hunt, 2004).  As this relationship variable has been identified as 
contributing to placebo responding, treatment expectancies and health outcomes, it is 
considered a relevant variable to include in the proposed research.   
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XI. IBS as the Proposed Illness Model 
To give a full account of the background and significance of the proposed 
research, it is important at this point to outline the rationale for choosing irritable bowel 
syndrome as the specific illness model to be explored herein.  Irritable bowel syndrome 
(IBS) is a common functional gastrointestinal motility disorder that affects 10-20% of the 
general population, both males and females from a wide age-range (Cremonini & Talley, 
2005).  It is termed a „functional syndrome‟ as the primary pathology is an altered 
physiological function (the way the body works), rather than an identifiable structural or 
biochemical cause.  This disorder is characterized by abnormal stool consistency and 
frequency accompanied by abdominal pain.  There are three different sub-types of IBS, 
including a constipation-predominant subtype (IBS-C), a diarrhea-predominant subtype 
(IBS-D) and an alternating sub-type (IBS-A). 
IBS is an ideal illness model to study in this type of research for several reasons.  
First, IBS is diagnosed using a specific set of self-report symptom criteria and there are 
no physical findings or diagnostic tests needed to confirm the diagnosis; this makes it 
easier to conduct research online with this illness group.  Second, IBS is known to be 
responsive to placebo treatment (Enck & Klosterhalfen, 2005; Mertz, 2003; Patel et al., 
2005; Vase, et al., 2003), and thus presumably to variations in treatment expectancies, 
making it quite relevant to be studying the psychosocial correlates of treatment 
expectations in this sample.  Although there have been relatively few studies examining 
the psychosocial correlates of placebo responding in people with IBS (Patel et al., 2005), 
one study that has directly addressed this research question identified patients‟ 
expectations as a contributing factor (Vase, et al., 2003).   
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A final benefit of studying expectancies in people with IBS stems from the 
elusive nature of this syndrome.  As there are no known organic indicators present in 
IBS, and since it has been shown to be responsive to psychological interventions 
(Lackner, Mesmer, Morley, Dowzer & Hamilton, 2004; Matsumoto, Sato, Yokoi, 
Yoshinaga, Shimura, & Sakano, 1998), there is a research literature examining the 
psychosocial correlates of IBS symptom reporting.  In particular, the IBS literature is 
somewhat unique in that there has been a specific effort to examine the relationship of 
IBS symptomotology to health belief variables.  As such, a review of this literature will 
be informative in identifying various psychosocial variables that may contribute to the 
activation of treatment-specific expectations.  Ultimately, the results of this investigation 
should be able to contribute valuable information about the correlates of treatment 
expectancies in this sample, information that can be used to inform and improve 
intervention efforts in the treatment of IBS.     
XII. Psychosocial Factors Identified from IBS Literature 
A. Self-focused attention & Anxiety 
Most research on the psychosocial variables relevant to IBS has focused on 
individual attributes that tend to present in people with IBS.  Some of this research has 
found that individuals who seek treatment for IBS report higher than average levels of 
bodily preoccupation (or self-focused attention; Crane & Martin, 2002, 2004b; 
Gomborone, Dewsnap, Libby, & Farthing, 1995; Silverman et al., 1997) as well as higher 
levels of general and health anxiety (Barahmand, 2008; Crane & Martin, 2004; Hazlett-
Stevens, Craske, Mayer, Chang, & Naliboff, 2003).  In this literature as well, both self-
focused attention and anxiety are associated with less favourable outcomes.  It is 
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important to note, however, that this literature does not support a causative model.  Crane 
and Martin (2002) have speculated that the relationship between body preoccupation and 
IBS symptomotology may be reciprocal.  In particular, it is hypothesized that the 
sustained presence of discomforting and unexplained IBS symptoms likely contributes to 
increased anxiety as well as vigilance towards internal bodily states and sensations.  In 
turn, as noted above, there is evidence that attending to internal experiences such as 
sensations can amplify these experiences (Franzoi, 1996).  Moreover, there is an ever-
expanding literature concerning the neurobiochemical relationships between 
emotionality, hypervigilance and gut motility (see Jones, Dilley, Drossman & Crowell, 
2006; Mulak & Bonaz, 2004).           
B. Illness Attributions 
 There have been a handful of studies investigating the illness attributions of 
people with IBS.  In general, there has been an informal consensus that people with IBS 
tend to make somatic attributions for their symptoms, and this has been confirmed in 
early research (van Dulmen, Fennis, Mokkink & Bleijenberg, 1996).  It has also been 
noted that individuals who seek treatment for their IBS make more somatic attributions 
for their IBS symptoms (as well as for non-IBS symptoms) than do non-treatment seekers 
(Martin & Crane, 2003).  More recent research has contradicted this assumption 
somewhat; in one study it was found that people with IBS did not make more somatic 
interpretations of their symptoms than did other patients presenting to a GI clinic (Bray, 
Nicol, Penman & Ford, 2006).   Another recent study found that levels of somatic 
symptom attribution were unrelated to quality of life in an IBS sample, whereas levels of 
psychological symptom attribution were positively correlated with quality of life 
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(Barahmand, 2008).  The results have also been mixed when attributional styles have 
been examined in relation to symptom severity; in one study symptom severity was more 
strongly correlated with levels of somatic attributions (Gerson et al., 2006), yet in another 
it was more strongly correlated with levels of psychological interpretations (Bray et al., 
2006).  Although limited, this research suggests that illness attributions may be a relevant 
variable for individuals with IBS, as has been demonstrated for individuals with chronic 
fatigue syndrome (reviewed above).   
C. Control Beliefs 
As in the general health psychology literature, control beliefs have been studied 
among individuals seeking treatment for IBS.  As we would perhaps expect, it has been 
shown that a weaker perception of personal control over one‟s IBS symptoms is 
associated with less favourable outcomes (lower quality of life, lower satisfaction with 
health; Rutter & Rutter, 2002).  Again, it should be noted that this relationship is not 
presumed to be unidirectional; on the contrary it is logical that increased symptom 
severity can be accompanied by a decreased sense of control over symptoms.  Individuals 
with IBS have been found to endorse greater external locus of control than healthy 
participants (Hobbis, Turpin, & Read, 2003).  Thus, here again, control beliefs have been 
associated with health status.  However, the relationship between control beliefs and 
outcome expectancies has not been studied in this illness population.       
D. Vulnerability to Illness 
Another finding that has emerged is that individuals seeking treatment for IBS 
show high levels of what could be called beliefs of „vulnerability to illness.‟  In 
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particular, this patient group reports greater levels of disease phobia (fear of contracting a 
disease), and perceive themselves as being more at risk of developing health problems 
unrelated to their IBS symptoms (Crane & Martin, 2004b; Gomborone et al., 1995; 
Martin & Crane, 2003).  One study found that an IBS patient group reported greater 
perceived illness vulnerability than other groups with chronic health problems, even 
while controlling for levels of self-focused attention, anxiety, depression, as well as 
levels of recent and current symptoms.   Crane and Martin (2002) argue that if these 
beliefs are a part of one‟s enduring „illness schema,‟ they are likely to reduce an 
individual‟s expectations for their own recovery.   
E. Catastrophizing 
Similarly, studies report that individuals with IBS often present reporting belief in 
the presence of serious pathology, as well as catastrophizing beliefs about their symptoms 
(Gomborone et al., 1995; Kolowski, Boyce & Talley, 2005).  Such catastrophizing beliefs 
have been linked to poorer health outcomes among women with gastrointestinal disorders 
(Drossman et al., 2000; Rutter & Rutter, 2002), and have been found to partially mediate 
the relationship between depression and pain severity among individuals with IBS 
(Lackner, Quigley & Blanchard, 2004). By virtue of the fact that these negative health 
beliefs have been found to influence health outcomes, an empirical investigation of their 
contribution to outcome expectancies seems warranted.  
XIII. Identifying Additional Variables 
This study also included a qualitative component, primarily designed to identify 
relevant psychosocial variables that may not have been identified in the literature review.  
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An open-ended question format was used, designed to provide participants with the 
opportunity to directly communicate their thoughts about their treatment expectancies.  
This type of qualitative research can be of great value in uncovering information in new 
areas of investigation such as this.  Recently there has been one qualitative study 
examining factors that influence expectations to benefit from treatment among 
individuals participating in a Phase I randomized clinical trial for cancer medication 
(Stone et al., 2005).  This study was among the first to demonstrate that several different 
variables (e.g., past experiences) may affect one‟s expectations of treatment, whereas 
previously it was thought that expectations were primarily a function of one‟s hope for 
benefit.  This example highlights how qualitative research can complement a quantitative 
approach in identifying factors that contribute to the strength of treatment expectancies. 
XIV. Aims 
The global aim of this study was to work towards better and more cost effective 
medical interventions by encouraging increased attention to and improvement of a 
patient‟s expectations of treatment outcome.  To facilitate this global aim, this project has 
surveyed several literatures to provide support for the central role of treatment 
expectancies in health interventions and to identify psychosocial variables that may 
contribute to the formation of such expectancies.  Three models of placebo responding/ 
expectation formation were combined into a single model that was used to guide this 
literature review, which has resulted in the identification of several psychosocial 
variables that may be relevant correlates of treatment expectancies.  Many of these 
variables have been shown to directly influence the formation of treatment expectancies, 
whereas others are presumed to influence expectancies based on their relationship to 
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placebo responding, health outcomes, symptom reporting or to each other.  Please refer to 
Table 1 for a summary of the type of support available in the literature to inform the 
inclusion of each variable in the current study.    
Table 1 
Summary of the Type of Empirical Results Available in the Literature to Link Each 
Independent Variable to Outcome Expectancies 
Independent Variable 
Differential 
Placebo 
Responses 
Differential 
Health 
Outcomes 
Association with 
Outcome 
Expectancies 
Self-focused Attention Yes   
Anxiety Yes Yes Yes / No 
Optimism Yes Yes Yes 
Pessimism Yes Yes Yes 
Hope  Yes Yes 
Perceptions of Health  Yes Yes 
Control Beliefs  Yes Yes 
Self-Efficacy (Health & Coping)  Yes  
Vulnerability Beliefs  Yes  
Catastrophizing  Yes  
Past Experiences Yes Yes Yes 
Illness Attributions Yes Yes Yes 
Motivation Yes   
Patient-Provider Relationship Yes Yes Yes 
Note.  A „Yes‟ in a particular column indicates that the specific variable has been shown 
to be associated with the result in that column.  A „No‟ indicates that that the specific 
variable has been found to not be associated with the result in that column.  An empty 
cell indicates that the relationship between a specific variable and the result in that 
column has not been studied.   
 
Figure 1 displays the resulting complex model that includes each of the variables 
identified as potentially relevant contributors to the magnitude of one‟s treatment 
expectancies.  One of the main purposes of the current investigation was to test the 
relationships of each of these variables to the magnitude of one‟s treatment expectancies.   
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Figure 1. The full model of potentially relevant psychosocial variables contributing to 
treatment expectancies.  
 
A further purpose was to create a more parsimonious list of relevant variables by 
ascertaining the relative contributions of each of these variables.  The objective of 
creating a more parsimonious list of variables was to increase the feasibility of assessing 
these relevant factors in a clinical setting.  This focus on parsimony and feasibility fits 
well with the global aim of increasing the efficiency and effectiveness of medical 
interventions.  
The qualitative data was used to facilitate the aforementioned aims through 
accomplishing two additional specific aims.  One specific aim of this component was to 
identify any additional psychosocial variables that may influence treatment expectancies 
that have not been identified from the literature.  Secondly, this data was used to shed 
light on null or unexpected quantitative findings.   
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XV. Research Questions: 
This research was designed to address these aforementioned aims through 
addressing the following specific research questions: 
1. Which of the identified psychosocial variables are related to the magnitude of 
positive treatment expectancies in an IBS sample? 
2. What is the relative contribution of these psychosocial variables for predicting 
levels of treatment expectancies in an IBS sample? 
3. Are there additional psychosocial variables that are commonly cited by IBS 
sufferers as contributing to expectations of treatment benefit in this context? 
XVI. Design 
To address these specific research questions, a sample of individuals meeting 
criteria for a diagnosis of irritable bowel syndrome were recruited to participate in this 
cross-sectional research by completing an online battery of self-report questionnaires.  
Individuals were presented with two vignettes describing hypothetical treatments for 
irritable bowel syndrome; they were then asked to rate their expectations of personally 
benefiting from the proposed treatments
1
 on two visual analogue scales (dependent 
variables), and asked to identify the treatment that they would hypothetically prefer.  The 
self-report questionnaire battery that followed contained measures of all independent 
variables (identified psychosocial variables).  Finally, individuals were asked an open-
ended question regarding factors they felt influenced their expectations of treatment 
benefit in this hypothetical context.    
                                                 
1
 Also referred to throughout as „treatment expectancies.‟ 
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XVII. Hypotheses 
A number of specific hypotheses, informed by the literature review, follow from 
the aforementioned specific research questions.   
Research Question 1: Which of the identified psychosocial variables are related to the 
magnitude of positive treatment expectancies in an IBS sample? 
Hypothesis 1a: Levels of self-focused attention would be correlated with levels of 
treatment expectancies
2
. 
Hypothesis 1b: Levels of trait anxiety would be negatively correlated with levels 
of treatment expectancies. 
Hypothesis 1c: Levels of optimism will be positively correlated with levels of 
treatment expectancies and levels of pessimism would be 
negatively correlated with levels of treatment expectancies. 
Hypothesis 1d: Levels of hope would be positively correlated with levels of 
treatment expectancies.   
Hypothesis 1e: Levels of perceived current health would be positively correlated 
with levels of treatment expectancies.  Number of acute health 
problems will be negatively correlated with levels of treatment 
expectancies.   
Hypothesis 1f: Levels of perceived personal control over health and symptoms 
would be positively correlated with levels of treatment 
expectancies. 
                                                 
2
 The direction of this relationship was not specified as findings in the literature have 
been mixed. 
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Hypothesis 1g: Levels of health and coping self-efficacy would be positively 
correlated with levels of treatment expectancies. 
Hypothesis 1h: Levels of perceived vulnerability to illness would be negatively 
correlated with levels of treatment expectancies. 
Hypothesis 1i: Levels of symptom catastrophizing would be negatively correlated 
with levels of treatment expectancies. 
Hypothesis 1j: Levels of past satisfaction with similar treatments would be 
positively correlated to levels of treatment expectancies.  Number 
of previous treatments attempted would be negatively correlated 
with levels of treatment expectancies. 
Hypothesis 1k: Levels of illness attribution (somatic and psychological) and the 
treatment‟s perceived focus (somatic and psychological) would be 
correlated with levels of treatment expectancies
3
. 
Hypothesis 1l: Levels of desire to see relief would be positively correlated with 
levels of treatment expectancies.  Levels of symptom severity and 
interference of IBS symptoms in daily activities would be 
negatively correlated with levels of treatment expectancies. 
Hypothesis 1m: Levels of social desirable responding would be positively 
correlated with levels of treatment expectancies.  
Hypothesis 1n:  Level of positive perception of treatment provider would be 
positively correlated with levels of treatment expectancies. 
                                                 
3
 Again, directionality was not hypothesized due to mixed findings in the literature.   
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Research Question 2: What is the relative contribution of these psychosocial variables for 
predicting levels of treatment expectancies in an IBS sample?  
Hypothesis 2: This research question was largely exploratory, as not all variables 
had been empirically linked to treatment expectancies at the time 
of this study.  However, several hypotheses were made based on 
the literature review presented above.  For example, in accord 
with the general expectancy literature, past satisfaction with a 
similar treatment was hypothesized to be a strong predictor of 
current expectations of treatment.  In addition, personal illness 
attributions and the perceived focus of the preferred treatment 
(i.e., somatic vs. psychological) were hypothesized to be moderate 
predictors of current expectations to benefit from treatment.  
Research Question 3: Are there additional psychosocial variables that are commonly 
cited as contributing to one‟s expectations of treatment benefit in this context? 
Hypothesis 3: Due to the exploratory nature of this research question, no specific 
hypotheses were generated a priori.   
 Chapter 2 
 METHOD 
I. Overview of Studies  
 Prior to initiation of the main study, a pilot study was conducted to assess the 
credibility of three hypothetical treatment vignettes, and to ensure that the outcome 
expectancy ratings generated from these vignettes followed a relatively normal 
distribution and demonstrated adequate variance.   Many features of the two studies were 
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the same, including participant recruitment and inclusion criteria, informed consent 
procedures, vignette presentation, and the assessment of treatment expectancies and 
treatment preference.  These features will thus be described together in more detail in the 
following sections of this chapter.  Areas of departure in study methods will also be 
described.  In particular, the main study used only two of the hypothetical treatment 
vignettes, chosen based on results of the pilot study, and measured an expanded set of 
demographic and psychosocial variables. 
II. Participants 
A. Participant Recruitment (Pilot & Main Study) 
 The current research was focused on individuals with irritable bowel syndrome 
(IBS).  After securing clearance from the University of Windsor Research Ethics Board, 
participants were recruited to participate using recruitment messages posted on three 
types of websites, as well as in gastroenterology clinics for the main study.  First, 
websites designed to provide online support and information to individuals suffering 
from IBS were contacted.  In this instance, if appropriate, the IBS support site board 
moderator was contacted via email and presented with information about the study, a link 
to the study website and a request to post recruitment messages.  The information 
provided to the moderator is presented in Appendix A and contains information regarding 
the rationale and aims of the current study, data collection timelines, and informed 
consent and anonymity. The board moderator was asked to return an email to the study 
investigator providing written „consent to post.‟   
  The second venue for posting online recruitment messages was on social science 
Internet research sites.  Such sites usually follow a specific protocol for allowing study 
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recruitment messages to be posted; these protocols were observed in attempting to have 
this study‟s recruitment message posted.  The final Internet recruitment venue was online 
sites where researchers can post free classifieds advertisements to recruit participants, 
such as „craigslist.com,‟ and „kijiji.com.‟    
For the main study, participants were also recruited from gastroenterology clinics 
in major urban centres throughout Canada.  A list of gastroenterologists in one major city 
from each province was compiled from the College of Physicians and Surgeons online 
membership lists.  These gastroenterologists were contacted by phone in order to access 
an email address or fax number where a description of the study procedures, as well as a 
recruitment flyer, could be sent.  Each physician who provided a contact address was sent 
these materials and asked to participate in the study by posting the recruitment flyer in 
the waiting area of their office.  The phone script, the letter of study description and the 
recruitment flyer are presented in Appendix B.       
 The recruitment messages explained that the study was looking for individuals 
with diagnosed IBS to participate in a study interested in assessing factors that contribute 
to an individual‟s thoughts and beliefs about particular treatments.  The recruitment 
message also specified the predicted amount of time to complete the study, as well as the 
potential for remuneration.  Potential minimal remuneration for participation was offered 
in the form of a draw.  Participants were informed that at the end of the data collection 
period, participants would be selected at random to receive a 20 CAD (18 USD, 14 EUR, 
or 10 GBP) gift certificate to a major book retailer (e.g., Amazon.com).  The number of 
participants selected in the draw was two for the pilot study and ten for the main study.  
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Please note that the recruitment messages (for the pilot and main study) can be found in 
Appendix C.   
Participants were recruited for the pilot study over a 4-month period in early 
2007, and over a 9-month period for the main study.  Inclusion criteria specified that 
participants be over 16 years of age and have a diagnosis of IBS.  Verification of illness 
status was accomplished by having participants complete a self-report survey of the 
Rome III criteria for this diagnosis, which is the standard criteria for making this 
diagnosis, created by an international group of experts in functional gastrointestinal 
motility disorders.  The Rome III questionnaire of IBS criteria is presented in Appendix 
D, along with the diagnostic scoring procedures (Appendix E).  These criteria also allow 
for IBS sub-type diagnosis.  Individuals were excluded who a) did not meet criteria for 
IBS, b) who clearly responded to the study questionnaires in a random or careless 
fashion, or c) did not provide a response for at least 80% of study items.  Table 2 presents 
the percentage of respondents recruited from each venue for the pilot and main study. 
B. Participant Numbers and Characteristics (Pilot and Main) 
Of the 35 participants recruited for the pilot study and who completed the survey 
online, 31 met criteria for IBS and were retained in the dataset.  In the main study, a total 
of 358 participants were recruited; however, only 294 met inclusion criteria.
4
    
 
 
 
                                                 
4
 Five participants later excluded during data screening in results section, leaving N = 
289. 
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Table 2 
Source of Participant Recruitment by Percentage in Pilot and Main Study 
Source 
Study 
Pilot Main 
Online classifieds 
IBS support website 
Research website 
Friend / Relative referral  
Undisclosed 
Gastroenterology clinic 
64.5 
3.2 
22.6 
9.7 
0 
n/a 
73.1 
14.4 
6.1 
3.3 
2.5 
0.6 
General demographic characteristics.   
 Table 3 summarizes the demographic characteristics of the samples for both the 
pilot and main study.  In both samples, the majority of participants were women, 
Caucasian, well educated, employed full-time and residing in North America.  In the 
main sample, the majority of participants were married, whereas in the pilot sample, more 
participants had never been married.    
IBS-related demographic characteristics.  
 Table 4 presents IBS-related demographic characteristics of the pilot and main 
samples.  Although all participants met the Rome III criteria for a diagnosis of IBS, a 
small percentage of participants in both samples reported that they had not been 
diagnosed with IBS.  
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Table 3 
Demographic Characteristics of the Pilot and Main Samples 
Characteristic 
Sample 
Pilot Main 
N 31 294 
Sex (% [N]) 
Women 
 
28 (90) 
 
250 (85.0) 
Age 
M (SD) 
Range 
 
37.1 (13.5) 
20-63 
 
33.9 (11.4) 
16-68 
Country of residence (% [N]) 
USA 
Canada 
Europe 
Australia 
Other 
 
20 (64.5) 
7 (22.6) 
2 (6.5) 
2 (6.5) 
0 
 
143 (48.5) 
135 (45.9) 
13 (4.4) 
1 (0.3) 
1 (0.3) 
Ethnicity (% [N]) 
White 
Hispanic 
Asian 
Other 
Mixed 
East Indian 
Black 
 
25 (80.6) 
1 (3.2) 
1 (3.2) 
1 (3.2) 
1 (3.2) 
0 
2 (6.5) 
 
253 (86.1) 
10 (3.4) 
8 (2.7) 
8 (2.7) 
6 (2.0) 
5 (1.7) 
3 (1.0) 
Marital Status (% [N]) 
Married/ living with intimate partner 
Never married 
Separated/ divorced 
Widowed 
 
11 (35.5) 
14 (45.2) 
5 (16.1) 
1 (3.2) 
 
149 (50.7) 
116 (39.5) 
25 (8.5) 
3 (1.0) 
Level of Education (% [N]) 
High school   
College/ university  
Graduate 
 
5 (16.1) 
20 (64.5) 
6 (19.4) 
 
38 (12.9) 
190 (64.6) 
65 (22.1) 
Employment Status (% [N]) 
Full-time 
Not at all 
Part-time 
Disabled 
Student 
Retired 
 
14 (45.2) 
3 (9.7) 
7 (22.6) 
2 (6.5) 
5 (16.1) 
0 
 
152 (51.7) 
46 (15.6) 
42 (14.3) 
24 (8.2) 
24 (8.2) 
5 (1.7) 
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The majority of participants reported being diagnosed by a physician and having diarrhea 
predominant IBS (43.0%).  Interestingly, when IBS subtype was diagnosed based on the 
Rome III diagnostic criteria, the majority of both samples met criteria for alternating 
subtype IBS.  On average, in the main sample participants reported that they had 
symptoms of IBS for 11.4 years (SD = 9.18; range = 1-51) and had been diagnosed with 
IBS for 6.56 years (SD = 6.80; range = 1-18).   
Table 4 
IBS –Related Demographic Characteristics of the Pilot and Main Samples 
Characteristic 
Sample 
Pilot Main 
IBS diagnosis (% [N]) 
Yes 
No 
Undisclosed 
 
27 (87.1) 
3 (9.7) 
1 (3.2) 
 
269 (91.5) 
24 (8.2) 
1 (0.3) 
Source of diagnosis (% [N]) 
Physician 
Self 
 
26 (83.9) 
5 (16.1) 
 
251 (85.4) 
43 (14.6) 
History of misdiagnosis (% [N]) 
Yes 
No 
Undisclosed 
 
12 (38.7) 
19 (61.3) 
0 
 
76 (25.9) 
214 (72.8) 
4 (1.3) 
Self-report IBS subtype (% [N]) 
Constipation predominant 
Diarrhea predominant 
Alternating subtype 
Unknown 
 
4 (12.9) 
17 (54.8) 
9 (29.0) 
1 (3.2) 
 
56 (19.0) 
129 (43.9) 
91 (31.0) 
18 (6.1) 
Rome III IBS subtype (% [N]) 
Constipation predominant 
Diarrhea predominant 
Alternating subtype 
 
3 (9.7) 
8 (25.8) 
20 (64.5) 
 
23 (7.8) 
60 (20.4) 
211 (71.8) 
Years with symptoms  
M (SD) 
Range 
Years since diagnosed 
M (SD) 
Range 
 
12.6 (8.47) 
1 -35 
 
10.0 (9.5) 
1-35 
 
11.4 (9.2) 
1-51 
 
6.5 (6.8) 
1-18 
 72 
III. Procedures 
 After receiving permission to recruit participants on the target websites, brief 
recruitment messages were posted on each website.  The brief recruitment messages 
included a link to the University of Windsor server where the online survey study was 
hosted.  Interested individuals could click on the link provided in the recruitment message 
and be directed to the study homepage.  Here, potential participants were first informed 
that should they wish to participate in the study using hardcopy forms and surveys, they 
should indicate so by sending an email, containing their mailing address, to the principal 
investigator with „IBS Study‟ written in the subject line.   A study package (consent form 
and study survey) was then mailed to the participant along with a self-addressed postage 
paid return envelope.  In the main study, 11 participants requested a paper version of the 
survey; only one was returned and included in the dataset. 
Participants willing to participate in the online version of the study were directed 
to click on the „continue‟ button, which directed them to the consent form.  Participants 
were asked to read the informed consent form for the proposed study.  The consent forms 
(presented in Appendix F) contained information regarding the purpose of the study, the 
procedure, potential risks and benefits of participating, and the rights of the participant 
including withdrawal from the study without penalty.  In addition, participants were 
informed about the potential for remuneration, the exclusion criteria, the anonymous 
nature of the study, and the researcher‟s identity and contact information.  Participants 
were instructed that in order to participate, they must „click‟ on the box provided to 
indicate their informed consent.  After indicating their consent to participate, they were 
automatically directed to the first page of one of two versions of the survey that were 
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counterbalanced in terms of the order of presentation of the treatment vignettes and the 
study scales.  The link to the survey was set up to direct participants to one version of the 
two versions of the survey in a random fashion.     
 The following is an overview of the procedures involved in the current studies; 
more detailed descriptions of the specific measures and components are provided in the 
following section.  After providing information regarding their general and IBS-related 
demographic characteristics (Appendix G), participants were then asked to read vignettes 
detailing hypothetical treatment protocols for irritable bowel syndrome.  Following these 
vignettes there were several questions specifically regarding the treatment vignettes, 
including their expectation of benefiting from each treatment, and the treatment option 
that they would personally prefer.  In the pilot study, participants rated the credibility 
levels for each treatment vignette.  In the main study, participants were asked to complete 
a series of questionnaires (counterbalanced and each on their own webpage) that 
measured the independent variables of interest in the current study.  They were also 
presented with the opportunity to express, in a narrative fashion, their thoughts about 
what factors they felt contribute to their expectations of benefit for the treatment that they 
had chosen as their preference.  This is described further in the next section.  
 At the end of the survey participants in both studies were then given the 
opportunity to be included in the draw for potential remuneration.  It was explained that 
participation would remain anonymous even if they choose to be entered in the draw.  If 
they chose not to participate in the draw by clicking on the „No Thanks‟ button, they 
were thanked for their time and consideration, and participation was over.  An individual 
could choose to participate in the draw by clicking on the „Sign me up!‟ button.  This 
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action caused a pop-up window to open describing the options for draw participation.  
Specifically, participants were asked whether they would prefer to be contacted via mail 
or email should they be selected for remuneration.  It was described that at the time of the 
draw, the draw winners would be contacted by their preferred method to ascertain how 
they would prefer to receive remuneration.  Individuals who preferred to be contacted by 
email were asked to provide their email address.  Individuals who preferred to be 
contacted by mail were asked to provide their address, but to withhold their name.  In the 
latter case, a letter was sent to the „Study Participant‟ at the given address.  In either case, 
this first contact was used to inform selected individuals of their „winning status,‟ and to 
request that an email be sent to the study administrator indicating whether an electronic 
or a hard copy of the gift certificate was preferred, and in what currency (USD, CAD, 
GBP, Euro).  Participants were reassured that their contact information would be stored 
separately from their survey information to maintain the anonymity of their responses.  
Once contact information was entered, clicking the „submit‟ button registered this 
information in a designated data file on the server, and participants were directed to the 
„letter of explanation‟ page, which was designed to debrief participants about the purpose 
of the study.  At the end of the letter of explanation, participants were thanked for their 
time and consideration, thus ending study participation.  The letter of explanation can be 
found in Appendix H.  
IV. Measures 
A. Treatment Vignettes 
 Participants were asked to read hypothetical treatment vignettes while imagining 
they were participating personally in the scenario.  Treatment vignettes are presented in 
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Appendix I.  These vignettes were created by the author, and designed to represent a 
thorough and credible treatment planning and procedure scenario.  The first part of the 
vignette described a thorough clinical interview by a gastroenterologist, as well as the 
possibility for additional data collection as needed.  Research has found that individuals 
with IBS often feel that their treatment provider does not pay adequate attention to their 
illness experience (Chang et al., 2006; Dixon-Woods & Critchley, 2000), thus efforts 
were made to present the hypothetical specialist as being thorough.  Efforts were also 
made to describe the hypothetical provider and the interaction in a way as to minimize 
affective aspects of the relationship, in order to a) reduce demand characteristics (e.g., 
desire to please the provider) and b) allow participants to potentially project their own 
perceptions of such a provider into the scenario.  
It was then described that based on all the information that is provided, the 
participant would be assigned to one of the possible treatments for their IBS.  Each of the 
three treatment vignettes included a dietary consult along with dietary recommendations, 
as well as an educational component relating to what is currently understood about the 
biopsychosocial contributors to IBS symptom presentation (Barahmand, 2008).  These 
treatment components were emphasized in each treatment to increase treatment 
credibility, as they are accepted as the first plan of action in any treatment of IBS.  Over 
and above the dietary and educational components, each treatment vignette described a 
detailed treatment plan that contained a pharmacological approach, a psychological 
approach, or a combined pharmacological and psychological approach.  More than one 
treatment vignette was used as there are no accepted prescribed treatments for IBS at this 
time, and it is fairly well known that both pharmacological and psychological approaches 
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can be beneficial.  All treatment plans included comparable treatment timelines and 
regular monitoring by the provider, and were designed to provide equal amounts of 
information.  Each treatment was labeled using only a letter (i.e., Treatment A).  Three 
vignettes were presented in the pilot study, with the aim of choosing two vignettes to use 
in the main study (to reduce sample fragmentation). 
 The „pharmacological treatment‟ involved the prescription of one of two state-of-
the-art pharmaceutical drugs (depending on IBS subtype) designed to provide global 
symptom improvements.  The descriptions of the drugs included information about the 
drug‟s performance in clinical testing and potential side effects.  The drug information in 
this vignette was taken directly from reviews of current promising drug treatments for 
IBS (Gilkin, 2005; Tack, Fried, Houghton, Spicak & Fisher, 2006).  The drugs that were 
offered have been tested for use with either the diarrhea – predominant subtype (IBS-D) 
or the constipation – predominant subtype (IBS-C).  At the time of the study, there were 
no drugs of this caliber designed for use specifically with the alternating subtype (IBS-A; 
Gilken, 2005).  However, in the treatment vignette, it is indicated that one drug is 
designed for use with both IBS-C and IBS-A.  Although this is somewhat counterfactual, 
it is not incredible.  For example, research has found that individuals with alternating 
subtype IBS (25% of IBS sufferers), typically report symptoms very similar to those 
reported by IBS-C sufferers, with the exception of reporting defecatory urgency (Mearin, 
et al., 2003).  In addition, there have been very few pharmacological studies aimed at 
treating IBS-A specifically, and often the same agent is tested among IBS-C and IBS-A 
groups (Tack, et al., 2006).     
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 The „psychological treatment‟ involved a combined trial of cognitive-behavioural 
therapy and hypnotherapy.  The latter treatment was described only as relaxation training 
with guided imagery, as the term „hypnotherapy‟ has been found to produce biased 
responses in other studies (see Gandhi & Oakley, 2005).  These treatments were chosen 
as they have both been found to be effective in treating IBS in quantitative and narrative 
reviews of the literature (Blanchard, 2001; Blanchard & Scharff, 2002; Lackner, Mesmer, 
Morley, Dowzer & Hamilton, 2004; Whitehead, 2006).  The vignette provided 
information about the empirical support for this approach, and a description of the 
specific components of the treatment, modified slightly from a paper describing the 
successful use of this approach (Taylor, Read & Hills, 2004).  These first vignettes were 
counterbalanced in both studies.   
 The „combined treatment‟ involved the prescription of a pharmaceutical drug as 
well as a trial of cognitive-behavioural therapy.  This option was presented as it is 
accepted that a multimodal approach can be helpful (Levy et al., 2006; Spanier, Howden 
& Jones, 2003).  To minimize a false advantage to this treatment due to a dose-response 
phenomenon (i.e., larger expectations for this treatment because it provides more 
treatment than either of the others), this treatment offered the combination of smaller 
„doses‟ of the other treatments.  In particular, the subtype-specific drug was offered at a 
lower dose, specifically 50% of the dose offered in the pharmacological only treatment.  
The „relaxation training with guided imagery‟ component of the psychological treatment 
was removed, and fewer sessions of therapy were offered.  This vignette was used only in 
the pilot study; the rationale for excluding it is described in the results section.  
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B. Expectancy Ratings 
 After reading treatment vignettes, participants were asked to rate how much they 
expected those specific treatments to ameliorate their symptoms of IBS.  As is often done 
in placebo research (De Pascalis et al., 2002; Goosens et al., 2005; Price et al., 1999; 
Vase et al., 2003; Weinfurt et al., 2003), expectations were measured on a visual 
analogue scale (VAS).  The VAS is a horizontal line drawn from 0 (no expected benefit) 
to 10 (excellent expected benefit).  Participants indicated their level of expectation of 
benefit for each treatment by making a mark along such lines.  The expectancy rating 
scales are presented in Appendix J.        
C. Treatment Credibility 
 Treatment credibility, assessed only in the pilot study, was also measured using a 
VAS from 0 (not at all credible) to 11 (completely credible).  Participants were asked to 
rate the credibility of each treatment vignette by making a mark on the appropriate scale.  
The credibility rating scales are presented in Appendix K. 
D. Treatment Preference 
 Both in the pilot study and in the main study, participants were asked to indicate 
what their treatment preference would be, should they actually be participating in the 
hypothetical treatment scenario.  The rationale for this question was as follows.  
Hypothetically, the sample could be divided as to their preferred treatment scenario.  It is 
likely that preferred treatment would vary as a function of an individual‟s illness 
attributions, i.e., what they consider to be causing their IBS symptoms, or their recovery 
attributions, i.e., what type of treatment they consider to be the best approach to treating 
 79 
their IBS symptoms.  It is also likely that these attribution variables could influence one‟s 
expectations to benefit from a particular treatment.  For example, for an individual who 
considers their symptoms to be caused mainly by psychological factors, a 
pharmacological treatment may not be expected to be of much benefit.  On the other 
hand, for those who feel their symptoms are influenced mainly by organic causes, a 
psychological treatment may not be expected to be of benefit.  Without controlling for 
these likely important contributors to expectations of benefit, there is a risk that the 
majority of the variance in expectancies could be predicted by illness and/ or recovery 
attributions.  This would significantly limit the variance in expectations that may be 
predicted by other independent variables, and thus limit the utility of the study to 
accomplish its aims.  In order to avoid this situation, participants were given a choice of 
preferred treatment, and their expectations of benefit for this preferred treatment then 
served as the main dependent variable.  Furthermore, by using „expectations of benefit 
for preferred treatment‟ as the main outcome variable, data from the entire sample could 
be collated for analysis, preserving statistical power.       
E. Individual Difference Variables 
Self-focused attention. 
 Self-focused attention was measured using the Revised Self-Consciousness Scale 
(SCS-R; Scheier & Carver, 1985). The original scale (Fenigstein, Scheier & Buss, 1975) 
was comprised of 23 items that loaded on three subscales, the private self-consciousness 
subscale, the public self-consciousness subscale and a social anxiety subscale.  This scale 
was revised as it was found that the original wording was too abstract for non-college 
samples, thus it was revised for use with non-college samples.  For the purposes of the 
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present study, only the private self-consciousness subscale was used.  This subscale is 
designed to measure one‟s dispositional tendency to attend to inner thoughts and feelings, 
with higher scores indicating greater levels of self-focused attention.  There have been 
several studies examining the factor structure of the total scale, as well as the private self-
consciousness subscale (for a review see Martin & Debus, 1999).  Each study has 
confirmed that the private self-consciousness subscale can be divided into two related 
factors, although there is disagreement regarding how the items on the subscale should be 
divided and conceptualized.  The most commonly used factor structure contains a „Self-
reflectiveness‟ factor and an „Internal state awareness‟ factor.  Self-reflectiveness is seen 
as a disposition to think about the self; it contains 4 items thought to reflect negative 
private self-consciousness (Anderson, Bohon & Berrigan, 1996; Ben-Artzi, & 
Hamburger, 2001-2002).  Internal state awareness is seen as a dispositional awareness of 
one‟s inner feelings and states; it contains 3 items thought to reflect neutral or positive 
private self-consciousness.  
 This is the most popular measure of dispositional self-focused attention in the 
literature and the only one to differentiate between public and private self-focused 
attention.  It has been found to have adequate psychometric properties, with internal 
reliability ranging from .73 to .84, and test-retest reliability ranging from .77 to .79 
(Govern & Marsch, 2001; Martin & Debus, 1999; Mor & Winquist, 2002).  The Private 
Self-Consciousness Scale is presented in Appendix L. 
Trait anxiety. 
 Two separate scales were used to measure trait anxiety in the current study.  The 
Anxious Arousal subscale of the Mood and Anxiety Symptom Questionnaire (MASQ; 
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Watson & Clark, 1991) was used to capture the somatic anxiety symptoms that are 
unique to the construct of anxiety.  To capture the cognitive aspect of the anxiety 
disorders, the Penn State Worry Questionnaire was employed (PSWQ; Meyer, Miller, 
Metzger, & Borkovec, 1990).  The decision to use these two scales was based on two 
trends emerging in a growing literature regarding the measurement of anxiety and 
depression.  First, several studies have found that common measures of anxiety typically 
do not have adequate discriminant validity to distinguish between the constructs of 
anxiety and depression (e.g., Watson et al., 1995; Nitschke, Heller, Imig, McDonald & 
Miller, 2001).  For example, the commonly used State-Trait Anxiety Inventory (STAI; 
Spielberger, Gorsuch, Lushene, Vagg & Jacobs, 1983) has been shown to be more 
strongly related to general symptoms of distress, depression and negative affect than to 
measures more specific to anxiety (Nitschke et al., 2001).  In contrast, the Anxious 
Arousal subscale of the Mood and Anxiety Symptom Questionnaire has been found to 
have excellent discriminant validity across several samples (Keogh & Reidy, 2000; 
Nitschke et al., 2001; Ruth & Mehrotra, 2001; Watson et al., 1995).  Secondly, analysis 
of the symptom patterns among the anxiety disorders have demonstrated that cognitive 
anxiety (anxious apprehension or worry) is more characteristic of certain anxiety 
disorders (i.e., generalized anxiety disorder and obsessive-compulsive disorder), whereas 
somatic anxiety (anxious arousal) is more characteristic of other anxiety disorders (e.g., 
panic disorder, specific phobias; Andrews & Borkovec, 1988; Nitschke, Heller, Palmieri 
& Miller, 2000).  A recent study has confirmed that anxious apprehension (as measured 
by the PSWQ) is relatively unrelated to anxious arousal (measured using the MASQ-AA) 
and Anhedonic Depression (depression-specific symptom subscale of the MASQ; 
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Nitschke et al., 2001).  In light of these findings, it is reasoned that the use of these two 
separate anxiety subscales was best able to capture the specific symptom clusters of trait 
anxiety that present in various anxiety disorders and have also been found to be distinct 
from symptoms that are unique to the presentation of depression.   
 The Anxious Arousal subscale of the MASQ (MASQ-AA) consists of 17 items 
that represent symptoms that, as mentioned, are relatively unique to the somatic arousal 
aspects of the construct of anxiety.  Respondents indicated to what extent they have 
experienced each symptom on a 5-point scale ranging from 1 (not at all) to 5 (extremely), 
with a higher score indicating more anxious arousal.  To capture a more stable „trait‟ 
aspect of anxious arousal, respondents were asked to complete each item while 
considering to what extent they experience each symptom „generally.5‟  This subscale has 
been found to have good internal reliability (Cronbach‟s alpha = .86 - .90; Watson et al., 
1995).  The MASQ-AA is presented is Appendix M.         
 The Penn State Worry Questionnaire (PSWQ) was designed as a measure of trait 
worry for general use.  It contains 16 items; respondents indicate to what extent each 
statement applies to them on a 5-point scale ranging from 1 (not typical of me) to 5 (very 
typical of me).  Several items are reverse scored and a higher sum score represents 
greater levels of trait anxious apprehension.  The scale has been found to have excellent 
psychometric properties (internal reliability = .93; test-retest = .92) and good convergent 
and discriminant validity (Meyer et al., 1990; Nitschke et al., 2001).  The PSWQ is also 
presented in Appendix M.     
                                                 
5
 Using a „general‟ frame as opposed to a specific time frame (i.e. in the last week) is how 
the STAI distinguishes the trait versus the state version of the scale.   
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Optimism / Pessimism.  
 Dispositional optimism and pessimism were measured using the popular Life 
Orientation Test – Revised (LOT-R; Scheier, Carver & Bridges, 1994). The scale was 
originally designed to assess optimism and pessimism as a bipolar unidimensional 
construct with high scores representing optimism and low scores representing pessimism.  
However, the authors of the LOT-R also reported that the optimism and pessimism items 
could be used in analyses as separate constructs.  There has been a fair amount of 
research that confirms that the LOT-R is best considered to  measure optimism and 
pessimism as two related but distinct constructs (e.g., Creed, Patton, Wendy & Bartrum, 
2002), including a large sample confirmatory factor analysis with findings consistent 
across gender, age and medical diagnosis (Herzberg, Glaesmer & Hoyer, 2006). 
This scale has 10 items; three positively worded optimism items, three negatively 
worded pessimism items and four filler items.  Respondents indicated their level of 
agreement with each item on a four-point scale from 1 (strongly disagree) to 4 (strongly 
agree).  Subscale (optimism or pessimism) scores were calculated by summing the scores 
for each item on that subscale. These subscales have demonstrated only adequate internal 
reliability (Cronbach‟s alpha = .71 & .68 for optimism and pessimism, respectively; 
Herzberg et al., 2006). The LOT-R is presented in Appendix N.       
Hope. 
 Hope was measured using the Adult Hope Scale – Trait version, considered a 
measure of dispositional hope (AHS; Snyder et al., 1991).  The scale represents the 
conceptualization of hope as consisting of a successful sense of agency (goal-related 
determinism; 4 items) and pathways (ability to generate means to reach goals, 4 items).  
 84 
Respondents indicated the veracity of each statement (including 4 filler items) on an 8-
point scale ranging from 1 (definitely false) to 8 (definitely true).  A total hope score was 
calculated by summing the scores for each of the 8 hope items.  Factor analytic studies 
have confirmed that the scale consists of an overarching hope construct and two 
underlying factors (Babyak, Snyder & Yoshinoba, 1993).  Internal consistency has been 
found to be good (Cronbach‟s alpha = .74 to .84) and the scale has been reported to have 
good test-retest reliability (.85).   The two subscales are moderately correlated in clinical 
samples (r = .46 - .57; Steed, 2002).  The Adult Hope Scale is presented in Appendix O.              
F. Health Belief Variables 
Current health. 
 Current health was assessed by asking about participants‟ perception of their 
health as well as about their current health problems.  To measure „Perceptions of 
Health,‟ three questions were used, adapted from questions used in previous research 
with illness groups (Sirois, 2003).  These questions asked participants to rate: 1) How 
good their health is relative to others their age, 2) How good their health is relative to 
others with IBS, and 3) In general how they would rate their health.  Participants 
indicated their perceived health for each item on a 5-point scale ranging from 1 (very 
poor) to 5 (excellent).  A total score was calculated by summing scores for the individual 
items.  It has been established that brief measures of overall health such as this are highly 
reliable and strongly correlated with other measures of health, such as physicians‟ 
assessments (Kubzansky, Kubzansky & Maselko, 2004).  These items are presented in 
Appendix P.  
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 As another measure of current health, participants were asked to complete a brief 
health history checklist.  This measure had participants indicate with a check the presence 
of acute / transitory health problems experienced in the last six months.   This second 
current health variable, „Acute health problems‟ represented the sum of the health 
problems endorsed on this checklist.  The Brief Health History Checklist (Sirois & Gick, 
2002) is presented in Appendix Q.   
Control Beliefs. 
 Health-related control beliefs were measured using two subscales of the Control 
Beliefs Inventory (CBI; Sirois, 2003).  The six-item general control subscale measured 
perceived control over health in general.  A sample item from this subscale is “If I set my 
mind to it, I can improve my health.”  This subscale correlates highly (r = .73) with the 
internal locus of control subscale of the Multidimensional Health Locus of Control Scale 
(Wallston, Wallston & De Vellis, 1978), but it is free from the self-blame bias found in 
the traditional scale.  Internal consistency has been found to be good in samples with 
various chronic health conditions (Cronbach‟s alpha = .85 - .91; Sirois, 2003; Sirois, 
Davis & Morgan, 2006). 
 Perceived control over symptoms was assessed with the five-item symptom 
control subscale of the CBI.  This scale assessed the perceptions that one can manage the 
symptoms of a specific illness (here, IBS).  For this study, participants were instructed 
that the term „symptoms‟ refers specifically to IBS symptoms.  Sample items include „If I 
make the effort, I can manage my symptoms‟ and „There are things that I can do to make 
my symptoms easier to deal with.‟  This scale has demonstrated good internal consistency 
with alphas ranging from .80 to .89 in chronic health samples (Sirois, 2003).  For both 
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subscales, participants were asked to rate their agreement with each item on a six-point 
scale ranging from 1 (strongly disagree) to 6 (strongly agree).  Higher scores represent 
greater perceived control over one‟s health in general and one‟s symptoms, respectively.  
These two subscales are presented in Appendix R.          
Self-Efficacy. 
 Health-related self-efficacy was measured using the Health Efficacy subscale of 
the Control Beliefs Inventory (CBI; Sirois, 2003).  This 8-item scale assessed feelings of 
competence and confidence to carry out actions important for maintaining and taking care 
of one‟s health.  Five items are scored in the positive direction and three items are 
reversed scored.  Respondents rate the extent to which each statement applies to them on 
a 6-point scale ranging from 1 (strongly disagree) to 6 (strongly agree).  This scale has 
been found to have good psychometric properties; internal consistency is high in various 
chronic health conditions (Cronbach‟s alpha = .82 - .86), and it shows good convergent 
validity (Sirois, 2003; Sirois, Davis & Morgan, 2006).  A total self-efficacy score was 
calculated by summing the scores for each item, with higher scores representing higher 
levels of self-efficacy.  The Health Efficacy subscale is presented along with the other 
Control Beliefs Inventory subscales in Appendix R.   
 Coping self-efficacy was assessed using three questions regarding how well 
participants were coping with their IBS.  This Coping Efficacy scale (Gignac, Cott & 
Badley, 2000) has been used in research regarding adaptation to chronic illness, and was 
found to have adequate internal reliability (Cronbach‟s alpha = .79).   Respondents rated 
their agreement with each coping question on a 5-point scale ranging from 1 (strongly 
disagree) to 5 (strongly agree).  Total scores were calculated by summing the score for 
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each item, with higher scores representing greater levels of coping.  The Coping Self-
efficacy scale is presented in Appendix S. 
Vulnerability to Illness. 
 Beliefs about vulnerability to illness refer to the extent that individual feels that 
they are vulnerable to health problems.  To measure this health belief variable, the 
Resistance to Illness subscale of the Health Perceptions Questionnaire was used (Ware, 
1976).  Participants rated their agreement with each of four items (e.g., „I seem to get sick 
a little easier than other people) on a 5-point scale from 1 (definitely false) to 5 (definitely 
true).  Two of the items are reversed scored; a total score is the sum of scores on each 
item, with higher scores indicating greater „vulnerability to illness.‟ Although the 
psychometric properties of this scale are only adequate (internal consistency = .71; test-
retest reliability = .73), this subscale is the only published English scale to measure 
general beliefs about perceived vulnerability to illness.  This subscale is presented in 
Appendix T.  
Catastrophizing. 
 The tendency to catastrophize about bodily sensations and symptoms was 
measured by the Catastrophizing Interpretation of Bodily Complaints (CIBC) subscale of 
the Cognitions about Body and Health Questionnaire (Rief, Hiller & Margraf, 1998).  
This 14-item scale contains a series of statements about the interpretation of bodily 
complaints and asks the respondent to indicate the accuracy of such statements on a 5 -
point scale from 0 (completely wrong) to 4 (completely right).  A total score was 
obtained by summing the scores for each item, with higher scores representing an 
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increased tendency to catastrophize about bodily sensations and symptoms.  This scale 
has been shown to have good internal consistency in a clinical sample (Cronbach‟s alpha 
= .88), and to have good construct validity (Rief et al., 1998).  The CIBC subscale is 
presented in Appendix U.  
G. Context-Dependent Variables 
Treatment Experience. 
Participants‟ previous experiences with treatment were measured using several 
author-created questions.  The main measure of the influence of previous treatment 
experience was labeled Previous satisfaction with preferred treatment.  First participants 
were asked to recall one of the treatment plans presented in the vignettes (e.g., drug 
treatment), and were asked if they had previous experience with a similar treatment.  If 
they responded in the affirmative, they were directed to rate their satisfaction with that 
treatment on a visual analogue scale from 0 (not at all successful) to 10 (completely 
successful).  They were also asked a similar question about the other treatment plan (e.g., 
psychological treatment).  The response that corresponded to the treatment they chose as 
their „preferred‟ treatment was then used to create the variable Previous satisfaction with 
preferred treatment.  
   As a second measure of treatment experience, participants were also asked 
about current and past treatments.  A list of common treatments for IBS was presented 
and participants were asked to check off any treatments they were currently using.  
Participants were also asked to rate their satisfaction with each treatment on a 6-point 
scale ranging from 1 (very dissatisfied) to 6 (very satisfied).  Following this section was 
an identical section pertaining to past treatments.  Several indices were calculated from 
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these items, including: Number of current treatments and Satisfaction with current 
treatments, Number of past treatments and Satisfaction with past treatments.  Finally, 
participants were asked whether or not they had previously been treated by a 
gastroenterologist, and to rate satisfaction with this treatment on a 5-point scale ranging 
from 1 (not satisfied) to 5 (extremely satisfied).  These items are presented in Appendix 
V.      
IBS Symptom Attributions. 
 Symptom attributions refer to what an individual perceives to be the cause(s) of 
their illness-specific symptoms.  For example, illness-specific symptoms may be 
attributed to physical/ somatic causes (such as genetics, bacteria, viruses, structural 
abnormalities, etc) or to psychological causes (such as stress or anxiety).  Individuals 
may also attribute their symptoms to a combination of somatic and psychological causes, 
or to more transitory causes (poor sleep, diet changes, lack of exercise, etc).  Two 
questions were used to assess participants‟ personal illness attributions for their 
symptoms of IBS.  These questions present a particular symptom of IBS and are followed 
by three explanatory statements that describe a somatic, psychological or transitory 
reason for the symptom.  (Two filler questions also were presented that describe non-IBS 
symptoms).  For each statement, respondents indicated on a 10-point VAS how much 
they felt that the reason explained each symptom from 0 (Not at all true) to 10 (Very 
much true).  Averaging ratings across the two questions resulted in two variables labeled 
Somatic symptom attribution and Psychological symptom attribution.  These symptom 
attribution items are presented in Appendix W.    
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Perception of Treatment Focus. 
 Further taking into account individuals‟ different illness / symptom attributions, 
participants were asked to identify how much they perceived their preferred treatment as 
targeting the somatic or psychological causes of IBS.  Two 10-point visual analogue 
scales were used to measure these perceptions.  On one scale, labeled „Perceived somatic 
focus of treatment,‟ participants were asked to indicate how much they believed that the 
treatment targeted the physical causes of IBS from 0 (not at all true) to 10 (very much 
true).  On another scale, labeled „Perceived psychological focus of treatment,‟ they were 
asked to indicate how much they perceived that their preferred treatment targeted the 
psychological causes of IBS.  These items are presented in Appendix X.  
Motivation. 
 There are three aspects of motivation that were assessed in the current study.  The 
first aspect is motivation to benefit from treatment, or Desire for relief.  This was 
measured similarly to how it has been measured in placebo research, on a visual analogue 
scale (VAS; Price et al., 1999; Vase et al., 2003).  Participants were asked to indicate on a 
10-point VAS: „How strong is your desire to see relief from your IBS symptoms at this 
time?‟   
As a second measure of motivation/ desire for relief, current IBS Symptom 
Severity was also assessed. A 7-item scale was used to assess the severity of participant‟s 
IBS symptoms within the last week (Dancey, Whitehouse, Painter & Backhouse, 1995) 
on a 8-point scale ranging from 0 (no symptoms) to 7 (extremely severe).  A mean score 
was calculated, with higher scores indicating more severe IBS symptomotology.  Internal 
consistency has been found to be acceptable, Cronbach‟s alpha = .74.  To complement 
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this aspect of motivation, participants were also asked, “To what extent has IBS affected 
your daily activities” and were directed to respond on a 4-point scale from 1 (not at all) to 
4 (a lot).  These items are presented in Appendix Y. 
 The third aspect of motivation that was examined concerns the general area of 
demand characteristics.  This refers to a subject‟s perception of what the experimenter‟s 
hypotheses might be, along with the participants‟ desire to help confirm those 
hypotheses, or otherwise „please the experimenter.‟  There are currently no self-report 
survey measures to assess the impact of demand characteristics.  To approximate an 
assessment of this motivational factor, this study first attempted to minimize demand 
characteristics, and second measured participants‟ tendency towards socially desirable 
responding.  Demand characteristics were minimized through the use of neutral language 
in the recruitment messages, consent forms and treatment vignettes.   
 Socially desirable responding was measured using the newly developed Social 
Desirability Scale – 17 (SDS-17; Stober, 1999).  This scale was developed to address 
criticisms and overcome the limitations of the two currently most popular measures of 
social desirability, the Marlowe-Crowne Social Desirability Scale (Crowne & Marlowe, 
1960) and the Balanced Inventory of Desirable Responding (Paulhus, 1998).  Although 
popular, both of these measures have been criticized for having weak psychometric 
properties (see Barger, 2002; Leite & Beretvas, 2005; Pauls & Crost, 2004).  The SDS-17 
contains 16 true-false items.  High scores represent a greater tendency to present oneself 
in a desirable light.  It has been found to be internally reliable (KR-20 = .70 to .92) and to 
have good construct validity (Blake, Valdiseei, Neuendorf & Nemeth, 2006; Stober, 
2001).  This scale is presented in Appendix Z.      
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Patient-Provider Relationship. 
 Perceived quality of the patient-provider relationship was measured using a 
modified version of the Patient Reactions Assessment (PRA; Galassi, Schanberg, & 
Ware, 1992).  This 15-item measure contains three subscales, each of which is designed 
to assess an important component of the patient-provider relationship.  The Patient 
Information Index (PII) contains items concerning the quality and clarity of the 
information provided to the patient with regards to a specific treatment.  For example, 
items query whether the patient feels that the treatment procedure has been clearly 
explained, whether potential side effects are adequately understood.  The Patient 
Affective Index (PAI) assesses socio-emotional aspects of the relationship and includes 
items regarding the perceived warmth and interest of the provider, and the patient‟s 
comfort discussing personal issues, etc.  The Patient Communication Index (PCI) 
contains items assessing the perceived ease with which the patient can solicit or provide 
additional information regarding symptoms or the treatment.  Coefficient alpha for the 
15-item PRA was .91.  For the PII, PCI, and PAI, the values are .91, .90, & .87, 
respectively.  Respondents were asked to respond to each item on a 5-point scale ranging 
from 1(strongly disagree) to 5 (strongly agree), and total scores are computed by 
summing the item scores.   
 For the proposed research, this measure was modified to reflect the hypothetical 
nature of the treatment scenario.  Participants were asked to respond to items while 
considering how they imagine the patient-provider interaction would occur.  Because the 
treatment vignettes do not provide enough information to respond to each item, it is likely 
that participants‟ implicit beliefs were activated in completing this measure, or their 
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beliefs formed through previous treatment experiences, if applicable.  The modified 
version of the PRA is presented in Appendix AA.    
H. Qualitative Component 
 In the main study, a narrative regarding factors that may contribute to 
expectations of benefit was requested from participants.   A single open-ended question 
was used.  The purpose of this question was to have participants express, in a narrative 
format, what they thought influenced their expectations of treatment benefit.  The 
question was designed to elicit responses that do not only focus on treatment or situation-
specific variables (e.g., preference for the treatment type), but also on personal 
psychosocial variables.  Participants were provided with a blank space in which to write 
their responses.  There was no word limit for this question.  The specific question was as 
follows: 
 People have different reasons for why they expect treatments to work.  
 Often people have unique characteristics, such as their personal history, 
personality or beliefs that affect their expectations about whether treatment will 
work.  Some characteristics may increase expectations while some may decrease 
expectations.  Either way, we think it is important to learn more about these 
unique characteristics so we can better understand people‟s expectations about 
treatment.  
  
Think back to the treatment that you chose earlier as the one that you preferred.  
Think back to whether you thought it would work well for you or not.   
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In the space provided, we would appreciate if you could share your thoughts by 
answering the following question:  Why did you think that that treatment may or 
may not work for you?  Try to keep in mind how your personal characteristics 
may influence your opinion.   
V. Data Analyses 
A. Preliminary Analyses 
After data screening, descriptive analyses were run on all main variables and tests 
of mean differences were run on the main dependent variable to assess for possible order, 
gender, IBS subtype and recruitment source effects.  Simple analyses were conducted to 
compare the mean expectations of benefit for the preferred treatment among those who 
prefer one treatment or the other.  There were no mean differences on levels of 
expectation for preferred treatment between those preferring one treatment vs. the other.  
Thus, a new dependent variable was created capturing participant‟s expectations to 
benefit from their preferred treatment, also referred to as „treatment expectancies.‟ 
B. Analysis of Hypothesis One 
 A series of Pearson zero-order correlations between the independent and 
dependent variables were used to test the hypotheses that each of the measured 
independent variables would be correlated with the main dependent variable.  
C. Analysis of Hypothesis Two 
 Hierarchical multiple regression analysis was used to answer the second research 
question regarding the relevant contributions of these psychosocial variables for 
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predicting levels of treatment expectancies.  All independent variables identified as 
having a significant zero-order correlation with the dependent variable were included in 
the regression in three steps.  Relevant individual difference variables were entered in the 
first step, relevant health belief variables were entered in the second step, and relevant 
context- specific psychosocial variables were entered in the last step.  The rationale 
behind this hierarchy is as follows.  Individual difference variables are thought to be the 
most stable of the psychosocial variables being tested in the model.  These are the 
variables that are presumed to be context-independent and have been theorized to alter 
treatment-specific expectations through their effects on cognitive processing, particularly 
attention.  Health belief variables were entered in the second step as they are presumed to 
exert an influence on context-specific expectations in conjunction with/ conditional upon 
the role of individual difference variables (Sirois, 2001, 2009).  Furthermore, there is also 
the least amount of empirical support for the relationship between these variables and 
treatment expectations; including them in the second step allows for an assessment of 
what they contribute over and above the stable individual difference variables.  The 
context-dependent variables (e.g., previous treatment experiences, perception of 
treatment focus, patient-provider relationship) were entered in the final step of the 
regression.  These variables were hypothesized to be strongly related to treatment 
expectancies, due in part to their context-specific relevance to „expectations about the 
current treatment‟ and based on prior theory and research.  Including them in the last step 
allows for this research to identify which of the more internal psychosocial variables 
remain significant predictors of treatment expectancies after these presumably strongly 
relevant variables are included in the model.    
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In order to ascertain the relative importance of each independent variable in 
predicting variance in the dependent variable, a number of indicators were examined.  
The standardized regression coefficients (beta weights) and the associated significance 
levels were examined to ascertain the contribution of each IV to the DV while the other 
IVs are held constant.  This allowed for a comparison of the relative predictive power of 
each IV.  The squared semipartial correlations (and their significant levels) were also 
examined, as they reflect the amount of unique and joint variance explained by each IV 
when other IVs are held constant.  The joint variance is important to consider, as some of 
these variables will likely be correlated with each other and thus contribute joint variance 
to the DV.      
D. Analysis of Research Question Three 
 The third main research question concerned the narrative data that was solicited 
from participants regarding their thoughts about what influenced their expectations of 
treatment benefit.  Two independent raters examined the qualitative responses from a 
random sample of 100 participants from the total sample.  Responses ranged in length 
from a few words to a few sentences.  The transcripts were read multiple times by the 
principle investigator and a trained graduate student, guided by the research question 
regarding whether there were additional psychosocial variables, over and above the 
variables identified as potentially relevant throughout the literature review in Chapter 1, 
that are commonly cited as contributing to one‟s expectations of treatment benefit.  The 
responses were first explored deductively through a qualitative content analysis. 
Responses were deductively tagged for common themes and placed in pre-defined 
conceptual categories, specifically corresponding to the pre-identified independent 
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variables.   In addition, responses were reviewed in search of emergent categories that 
became apparent in the data but that did not fit into any of the preset categories.  The goal 
of this conceptual analysis was to a) enumerate the number of references made to each of 
the pre-set categories and to b) identify themes as they emerged from the data that 
represented „additional psychosocial variables‟ related to treatment expectations.  
Discrepancies were discussed and consensus about category codes was reached.  Cohen‟s 
(1960) kappa (K), which corrects for agreement by chance, was used to assess inter-rater 
reliability of the coding categories.  The percent agreement was 88.9%, with Cohen‟s 
kappa = .88, which indicates very good agreements beyond chance (Fleiss, 1981).   The 
final coding manual includes (a) a list of all categories (independent variables plus 
emergent categories), (b) definitions of each category, and (c) examples of each category 
(see Appendix AB).  
 Chapter 3 
 RESULTS  
The results of the statistical analyses are presented in four sections of this chapter.  
The first section presents results of the pilot study.  The second section presents the steps 
taken to clean and normalize the dataset.  The third section outlines preliminary analyses 
conducted to assess scale reliability, order and gender effects, the identification of 
potential confounds and the creation of one main dependent variable.  This section 
includes information about participant treatment experiences.  The analysis of the main 
hypotheses is presented in the fourth section, and includes supplementary analyses.   
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I. Pilot Study Results   
A. Selection of Treatment Vignettes 
The selection of two treatment vignettes for use in the main study was informed 
through the examination of the distribution of treatment expectancy scores for each of the 
three treatment vignettes and of the treatment preferences of the pilot sample.  
Exploratory analyses were conducted to examine the distribution of expectancy ratings 
for each treatment vignette.  Descriptive statistics, presented in Table 5, indicate that 
expectancy ratings were normally distributed for each treatment vignette.  Shapiro-Wilk 
tests for normality confirmed the normality of these distributions.  
Table 5 
Descriptive Statistics for Treatment Expectancy Scores Across Pilot Treatment Condition  
Treatment 
Condition M SD Variance Skew/ SE Kurtosis/ SE 
Pharmacological 5.52 2.48 6.12 -.55 -1.17 
Psychological 5.23 2.76 7.65 .32 -1.31 
Combined 6.03 2.87 8.23 -.56 -1.37 
 
Frequency analyses were then conducted to examine participants‟ preferences 
among the three possible hypothetical treatments.  Figure 2 illustrates that only 3% of the 
sample chose the combined treatment as their least preferred treatment (shown in the 
right-most cluster on the graph). 
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Figure 2. Treatment preferences in order of choice in pilot sample. 
Thus, the majority of participants chose the combined treatment as either their 
first or second choice.  Although it may seem counterintuitive, this is the vignette that 
was excluded from the main study.  The rationale for this choice is as follows.  It was 
preferable that the two vignettes employed in the main study generate an approximately 
equal split in the sample of participants preferring one or the other treatment.  Also, it 
was desired that the treatment vignettes generate a full distribution of treatment 
expectancy scores and scores on the measures of „perceived somatic/ psychological 
focus‟ of treatment.  Therefore, it was decided to employ the pharmacological (Drug) and 
psychological (CBT plus relaxation) treatment vignettes as the two vignettes in the main 
study.  It was thought that if the combined treatment (strongly preferred in the pilot 
study) was presented in the main study, this treatment would be again strongly preferred, 
potentially creating skewed distributions of treatment expectancies, losing some variance 
in the dependent variable and inhibiting to power to examine the influence of attributions 
on expectations of treatment benefit. 
B. Examining Treatment Credibility 
Another component of the pilot study analyses was looking at the relationship 
between treatment credibility and expectation to benefit from treatment.  The purpose of 
this analysis was to serve as a manipulation check to confirm that the treatment vignettes 
were credible as veritable potential IBS treatment scenarios.   
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The distributions of treatment credibility ratings for each treatment were first 
examined and all were normally distributed.  Correlation analyses revealed that 
credibility ratings (range = 1- 11) were moderately to strongly positively correlated with 
ratings of expectation of benefit (Drug treatment: r = .625, p < .001; CBT: r = .739, p < 
.001; Combined treatment: r = .871, p < .001).  These results indicate that an individual‟s 
expectation of benefiting from treatment is related to the individual‟s judgment regarding 
the credibility of that treatment for their condition, and confirm the credibility of the 
treatment vignettes.  
II. Participant and Dataset Screening 
A.  Participant Screening 
An initial sample of 358 participants provided data.  All subjects were over 16 
years of age.  A total of 62 participants did not meet the inclusion criteria and were 
excluded from the study.  Specifically, 53 respondents were removed from the dataset as 
they did not meet the Rome III criteria to qualify for a diagnosis of IBS.  In addition, 8 
participants failed to complete at least 80% of survey items and 1 participant who had 
clearly responded in a careless fashion were removed from the dataset.  This left 296 
participants in the dataset (17.3% bad data).   
B. Data Screening 
All main variables were examined through various SPSS programs for accuracy 
of data entry, missing values, and fit between their distributions and the assumptions of 
multivariate analysis.  The majority of variables were missing values on some cases.  For 
variables missing less than 5% of cases (all but two variables, described below), SPSS 
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missing value analysis (MVA) was run and values for missing cases were imputed using 
expectation maximization (EM) method.  As part of this procedure, Little‟s MCAR Chi-
square statistic was found to be non-significant, indicating that missing values on these 
variables were indeed missing in a random fashion. 
The two variables missing values on more than 5% of cases were „Years since 
diagnosis‟ and „Years with symptoms.‟  As these two variables were not main variables 
of interest, the decision was made to exclude these variables from the analysis of main 
hypotheses.  
Exploring the distributions of the main variables revealed that several variables 
displayed significant skew and /or kurtosis, and that many also contained univariate 
outliers.  Variables that displayed both departures from normality as well as outliers were 
transformed to improve normality before addressing outliers.  Reflection and square root 
transformation was applied to 8 variables to improve moderate negative skew
6
.  
Reflection and inverse transformation was applied to one variable to correct severe 
negative skew (Desire for relief).  One variable with moderate positive skew was 
transformed using square root transformation (Number of current treatments used). 
Finally, three variables with substantial positive skew were corrected using logarithmic 
transformation (Number of past treatments used, Satisfaction with gastroenterologists, 
Anxious arousal).  For seven of these variables, transformation eliminated univariate 
outliers, whereas for five variables, outliers remained despite improvements in normality 
(Number of current treatments used, Number of past treatments used, Satisfaction with 
                                                 
6
 Variables include: Treatment expectancy: CBT, Treatment expectancy: Drug, Perceived 
somatic focus of treatment, Perceived psychological focus of treatment, IBS: Interference 
in daily activities, Satisfaction with current treatments, Control over health, Control over 
symptoms.   
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current treatments, Control over health, Control over symptoms).  Standardized (z) scores 
were calculated for these univariate outliers and none were found to be in excess of 3.29, 
the criterion recommended Tabachnick and Fidell (2001). Thus these outliers were left in 
the dataset as is.     
Univariate outliers were also identified on seven variables that were otherwise 
normal
7
.  Again, a standardized (z) score was calculated for each outlier; five cases with 
standardized scores greater than 3.29 were identified.  To improve variable distributions 
while maintaining sample size, the „deviance‟ of these cases was minimized, as 
recommended by Tabachnick and Fidell (2001).  This was accomplished by assigning the 
outlying cases a raw score on the offending variable that was one unit larger (or smaller) 
then the next most extreme score in the distribution.  Variables containing cases that were 
minimized include: Patient-provider relationship (2), Socially desirable responding (1), 
Hope (1) and Symptom severity (1).   
With transformed variables in the variable set, two cases were identified as 
multivariate outliers by using Mahalanobis distance with p < .01.  Both cases were 
deleted, leaving 294 cases in the dataset.  Pairwise linearity and homoscedasticity was 
checked using bivariate and residual scatterplots and was found satisfactory.     
III. Preliminary Analyses 
Before proceeding to analyses of main hypotheses, several preliminary analyses 
were performed.  This included creating new variables that would control for treatment 
preference, further examining the distributional and psychometric properties of main 
                                                 
7
 Variables include: IBS symptom severity, Perception of health, Socially desirable 
responding, Hope, Health self-efficacy, Catastrophizing, Patient-provider relationship. 
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variables in the dataset, and checking for possible confounding variables (e.g., gender and 
order effects).  These analyses are presented in this section.  
A. Treatment Preference Variables 
To minimize the impact of treatment preference while exploring the relationships 
between treatment expectancies and individual psychosocial variables, a new dependent 
variable was created, labeled Expectancy for preferred treatment.  This variable 
represents participants‟ treatment expectancy ratings for the treatment that they reported 
that they would prefer based on the two treatment vignettes.  Participant treatment 
preference was split nearly equally between those preferring psychological treatment 
(CBT; 48.6%) and those preferring the pharmacological treatment (Drug; 51.1%).  A 
univariate GLM (general linear model) was run to test for mean differences in preferred 
treatment expectancy ratings across groups preferring one or the other treatment.  This 
confirmed the null hypothesis that the mean treatment expectancy rating among those 
preferring CBT (M = 6.75, SD = 2.11) was not significantly different from the mean 
rating among those preferring the Drug treatment (M = 7.00, SD = 1.81), F (1,292) = 
1.25, p = ns.  The two treatment preference groups were thus combined into one main 
sample with Expectancy for preferred treatment as the main dependent variable.  The 
distribution of Expectancy for preferred treatment was found to be negatively skewed 
(skew/ SE of skew = -5.00) and to contain outliers (9 > = 3.00).  Reflection and square 
root transformation was applied to this variable, which improved skewness (skew/ SE of 
skew = 0.36) but did not eliminate outliers.  Five of these outliers with standardized (z) 
score greater than 3.29 were deleted from the dataset, leaving a total sample size of 289.  
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As described above, based on participants‟ reports of past experience and 
satisfaction with their preferred treatment, a variable labeled „Previous satisfaction with 
treatment‟ was created.  Although 120 participants had reported experience with drug 
treatment, and 68 participants had reported experience with CBT treatment, only 93 
participants reported that they had had experience with their „preferred‟ treatment.  The 
distribution of this variable (Previous satisfaction with treatment) was adequate and 
contained no outliers.  
B. Participant Treatment Experiences   
 Table 6 provides a summary of participants‟ treatment experiences.  Participants 
reported that they used an average of 2.74 current treatments (SD = 2.00; range = 0-12) 
and 2.42 past treatments (SD = 2.42; range = 0-12).    The most popular treatments were 
„diet changes‟ (current = 78.9%; past = 57.8%) and the use of „laxative/ antidiarrheals‟ 
(current = 43.5%; past = 48.3%).  Average satisfaction ratings were calculated among 
those who reported current or past treatment use (n = 254, n = 230, respectively).  
Participant‟s average satisfaction with their current treatments was between „mildly 
dissatisfied‟ and „mildly satisfied‟ (M = 3.64; SD = 1.23; range = 1-6) and their 
satisfaction with past treatment was between „dissatisfied‟ and „mildly dissatisfied‟ (M = 
2.89; SD = 1.39; range = 1-6).  The highest satisfaction ratings among both current and 
past treatments were for „diet changes,‟ making this treatment strategy both the most 
common and perceived as most successful.  Participants were also asked about their 
experience and satisfaction being treated by a gastroenterologist.  Just over half of the 
participants (55.4%) reported having been treated by a gastroenterologist, and on average 
 105 
participants rated their satisfaction with that treatment as „mildly satisfied‟ (M = 1.97; SD 
= 1.07; range = 1-5).         
Table 6 
Participant Treatment Experiences 
Treatment 
Current                                        Past 
Use Satisfaction  Use Satisfaction 
n  (%) M (SD)  n (%) M (SD) 
Diet changes 232 (78.9) 3.62 (1.36)  170 (57.8) 3.28 (1.55) 
Relaxation training 74   (25.2) 3.45 (1.36)  46   (15.6) 2.89 (1.64) 
Biofeedback training 17   (5.8) 2.59 (1.46)  16   (5.4) 2.38 (1.78) 
Laxative/ antidiarrheals 128 (43.5) 3.45 (1.59)  142 (48.3) 2.94 (1.62) 
Herbal/ mineral/ vitamin 
supplements 
96   (32.7) 3.59 (1.62)  75   (25.5) 2.77 (1.55) 
Probiotics 83   (28.2) 3.54 (1.45)  60   (20.4) 2.42 (1.43) 
Acupuncture 13   (4.4) 3.08 (1.89)  20   (6.8) 2.05 (1.47) 
Antispasmotics 53   (18.0) 3.21 (1.66)  66   (22.4) 2.61 (1.50) 
Serotonin (ant)agonists 14   (4.8) 2.29 (1.90)  17   (5.8) 1.94 (1.56) 
Hypnotherapy 9     (3.1) 3.67 (1.94)  6     (2.0) 2.83 (1.72) 
Psychotherapy 18   (6.1) 2.83 (1.92)  28   (9.5) 2.43 (1.64) 
Antidepressants 69   (23.5) 3.07 (1.56)  66   (22.4) 2.29 (1.58) 
C. Checking the Variables 
Table 7 provides a description of all main variables, including: number of items 
on the scale, mean, standard deviation, range and Cronbach‟s alpha for internal 
reliability.  It was noted that the symptom attribution scales had low values of internal 
reliability (Cronbach‟s alpha = .30 and .59, for somatic symptom attribution and 
psychological symptom attribution, respectively).  A number of steps were taken to 
attempt to validate these symptom attribution variables.  Analyses examining the 
relationships between participants‟ symptom attribution scores, treatment preferences and 
expectations to benefit from both the CBT and drug treatments, found that neither 
Somatic symptom attribution nor Psychological symptom attribution were significantly 
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related to Treatment expectations (transformed) for the CBT or drug treatment.
8
  
Furthermore, contrary to conventional wisdom, levels of psychological and somatic 
symptom attributions were not different among those who chose the psychological t(287) 
= 1.35, p = ns or the drug treatment t(287) = -.98, p = ns.  Although it is feasible that the 
lack of relationships between symptom attributions and treatment preferences or 
expectancies is a valid finding, clearly any results generated using these variables would 
be inconclusive.  These symptom attribution variables were thus dropped from the main 
analyses.   
Univariate GLM (general linear model) analyses were conducted to assess for any 
order or gender effects on the main dependent variable (Expectancy for preferred 
treatment – transformed).  There were no main effects for either order, F(1, 287) = .03, p 
= ns, or gender, F(2, 286) = .31, p = ns.  
Several other univariate GLM tests were conducted to ascertain whether there 
were any significant relationships between demographic variables and the main 
dependent variable.  Variables tested included: Referral source, Source of diagnosis, IBS 
subtype (self-report and Rome III criteria), Country of residence, Marital status, 
Ethnicity, Education, or Employment status.  No significant main effects were identified.  
For continuous demographic variables (i.e., age,) a correlation was run to check for a 
significant relationship to expectations for preferred treatment (transformed).  No 
significant relationship was identified at the .05 level. 
 
                                                 
8
 Correlation of Treatment expectation: drug with Somatic symptom attribution (r = -
.045, p = ns).  Correlation of Psychological symptom attribution with Treatment 
expectation: CBT (r = -.11, p = ns). 
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Table 7 
Description of Main Variables 
Variable 
No. 
items M SD Range 
Cronbach‟s 
alpha 
Treatment expectancy  
CBT  
Drug 
Preferred 
 
1 
1 
1 
 
5.42 
6.03 
6.88 
 
2.63 
2.37 
1.97 
 
1-10 
1-10 
1-10 
 
Self-focused attention 7 17.71 5.07 7-28 .844 
Trait anxiety 
Trait worry 
Anxious arousal 
 
16 
16 
 
53.38 
32.18 
 
14.13 
10.76 
 
20-80 
16-72 
 
.930 
.868 
Optimism  
Pessimism 
3 
3 
7.53 
7.13 
1.89 
2.16 
3-12 
2-12 
.727 
.849 
Hope 8 45.50 9.34 19-64 .856 
Current Health 
Perception of health 
Acute health problems 
 
3 
12 
 
9.44 
5.15 
 
2.38 
2.52 
 
3-15 
0-10 
 
.851 
Control Beliefs 
Health 
Symptoms 
 
6 
5 
 
26.53 
22.01 
 
6.00 
5.62 
 
6-30 
5-25 
 
.884 
.925 
Health self-efficacy 8 31.22 6.43 14-47 .737 
Coping self-efficacy 3 9.17 3.06 3-15 .883 
Vulnerability to illness 4 12.35 3.94 4-20 .874 
Catastrophizing 14 26.89 5.49 14-42 .798 
Treatment experience 
Previous satisfaction with preferred tx
a
 
Number of current treatments 
Satisfaction with current treatments
c
 
Number of past treatments 
Satisfaction with past treatments
d
 
 
1 
 
b 
 
b
 
 
6.19 
2.74 
3.64 
2.42 
2.89 
 
2.75 
2.00 
1.23 
2.42 
1.39 
 
0-11 
0-12 
1-6 
0-12 
1-6 
 
IBS symptom attribution 
Somatic 
Psychological 
 
2 
2 
 
5.76 
4.83 
 
2.05 
2.38 
 
1-10 
1-10 
 
.302 
.594 
Perceived focus of treatment 
Somatic 
Psychological 
 
1 
1 
 
7.02 
6.23 
 
2.39 
3.04 
 
1-10 
1-10 
 
Motivation 
Desire for relief 
Symptom Severity 
Interference in daily activities 
Socially desirable responding 
 
1 
7 
1 
16 
 
8.80 
33.40 
3.13 
6.94 
 
1.69 
7.95 
.76 
1.98 
 
1-10 
9-56 
1-4 
0-14 
 
 
.592 
Patient- provider relationship 15 54.71 8.42 15-75 .878 
Note. Statistics presented are for untransformed variables. tx = treatment.  
a
n= 93. 
b
Number of items used to create average varied by participant.
  c
n = 254. 
d
n = 230. 
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IV. Analysis of Main Hypotheses 
A. Testing Hypothesis 1 
The first main hypothesis was that each of the measured independent variables 
would be correlated with the main dependent variable (DV; Expectancy for preferred 
treatment – transformed)9.  To test this hypothesis, a series of zero-order Pearson 
correlations were run to test for linear relationships between the main dependent variable 
and each independent variable.  
Self-focused attention. 
Hypothesis 1a proposed that levels of self-focused attention would be correlated 
with treatment expectancies.
10
  Results of the correlational analysis for the total sample 
(N = 289) support this hypothesis, as it was found that higher levels of self-focused 
attention were positively correlated with higher levels of treatment expectancies (r = .16, 
p < .01).  In other words, it was found that participants who report a greater dispositional 
tendency to attend to their inner thoughts and feelings also reported greater expectations 
to benefit from treatment.   
Trait anxiety. 
Hypothesis 1b proposed that levels of trait anxiety would be negatively correlated 
with positive treatment expectancies.  To test this hypothesis, separate correlations were 
run examining the relationship between treatment expectancies and both levels of anxious 
arousal (transformed) and trait worry. This hypothesis was not supported, as levels of 
                                                 
9
 All analyses with this variable were done using the transformed variable. 
10
 The DV will alternatively be called „treatment expectancies/ expectancy‟ 
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treatment expectancy were not related to either Anxious arousal (r = -.01, p = ns) or Trait 
worry (r = .03, p = ns).  
Optimism / Pessimism. 
Hypothesis 1c proposed that levels of optimism would be positively correlated 
with levels of treatment expectancy and that levels of pessimism would be negatively 
correlated with treatment expectancy.  This hypothesis was partially supported; levels of 
optimism were positively correlated with levels of treatment expectancy (r = .17, p < 
.01).  However, levels of pessimism were not significantly correlated with levels of 
treatment expectancy (r = -.10, p = ns).  Thus, respondents who reported greater levels of 
optimism also reported higher positive expectations of benefiting from their preferred 
treatment, whereas levels of pessimism were not related to positive treatment 
expectancies.  
Hope. 
Hypothesis 1d proposed that levels of hope would be positively related to levels 
of treatment expectancy.  This hypothesis was unsupported as hope was found to be 
unrelated to levels of treatment expectancy (r = .07, p = ns). 
Current health. 
Hypothesis 1e proposed that levels of treatment expectation would be positively 
correlated with Perceived current health and negatively correlated with number of Acute 
health problems.  This hypothesis was not supported as analyses revealed that levels of 
treatment expectancy were not related to either Perception of health (r = .10, p = ns), nor 
Acute health problems (r = -.05, p = ns).  These results suggest that in this sample, one‟s 
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perceived level of current health is not related to one‟s expectation of benefiting from 
treatment.   
Control beliefs.   
Hypothesis 1f proposed that treatment expectancies would be positively 
correlated with both Control over health and Control over symptoms.  Correlational 
analyses supported these hypotheses, as it was found that greater levels of treatment 
expectancies were positively correlated with both Control over health (transformed; r = 
.22, p < .01) and Control over symptoms (transformed; r = .27, p < .01).  This suggests 
that in this sample, greater expectations to benefit from treatment were related to greater 
level of perceived control over health and perceived control over IBS symptoms.   
Self-efficacy.     
Hypothesis 1g proposed that levels of health self-efficacy and coping self-efficacy 
would be positively correlated with treatment expectancies.  This hypothesis was 
unsupported as neither levels of health self-efficacy nor coping self-efficacy were related 
to treatment expectancies (r = .03, p = ns; r = .11, p = ns). 
Perceived vulnerability to illness. 
Hypothesis 1h proposed that levels of perceived vulnerability to illness would be 
negatively correlated with treatment expectancies.  This hypothesis was unsupported as 
the zero-order correlation between these variables was non-significant (r = .03, p = ns).         
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Catastrophizing. 
Hypothesis 1i proposed that levels of symptom catastrophizing would be 
negatively correlated with treatment expectancies.  Correlational analysis did not support 
this hypothesis.  In contrast, it was found that levels of symptom catastrophizing were 
positively related to treatment expectancies (r = .12, p < .05).  This suggests that in this 
sample, the tendency to catastrophize about bodily symptoms and sensations was related 
to higher levels of treatment expectancies. 
Treatment Experiences.   
Hypothesis 1j proposed that levels of satisfaction with previous similar treatments 
would be positively correlated with current treatment expectancies.  Among the 93 
participants who did report previous experience with their preferred treatment, there was 
a strong positive correlation between Previous satisfaction with preferred treatment and 
current treatment expectancies (r = .50, p < .01).  Thus, greater satisfaction with similar 
treatments in the past was strongly related to one‟s level of expected benefit from their 
preferred hypothetical treatment.    
Also relevant to treatment experiences, Hypothesis 1j proposed that past treatment 
history (Number of past treatments, transformed) would be negatively correlated with 
current treatment expectancies.  Using the full sample (including those who report using 
zero treatments in the past), this hypothesis was not supported, (r = .02, p = ns).  
Similarly, there was no relationship found between current treatment expectancies and 
Number of current treatments (transformed; r = .00, p = ns).   
Unplanned analyses examined the relationships between treatment expectancies 
and average satisfaction levels for past (n = 230) and current treatments (transformed; n = 
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254).  Neither relationship with was significant (current: r = .11, past: r = .05, p‟s = ns).  
These results suggest that treatment experiences, particularly past satisfaction with 
treatment, are relevant only in the context of a treatment situation that is similar to the 
one previously experienced.  Also unplanned, the relationship between treatment 
expectancies and Satisfaction with gastroenterologists (transformed; n = 159) was non-
significant (r = .06, p = ns).     
Illness attributions.  
Hypothesis 1k proposed that illness attribution variables, particularly IBS 
Symptom attributions (level of somatic or psychological attribution) and Perceived 
somatic/ psychological focus of treatment, would be correlated with expectancies for 
preferred treatment.  The relationships with IBS Symptom attributions could not be tested 
due to the poor psychometric properties of the scale used to measure these constructs. 
This hypothesis was supported, however, when tested using the variables tapping the 
levels to which participants perceived their preferred treatment as focusing on the somatic 
or psychological aspects of their IBS symptoms.  Specifically, Expectation to benefit 
from preferred treatment was moderately positively correlated with Perceived somatic 
focus of treatment (transformed; r = .51, p < .01) and weakly positively correlated with 
Perceived psychological focus of treatment (transformed; r = .16, p < .01).   These 
findings suggest that overall, participants‟ treatment expectations were influenced by how 
much they perceived their preferred treatment as targeting the somatic or psychological 
roots of their IBS symptoms, but more so by the perceived degree of somatic focus of the 
treatment.   
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Motivation.  
Hypothesis 1l proposed that various measures of motivation would be positively 
correlated with positive treatment expectancies.  Correlational analyses revealed that this 
hypothesis was unsupported, as treatment expectancies were not related to levels of 
desire for relief (transformed; r = -.01, p = ns), Symptom severity (r = -.03, p = ns), or 
IBS: Interference in daily activities (transformed; r = -.04, p = ns).  Hypothesis 1m 
proposed that levels of socially desirable responding would be positively related to levels 
of treatment expectancy.  This hypothesis was also unsupported, as these variables were 
uncorrelated in this sample (r = -.04, p = ns).           
Patient-provider relationship.   
Hypothesis 1n proposed that a more positive perception of the treatment provider 
would be positively correlated to treatment expectancies. Results from correlation 
analysis supported this hypothesis; more positive perceptions of the treatment provider 
were positively correlated with treatment expectancies (r = .12, p < .05).   
Summary for Findings of Hypothesis 1. 
In the full sample the following variables were significantly correlated with 
treatment expectancies (transformed) as hypothesized: Optimism, Self-focused attention, 
Control over health (transformed), Control over symptoms (transformed), Perceived 
somatic focus of treatment (transformed) and Perceived psychological focus of treatment 
(transformed) and Positive perception of the treatment provider.  Among those who had 
past experience with their preferred treatment (n = 93), there was a strong positive 
correlation identified between treatment expectancies and Previous satisfaction with 
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treatment.  One variable was identified as having significant relationship with treatment 
expectancies, although not in the hypothesized direction.  Specifically, tendency towards 
catastrophizing over symptoms demonstrated a weak positive correlation with treatment 
expectancies.    
The following variables did not show a significant linear relationship to levels of 
treatment expectancy: Trait anxiety (both trait worry and anxious arousal), motivation 
(including Desire for relief, Symptom Severity, IBS: Interference with daily activities and 
Socially desirable responding), Pessimism, Hope, Number of past treatments, perceived 
current health (including Perception of health and number of Acute health problems), 
Health self-efficacy, Coping self-efficacy and beliefs of Vulnerability to illness.  
B. Testing Hypothesis 2 
Research question 2 asked: What are the relative contributions of these 
psychosocial variables for predicting levels of treatment expectancies in an IBS sample?  
As only some of the psychosocial variables included in the current study had been 
previously empirically linked with treatment expectancies, the hypotheses made 
regarding this research question were limited.  Based on the literature review, two 
specific hypotheses were made: 1) Past satisfaction with a similar treatment was 
hypothesized to be a strong predictor of current expectations of treatment, and 2) illness 
attribution variables (now Perceived somatic/ psychological focus of treatment) were 
hypothesized to be strong predictors of current expectations of treatment.   
As described above, in testing the various hypotheses under Hypothesis 1, several 
other variables were found to demonstrate linear relationships to treatment expectancies.  
In order to answer research question 2, a hierarchical regression was conducted using the 
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relevant variables identified from research question 1 as predictor variables and 
Expectancies for preferred treatment (transformed) as the criterion variable.  In the first 
step of the regression, the following individual difference variables were entered: Self-
focused attention and Optimism.  In the second step of the regression, the following 
health belief variables were entered: Control over health (transformed), Control over 
symptoms (transformed), and tendency to Catastrophize over symptoms.  In the final 
step, the context-specific variables were entered:  Perceived somatic focus of the 
preferred treatment (transformed), Perceived psychological focus of the preferred 
treatment (transformed) and Patient-provider relationship.  
Unfortunately, the main treatment experience variable (Previous satisfaction with 
treatment) contained data from only 93 participants.  Thus, initial regression analyses 
proceeded using the full sample (N = 289), without including a treatment experience 
variable.  Subsequent to the results from the analyses with the full sample, a supplemental 
analyses section provides the results of conducting these analyses using a sample with 
previous experience versus a sample without previous experience.  
Table 8 displays the results of this hierarchical regression, including the 
unstandardized regression coefficients and their standard errors (B and SE B), the 
standardized regression coefficients (), the squared semipartial correlations (sr2), and R2 
after each step.  R was significantly different from zero at the end of each step.  After step 
3, with all IVs in the equation, R = .63, F (8, 280) = 22.88, p < .01, with R
2
 = .40 
indicating that 40% of the variance (37.8% adjusted) in the criterion variable was 
explained using these 8 independent variables.  
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After step 1, with Self-focused attention and Optimism in the equation, R = .24, F 
(2, 286) = 8.73, p < .01.  Beta weights for each predictor variable were examined to 
assess their relative importance in the prediction of treatment expectancies.  Both Self-
focused attention ( = .17) and Optimism ( = .18) were significant predictors of 
treatment expectancies (p’s < .01), together accounting for 6% of the variance in the 
dependent variable. 
When the health belief variables were entered in step 2, the proportion of 
explained variance increased significantly, to 13% (∆R2 = .07; F (3, 283) = 7.64, p < .01).  
Among the health belief variables, the two significant predictors were: Control over 
symptoms (transformed) ( = .21, p < .05) and Catastrophizing ( = .17, p < .01); Control 
over health was not a significant predictor ( = .04, p = .65).   Both individual difference 
variables remained significant during this second step, although their predictive power 
decreased somewhat (Self-focused attention:  = .12, p < .05; Optimism:  = .14, p < 
.05).    
The addition of the context-specific variables in the third step contributed to 
significant amounts of explained variance (∆R2 = .27; ∆F (3, 280) = 41.23, p < .01).  
Patient-provider relationship was not a significant predictor of treatment expectancies, 
both Perceived focus of treatment variables were.  Perceived somatic focus of treatment 
was a much stronger predictor than Perceived psychological focus of treatment ( = .55, 
p < .01 and  = .27, p < .01, respectively). 
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Table 8 
Summary of Hierarchical Regression Analysis for Variables Predicting Treatment 
Expectancies
a
 in Total Sample (N = 289) 
Variable B 
SE 
B  sr
2
 R
2b
  R2 
Step 1 
Self-focused attention 
Optimism 
 
.02 
.05 
 
.00 
.01 
 
.17** 
.18** 
 
.03 
.03 
.06**  
Step 2 
Self-focused attention 
Optimism  
Control over health
a
 
Control over symptoms
a
 
Catastrophizing 
 
.01 
.04 
.02 
.10 
.01 
 
.00 
.02 
.04 
.04 
.00 
 
 .12* 
 .14* 
  .04 
 .21* 
 
.15** 
 
.02 
.02 
.00 
.02 
.03 
.13** .07** 
Step 3 
Self-focused attention 
     Optimism  
Control over health
a
 
Control over symptoms
a
 
Catastrophizing 
      Patient- provider relationship 
Perceived somatic focus of tx
a
 
 Perceived psychological focus of tx
a
 
 
.00 
.02 
.01 
.04 
.01 
.00 
  .42 
  .18 
 
.00 
.01 
.04 
.03 
.00 
.00 
 .04 
 .03 
 
.07 
  .10* 
  .03 
  .08 
.13** 
.00 
.55** 
.27** 
 
.01 
.01 
.00 
.00 
.03 
.00 
.30 
.09 
.40** .27** 
Note. tx = treatment 
a
Transformed. 
b
Adjusted R
2
 after step 1 = .05, after step 2 = .11, after step 3 = .38.  
*p < .05.  **p < .01. 
 
In the full model, Optimism was the only remaining significant predictor among 
the individual difference variables ( = .10, p < .05).  Among the health belief variables, 
Catastrophizing remained the only significant predictor ( = .13, p < .01). 
Squared semi-partial correlations (sr
2
) were examined to ascertain the proportion 
of variance each significant predictor contributed uniquely to treatment expectancies, 
controlling for joint variance shared between variables.  As hypothesized, the illness 
attribution variables contributed the most unique variance to the model, with the somatic 
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attribution variable contributing uniquely to 30% of the variance in treatment 
expectancies and Perceived psychological focus of treatment contributing to 9%.  The 
tendency to catastrophize about symptoms independently accounted for 3% of the 
variance in treatment expectancies, while Optimism uniquely contributed to 1% of the 
variance.  The total amount of unique variance contributed by these independent 
variables was 43%.  
C. Supplemental Quantitative Analyses: By Experience 
Analyses presented above do not consider the important contribution of previous 
treatment experiences in predicting levels of treatment expectancies.  Thus, the analyses 
were repeated using the sample of those who reported having previous experience with 
their preferred treatment (n = 93; Experienced group) as well as with a sub-sample of 
participants reporting no prior experience with either treatment (n = 134; Inexperienced 
group).    
Preliminary analyses. 
Prior to repeating the analyses from Hypothesis 1 and 2 with these two samples, 
preliminary analyses were conducted to assess whether the two samples differed on any 
demographic variables, on the dependent variable or treatment preference or on any of 
the main independent variables.  These analyses were done using SPSS Univariate GLM 
and independent sample t-tests for mean comparisons, as well as Crosstabs for frequency 
comparisons.  The groups were found to differ on three variables.  First, the Experienced 
group reported greater numbers of current treatments (M = 3.49, SD = 2.38) than the 
Inexperienced group (M = 2.06, SD = 2.36), Kruskal-Wallis Chi-square (1) = 27.42, p < 
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.01.  Similarly, the Experienced group reported greater numbers of past treatments (M = 
329, SD = 2.77) than the Inexperienced group (M = 1.79, SD = 1.34), Kruskal-Wallis 
Chi-square (1) = 19.13, p < .01.  Thus, it appears that the Experienced was not only more 
experienced with respect to the preferred treatment, but was also more experienced with 
treatment overall.  Note that the groups did not differ in the number of years that they had 
been experiencing IBS symptoms or the number of years since diagnosis.  Thus, they 
were not necessarily more experienced with IBS despite being more experienced with 
IBS treatments.  The only other significant difference identified was that those in the 
Experienced group reported significantly higher levels of self-focused attention than 
those in the Inexperienced group (t(225) = 2.79, p < .01).  It is important to note that 
these groups did not differ in their levels of expectations to benefit from their preferred 
treatment.  
Correlational analyses. 
The correlational analyses of Hypothesis 1 were repeated with the two new sub-
samples.  These results are presented in Table 9, along with the correlation results from 
the full sample.  In terms of the individual difference variables, analyses revealed that the 
Inexperienced group had no significant relationships, compared to the Experienced group 
that showed three significant relationships. Specifically, it was found that levels of 
treatment expectancies were positively correlated with levels of self-focused attention (r 
= .32, p < .01), Optimism (r = .27, p < .01), as well as levels of hope (r = .22, p < .05).  It 
is interesting to note that the size of the correlations found in this sub-sample (n = 93) 
were noticeably larger than the size of the correlations found in the full sample, and in the 
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case of Hope, a significant relationship emerged among the Experienced that wasn‟t 
identified in the full sample.       
Among the health belief variables, the significant relationships identified among 
the Experienced group were more numerous then those in the Inexperienced group.  In 
the Experienced sample only, levels of treatment expectancies were negatively correlated 
with Acute health problems (r = -.21, p < .05), and positively correlated and with Coping 
self-efficacy (r = .42, p < .01).  Significant relationships between treatment expectancies 
and the control belief variables (transformed) were identified in both samples; the 
magnitudes of these associations were larger in the Experienced group (Control over 
health: r = .32, p < .01; Control over symptoms: r = .42, p < .01) than in the 
Inexperienced group (Control over health: r = .23, p < .01; Control over symptoms: r = 
.21, p < .01).   In fact, the 21-point difference between the correlations with Control over 
symptoms in the two groups reached statistical significance (z = 1.71, p < .05).  The 
difference in the correlations with Control over health did not (z = 0.71, p = .24). 
 Finally, when looking at the context-dependent psychosocial variables, both 
groups showed significant positive relationships between treatment expectancies and 
Perceived somatic focus of treatment (transformed).  In the Experienced sample, Previous 
satisfaction with preferred treatment displayed a robust positive correlation with levels of 
positive treatment expectancies (r = .50, p < .01).  None of the other treatment experience 
variables were related to treatment expectancies in either of the sub-samples.        
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Table 9 
Zero-order Correlations between Treatment Expectancies
a
 and Independent Variables in 
Three Samples. 
Note.  tx = treatment(s) 
a
Transformed. 
b
n = 254. 
c
n= 230. 
d
n = 111. 
e
n= 98. 
f
n = 86. 
g
n = 80.  
*p < .05. **p < .01. 
 
 Sample name (n) 
Variable 
Full 
(289) 
Inexperienced 
(134) 
Experienced 
(93) 
Individual difference variables    
Self-focused attention    .16* -.03      .32** 
Trait Anxiety 
Anxious apprehension
a
 
Trait worry 
 
-.01 
 .03 
 
-.02 
-.01 
 
-.06 
-.00 
Optimism 
Pessimism 
  .17* 
-.10 
  .11 
-.08 
     .27** 
-.14 
Hope  .07 -.02    .22* 
Health Belief Variables    
Current Health 
Perception of health 
Acute health problems 
 
 .10 
-.05 
 
  .12 
  .02 
 
 .14 
  -.21* 
Control Beliefs 
Health
a
 
Symptoms
a
 
     
.22**     
.27** 
 
      .23** 
    .21* 
 
      .32** 
      .42** 
Health self-efficacy  .03 -.05   .14 
Coping self-efficacy  .11   .04       .42** 
Vulnerability to illness  .03   .03  -.03 
Catastrophizing    .12*   .06   .19 
Context-dependent variables    
Treatment Experience 
Previous satisfaction with tx 
Number of current tx
a
 
Number of past tx
a
 
Satisfaction with current tx
a
 
Satisfaction with past tx 
n/a 
-.02 
.00 
.13
b
 
.05
c
 
n/a 
-.11 
-.06 
.16
d
 
.13
e
 
 
.50** 
-.08 
-.06 
.17
f
 
.05
g
 
Perceived treatment focus  
Somatic
a
 
Psychological
a
 
     
.51**     
.16** 
 
       .55** 
  .16 
 
       .40** 
  .15 
Motivation 
Desire for relief
a
 
Symptom severity 
IBS: Interference with daily activities
a
 
Socially desirable responding 
 
-.01 
-.03 
-.04 
-.04 
 
  .12 
-.15 
.02 
 .03 
 
  .10 
  .15 
.18 
-.12 
Patient-provider relationship    .12*  .11   .11 
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Regression analyses. 
The regression analyses used in testing Hypothesis 2 with the full sample were 
repeated for both the Experienced and Inexperienced sample.  In order to compensate for 
the relatively small sample sizes of both samples, the bootstrap method was used when 
performing these regression analyses.  The bootstrap method was described by Efron in 
1979 and is defined as a general procedure that mimics the sampling distribution of a 
statistic through successive resampling (Dalgleish & Chant, 1995).  This procedure is a 
means of estimating statistical accuracy from a single sample (Diaconis & Efron, 1983).  
That is, bootstrapping mimics the process of selecting many samples when it actually 
uses only one sample to find the probability that the values of a given test statistic fall 
within a certain interval.  Bootstrapping is a method that resamples with replacement, 
meaning that each time an observation is taken to resample it, the procedure replaces it 
before taking the next observation.  Because each observation is replaced, it means that 
the same observation can appear in the sample more than once.  Thus, the empirical 
distribution that consists of the bootstrapped samples can be treated as if it were a 
distribution constructed from many samples (Dianconis & Efron).  The bootstrap method 
produces a 95% confidence interval for each statistic of interest (e.g., regression 
coefficients and R
2); if this interval contains „0,‟ the statistic cannot be considered 
significantly different from zero. 
For the Experienced sample, as there were significant correlations identified for 
variables from each category, a three-step hierarchical regression was used, as with the 
full sample, with treatment expectancies (transformed) as the criterion variable. The 
results of the hierarchical regression are presented in Table 10.  The amount of variance 
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explained (R
2
) was significant after each step.  After step 1, with the three individual 
difference variables (Self-focused attention, Optimism and Hope) in the equation, an 
average of 22% of the criteria was explained (mean R
2
 = .22, 95% CI = .09-.31). Only 
Self-focused attention and Optimism had significant beta values (Self-focused attention:  
mean  = .32, 95% CI = .11-.45; Optimism:  = .31, 95% CI = .10-.45).  When the health 
belief variables (Control over health, Control over symptoms, Catastrophizing and 
Coping self-efficacy) were entered in step 2, the proportion of explained variance 
increased to 43% (38% adjusted).  Among the health belief variables, Control over 
symptoms and Acute health problems had significant beta values.  In the full model 
(including Previous satisfaction with treatment and Perceived somatic focus of treatment) 
the average R
2
 = .62 (SD = .04; 95% CI = .52 -.68), indicating that 62% (57% adjusted) 
of the variance in treatment expectancies was explained by these 10 variables. 
Beta weights for each predictor variable were again examined to assess their 
relative importance in the prediction of treatment expectancies.  In the full model, there 
were five variables that were significant predictors of treatment expectancies, including 
(in descending order) Previous satisfaction with treatment ( = .36, 95% CI = .20-.50), 
Perceived somatic focus of treatment ( = .27, 95% CI = .12-.38), Self-focused attention 
( = .26, 95% CI = .13- .33), Optimism ( = .21, 95% CI = .04-.46) and Acute health 
problems ( = -.12, 95% CI = -.28 - -.01).  Control over symptoms was not a significant 
predictor of variance in this full model.   
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Table 10 
Summary of Hierarchical Regression Analysis for Variables Predicting Treatment 
Expectancies
a
 in Sample with Previous Experience with Preferred Treatment (N = 93) 
Variable B SE B  sr
2
 R
2b
 
Step 1 
Self-focused attention 
Optimism 
Hope 
 
 .04 
 .09 
.00 
 
.01 
.03 
.00 
 
 .32* 
 .31* 
.00 
 
.11 
.08 
.00 
.22* 
Step 2 
Self-focused attention 
Optimism  
Hope 
Control over health
a
 
Control over symptoms
a
 
Coping self-efficacy 
Acute health problems 
 
 .03 
 .05 
-.01 
-.05 
 .19 
 .04 
-.02 
 
.01 
.03 
.01 
.08 
.08 
.02 
.01 
 
  .27* 
.18 
 -.14 
 -.08 
  .36* 
.22 
-.11* 
 
.11 
.03 
.02 
.00 
.07 
.05 
.02 
.43* 
 
Step 3 
Self-focused attention 
Optimism  
Hope 
Control over health
a
 
Control over symptoms
a
 
Coping self-efficacy 
      Acute health problems 
Previous satisfaction with preferred tx 
      Perceived somatic focus of treatment
a
 
 
 .03 
 .06 
 .00 
 .00 
 .14 
 .00 
  -.02 
 .07 
 .22 
 
.01 
.02 
.00 
.07 
.06 
.02 
.02 
.02 
.06 
 
  .26* 
  .21* 
 -.08 
.02 
  .14 
.05 
-.12* 
  .36* 
  .27* 
 
.12 
.05 
.01 
.00 
.05 
.00 
.02 
.18 
.13 
.62* 
Note. tx = treatment. 
a
Transformed. 
b
Adjusted R
2
 after step 1 = .19, after step 2 = .38, after step 3 = .57.  
*95% confidence interval does not include zero.  
 
Examining squared semi-partial correlations identified Previous satisfaction with 
treatment as predicting the most amount of unique variance in current treatment 
expectancies (18%), as predicted in the original hypotheses.  Perceived somatic focus of 
treatment was the second most important unique predictor (sr
2
 = 13).  Self-focused 
attention uniquely accounted for 12% of variance in levels of treatment expectancies.  
Although Optimism and Control over symptoms both uniquely accounted for 5% of 
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variance in the criterion variable, only Optimism was a significant predictor in the full 
model.  Acute health problems uniquely contributed to 2.0% of variance.  The total 
unique variance contributed by these independent variables was 50%. 
Table 11 
Summary of Hierarchical Regression Analysis for Variables Predicting Treatment 
Expectancies
a
 in Sample without Previous Experience with Preferred Treatment (N = 
134) 
Variable B SE B  sr2 R
2
 
Step 1 
Control over health
a
 
Control over symptoms
a
 
 
.08 
.06 
 
.05 
.05 
 
.17 
.13 
 
.02 
.01 
.09* 
Step 2 
Control over health
a
 
Control over symptoms
a
  
Perceived somatic focus of treatment
a
 
 
.05 
.01 
.38 
 
.05 
.06 
.05 
 
.10 
.02 
.52** 
 
.01 
.00 
.27 
.32* 
a
Transformed. Adjusted R
2 
after step 1 = .08, after step 2 = .31.  
*95% confidence interval does not include zero.  
The results for the Inexperienced group were quite different, and are presented in 
Table 11.  A two-step hierarchical regression was used for this analysis, as there was no 
individual difference variables identified as significant correlates of treatment 
expectancies in this sample.  Although the two control belief variables predicted a 
significant amount of variance when entered alone in step 1 (R
2
 = .09, 95% CI = .03-.16), 
neither had significant beta weights.  This suggests that individually, neither contributes 
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enough unique variance in the criterion variable.  In step two, the somatic illness 
attribution variable uniquely contributed to 27% of the variance in treatment expectancies 
(R
2
 =  .32, 95% CI = .20-.44; Adjusted R
2
 = .31).    
Comparing regression results between the three samples.  
The purpose of these analyses was to use a hierarchical regression to identify the 
best predictors of treatment expectancies (TE) from among those variables identified as 
having significant zero-order correlations with this criterion variable.  However, 
comparing the results of the full sample with the results from the two sub-samples has 
revealed differential findings regarding which variables are the best predictors, based on 
which sample is examined.  Although some variables were identified as significant 
correlates and/or predictors of treatment expectancies in all three samples (e.g., Perceived 
somatic focus of treatment and the two control belief variables), the relevance of several 
variables (the size of their correlation with TE or their significance in a regression model 
predicting TE) was found to vary based on which sample was used in the analysis.  For 
instance, three variables that were not significant correlates in the full sample emerged as 
such when considering only those participants with previous experience with their 
preferred treatment (i.e., Hope, Acute health, and Coping self-efficacy).  In addition, two 
of the individual difference variables that were identified as having a significant but weak 
relationship with TE in the full sample (Self-focused attention and Optimism) displayed 
more robust relationships in the Experienced group. As none of the variables were 
significant correlates among those in the Inexperienced group, these results suggest that 
the inclusion in the full sample of participants without previous treatment experience has, 
for lack of a better term, diluted the relationships that are relevant among the 
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Experienced.  In contrast, three variables were identified as significant correlates of 
treatment expectancies in the full sample, but were not significant correlates in either of 
the two sub-samples (i.e., Catastrophizing, Perceived psychological focus of treatment 
and Patient-provider relationship). This suggests a sort of additive effect, where trends 
towards significance in either one or both sub-samples are combined in the full sample to 
reach a level of statistical significance.  Alternatively, this finding could be a function of 
increased power to detect a significant effect provided by the larger sample size of the 
full sample.  Overall, these differential results suggest that previous experience with 
treatment had some influence on the number of psychosocial variables that were found to 
show a significant relationship to the dependent variable.  
Testing for Moderation. 
 A series of hierarchical regressions were conducted to assess whether Previous 
experience with preferred treatment truly moderated some of the relationships between 
the DV and the IVs, as suggested by the results presented above.  To test for moderation, 
first Previous experience with preferred treatment was coded as a dichotomous variable 
(0= Inexperienced; 1 = Experienced), and interaction terms were created to represent the 
interaction between Previous experience and the IV of interest (e.g., Experience*SFA).  
The IVs of interest included those variables that displayed significant relationships with 
the DV in the Experienced group but not the Inexperienced group (i.e., SFA, Optimism, 
Hope, Acute health problems and Coping self-efficacy).  Other variables of interest were 
those where the size of the correlations with the DV were notably larger or smaller in one 
group or the other (Control over symptoms, Perceived somatic focus of treatment).  In 
each hierarchical regression, the IV of interest and the dichotomous Experience variable 
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were entered into the model predicting treatment expectancies in the first step, and then 
their interaction term was entered into the second step.  Moderation is confirmed if the 
interaction term is significant.   
The full results of these analyses can be found in Appendix AC.  In brief, 
Previous experience with preferred treatment was confirmed as moderating the 
relationship between Treatment expectancies and i) SFA, ii) Coping self-efficacy 
(interaction terms significant at .05 level).  The interaction between Experience and 
Control over symptoms was almost significant (p = .06), whereas Treatment experience 
was not found to moderate the relationships between TE and Optimism, Hope, Acute 
health problems, or Perceived somatic focus of treatment.   
V. Examining the Qualitative Data 
Qualitative analysis was conducted using responses from 100 participants chosen 
randomly from the total sample.  The examination of the qualitative data was guided by 
the question of whether there were additional psychosocial variables, beyond those 
independent variables identified in the literature review, which were commonly cited as 
contributing to one‟s expectations of treatment benefit.  Among the 100 participants, 98 
participants offered at least one factor contributing to their expectations that could be 
coded.  The average number of factors generated was 1.96 (S.D. = .90), and the 
maximum number of factors mentioned was four.  The specific factors, both pre-set and 
emergent, are presented in Table 12. 
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A. Emergent Categories 
After coding the qualitative responses using the pre-set categories established in 
the introduction as potentially relevant psychosocial variables, the narrative responses 
were reviewed to identify additional psychosocial variables that may be mentioned as 
contributing to participants‟ expectations of benefiting from treatment.  These emergent 
categories captured statements provided by participants that were not appropriate for any 
of the pre-set categories.   Seven of such emergent categories were identified, falling 
under five general categories.  Although „treatment experiences‟ was a pre-set umbrella 
category, two new sub-categories Treatment experience: Vicarious and Treatment 
experience: Inexperience emerged from the qualitative data.  Similarly, two new sub-
categories, Attribution: Holistic and Attribution: Situational emerged to join the other two 
pre-set Illness Attribution categories.  Three emergent categories were original, not 
having been measured in the quantitative analysis.  These three categories were 
Convenience, Aversion and Side effects.   
Treatment Experience. 
Several participants made statements that can be considered to fall under the 
broader category of past treatment experiences, but were not appropriate for the pre-set 
categories of Past experience with similar treatment or Number of treatments previously 
attempted.  In particular, three participants cited vicarious experience with certain 
treatments as factors influencing their treatment expectancies.  The Treatment 
experience: Vicarious emergent category included statements such as „I have seen a lot of 
drug treatment in my family and friends be unsuccessful…‟ and „I have worked in the 
medical field in the past, and basically lost most confidence in medications.‟  Another 
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five participants made reference to previous inexperience with a treatment when asked to 
comment on why they thought a treatment may work for them.  Statements such as „It is 
one that I have not tried…‟ and „I have never tried cognitive/relaxation therapy and feel 
that this might help me‟ were coded on the emergent Treatment experience: Inexperience 
category.  
Attribution. 
The second most commonly cited emergent factor encompassed statements 
considered to refer to participants‟ attributions regarding the cause of their IBS 
symptoms.  It was found that some participants made attributional statements that did not 
fit into the pre-set categories of Attribution: Somatic and Attribution: Psychological, but 
instead made reference to either the holistic/ mind-body aspects (Attribution: Holistic) or 
the situational aspects (Attribution: Situational) of the treatments and/or their IBS 
symptoms.  Fourteen participant statements (14%) were coded as belonging to one of the 
two new attribution categories, with 11 (78%) coded as Attribution: Holistic statements 
and 3 (22%) coded as Attribution: Situational statements.  Examples of Attribution: 
Holistic statements include:  „I believe all treatments should deal with the mind and 
body,‟ or „I feel that my IBS is not only a symptom of my intestines but rather a symptom 
of my body as a whole,‟ or „I do not believe this can be cured by counseling or thoughts 
alone, I think that you need to combine both treatments together to get the best results.‟  
The statements coded as Attribution: Situational include: „I believe firmly that the 
symptoms of IBS can be best treated through diet and lifestyle…‟ and „…it is mostly the 
behaviours that make IBS “attacks” somewhat more frequent,‟ and „When a lot is going 
on in my life, I do have more stomach pain…‟  
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Table 12  
Number of Qualitative Statements in Each of the Pre-set and Emergent Categories 
Category n 
Pre-set Categories  
Self-focused attention 0 
Trait Anxiety 11 
Optimism/ Pessimism 6 
Hope 4 
Current health 
Perception of self as „healthy‟ or „sick‟ 
Other acute health problems 
10 
4 
6 
Control beliefs 
General health 
Symptoms 
6 
1 
5 
Health self-efficacy 6 
Perceived vulnerability to illness 0 
Catastrophizing 2 
Treatment Experience 
Previous experience with similar treatments 
Number of treatments attempted 
42 
34 
8 
Illness Attributions 
Somatic 
Psychological 
29 
10 
19 
Motivation  12 
Desire to see relief/ Symptom Severity  
Socially desirable responding 
11 
1 
Perceptions of the treatment provider 11 
Emergent Categories  
Aversion 17 
Side effects 5 
Illness Attributions 
Holistic 
Situational 
14 
11 
3 
Convenience 11 
Treatment Experience 
Vicarious 
Inexperience 
8 
3 
5 
Convenience. 
Another category to emerge captured statements referring to the convenience or 
inconvenience associated with a certain treatment regimen.  Examples of these statements 
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include: „Seems user friendly,‟ Fits into my lifestyle better,‟ „It may be too difficult to 
maintain if it involves strict dietary restrictions,‟ and „I sometimes do not have the time or 
finances to go through relaxation therapy.‟  A total of 11 participants made statements 
that were coded in this category.   
Aversion. 
The emergent variable most commonly cited by participants was labeled 
Aversion, which was endorsed by 17 (17%) participants.  This category encompasses 
statements regarding a participant‟s aversion to or bias against certain treatments, either 
drug treatments or psychological treatments.  Examples of statements coded as Aversion 
include: “I prefer treatments without the use of drugs,‟ or „I am sometimes resistant to 
therapy,‟ or „If I could solve the problem with drugs I would,‟ or „I feel medications only 
mask the symptoms and don‟t provide a cure.‟  Of the 17 statements coded as Aversion, 
11 of those (65%) were coded as aversion to drug treatment while 6 (35%) were coded as 
aversion to psychological treatment.  
Side effects. 
Another five percent of participants mentioned side effects in their narrative 
statements.  Examples include: „I have had negative side effects from conventional 
medications thus far...‟ and „My experience with drugs is … they can have side effects or 
be unpleasant or intrusive.‟  Statements in this category are somewhat similar to ones in 
the Aversion category.  However, these statements contained explicit mention of „side 
effects‟ and were noted not to occur exclusively in the context of an Aversion statement.  
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For example, „I think medication would probably be the route to go as long as side effects 
did not interfere more with my life…‟ 
B. Exploring Illness Attributions 
The second specific aim of including a qualitative component in the current 
research was to use participants‟ narrative responses to shed light on null or unexpected 
quantitative findings.  The following is a brief exploration of one instance where the 
qualitative data was useful in clarifying the nature of the relationships between the pre-
identified psychosocial variables and expectations to benefit from treatment.  
In the narrative data, illness attributions in general were mentioned by 29% of 
respondents (n = 29), making this general category the second most frequently 
referenced.  Including the statements coded into the emergent Illness Attribution 
categories (Holistic and Situational) raises the count to 43 statements that made reference 
to illness attributions.  In the quantitative analyses reported above, it was found that 
Perceived somatic focus of treatment was moderately related to treatment expectancies, 
whereas Perceived psychological focus of treatment was only weakly related.  In contrast, 
narrative statements regarding psychological illness attributions were somewhat more 
common than statements regarding the somatic aspects of symptoms/ treatments (19 and 
10 statements, respectively).   
Examination of the statements themselves speculatively sheds some light on this 
apparent discrepancy between the relevance of the perceived somatic vs. psychological 
focus of treatment.  For one, all of the Attribution: Somatic statements seemed to make 
reference to how the perceived somatic aspects of treatment or symptoms positively 
influence expectations of benefit (e.g., “Medications are geared specifically towards the 
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illness, therefore should work better than anything else” and “To me, physical symptoms 
are to be treated with physical remedies”).  In contrast, while some statements coded as 
Attribution: Psychological seemed to reference psychological aspects of treatment/ 
symptoms as positive influences on treatment expectancies (e.g., “I think the treatment 
may work because my IBS symptoms are mostly triggered by stress…), other statements 
in this category seemed to refer to factors that diminished one‟s expectation of benefiting 
from treatment (e.g., “I think I already have enough basic grasp of stress management 
and hearing a re-hash of it won‟t improve my ability to chill out… I believe there is a 
psychological aspect, but…”).  Still other statements in this category suggest some 
participants feel that the psychological contributors to their symptoms actually would 
impinge on their ability to benefit from a psychological treatment (e.g., “Sometimes my 
nerves and my poor ability to reason with stress affect me harshly.  It is easier on me to 
take medication to get through my issue”). This variety in statements regarding the 
psychological aspects of attributions / treatments seem to suggest that for some, the 
psychological foci of a treatment may contribute to greater expectations to benefit from a 
psychologically-based treatment, whereas for others, this perception may contribute to 
lower expectations from such a treatment.  
Chapter 4 
DISCUSSION 
I. Overview 
 In the last fifty years, our conceptualization and understanding of the placebo 
effect has come a long way.  We have gone from considering a placebo as a „sham‟ or 
„inert‟ treatment that must be „controlled for‟ in clinical trials, to discovering that a 
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placebo response is largely mediated by expectations and viewing the placebo (or 
expectation) effect as playing an active role in any treatment context (Papakostas & 
Daras, 2001).  The goal of much placebo research is not to ultimately justify the ethical 
use of placebos in medicine, but to understand the neurological, contextual and 
psychosocial correlates of placebo responding so that these factors can be targeted and 
enhanced to promote greater responsiveness to any therapeutic intervention (Price, 
Finniss & Benedetti, 2008).  Historically, much of this research has focused on 
identifying the contextual or „placebo-salient‟ factors that contribute to a greater placebo 
response.  In the last several years, there has also been increasingly more research 
focused on the neurophysiological processes that mediate placebo/ expectation effects.  
Although recent reviews now emphasize that the study of placebo responding and 
expectations effects should be focused on understanding the role of the individual in the 
context (Miller & Kaptchuk, 2008), there has been relatively little empirical research 
dedicated to this end.  The current research has been successful in contributing to our 
understanding of these processes by identifying a set of personal psychosocial factors that 
are associated with expectations for treatment benefit in an IBS sample.  
To accomplish this, two models of placebo responding (Kirsch, 1985; Sirois, 
2001, 2009) and one model of expectancy formation (Olson et al., 1996) were combined 
into a broad model that encompasses the contextual and psychosocial factors thought to 
contribute to expectation formation in the context of therapeutic interventions.  The 
psychosocial variables suggested by these combined models included the broad category 
of health beliefs, some specific individual difference factors (individual differences and 
anxiety) as well as certain context-dependent variables (such as previous learning and 
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attributions).  This combined model was used to guide a thorough literature review 
designed to identify the range of individual difference factors, the types of health beliefs, 
and the important context-dependent variables that, through their association with either 
placebo responding, health outcomes or expectations of treatment, could be considered as 
potentially relevant correlates of treatment expectancies (see figure 1).  The current 
research was then focused on empirically testing which of these psychosocial factors 
contribute to expectations regarding a hypothetical treatment in a sample of individuals 
with irritable bowel syndrome.   
The first research question asked which of the psychosocial factors, identified as 
relevant from the literature review, would be correlated with treatment expectancies (TE) 
in this sample.  The second research question asked which of these correlated variables 
would be the best predictors of treatment expectancies in a regression model.  The 
qualitative research question asked whether there were additional factors that participants 
reported as relevant.  Together these research questions were focused on identifying a 
parsimonious set of relevant psychosocial variables that had the strongest relationships to 
treatment expectancies in this sample.  Interestingly, the analyses associated with the first 
two research questions resulted in somewhat disparate findings when repeated in two 
sub-samples of the main sample, namely those with experience with their preferred 
treatment and those without experience with the hypothetical treatments. 
Figure 3 provides a visual summary of the main findings of the current research.  
In terms of psychosocial variables, this research has been successful in identifying a 
range of individual difference variables, the types of health belief variables as well as the 
important context-dependent variables that are associated with one‟s expectations to 
 137 
benefit from treatment (research question 1), as well as their relative ability to predict 
variance in treatment expectancies (research question 2).  
Figure 3. Summary of results. Variables that were identified as having a relatively greater 
contribution to the magnitude of one‟s treatment expectancies are displayed higher in the 
figure, and in text boxes of increased shading.  Directional arrows specify proposed 
interactions that will be discussed herein.  Briefly, treatment-specific cues are proposed to 
activate specific health beliefs, and when one has previous experience with a similar 
treatment, specific related health beliefs are proposed to be activated more strongly.  
Increased self-focused attention is also proposed to enhance the association of specific 
health beliefs to treatment expectancies.  Any influence of motivation and anxiety on 
placebo responding is proposed to occur unmediated by expectancies.   
 
In keeping with the study goal of identifying the psychosocial variables that are 
the best predictors of treatment expectancies, the discussion will first focus on those 
variables that were relevant across each of the samples (full sample, Experienced sample 
and Inexperienced sample), and next turn to examine those variables found to be relevant 
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correlates and/or predictors of TE in at least two samples, as so on.  Possible explanations 
for the disparate findings across samples will also be explored. 
II. Discussion of Main Findings 
A. Attributions for Symptom Improvement. 
One variable that stood out as an important correlate and predictor of treatment 
expectancies in all three samples was Perceived somatic focus of treatment.  In addition, 
both in the full sample and the Inexperienced sample, this variable explained the largest 
amount of unique variance in levels of treatment expectancies.  These results suggest that 
in this IBS sample, there was a strong relationship between how much one perceived 
their preferred treatment as focusing on the somatic roots of their IBS symptoms and how 
much one expected that treatment to work, with a greater somatic focus being associated 
with a greater expectation to benefit.  In comparison, Perceived psychological focus of 
treatment was a significant but weaker correlate and predictor of treatment expectancies 
in the full sample, but not in the other samples.  These variables cannot be considered 
direct measures of how much one attributes their IBS symptoms to somatic or 
psychological causes; instead they may capture participants‟ recovery attributions, or 
perhaps more aptly, their attributions for symptom improvement.  The specific question 
used to measure Perceived somatic/psychological focus of treatment asked participants to 
rate to what extent they agreed that their preferred treatment „targeted the physical/ 
psychological causes of IBS.‟  As the questions referred specifically to one‟s preferred 
treatment, it may be that participants‟ responses to these items were indeed inspired by 
their causal attributions for their symptoms of IBS.  On the other hand, it may be that 
participants‟ responses were inspired more by their preference for a treatment that 
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targeted somatic vs. psychological contributors to IBS, regardless of what causal 
attributions they use to understand their own symptoms.  It should also be noted that it is 
impossible to determine, using the current data, how much a person considered the 
dietary recommendations (offered in both treatment scenarios) as targeting the „somatic 
causes of IBS.‟  As diet changes are commonly accepted to be the first and most effective 
approach to managing IBS symptoms, it makes sense that greater level of perceived focus 
on these aspects of symptom management would be associated with greater expectations 
to benefit from these treatments.  Given the sizable amount of variance in treatment 
expectancies that was predicted by Perceived somatic focus of treatment (up to 27%), it 
seems that these relationships should be considered more closely.        
If we consider these findings as representing, at least to a certain extent, a link 
between illness attributions and treatment expectancies, they would be consistent with a 
large study of mixed illness groups wherein expectations regarding treatments in general 
were correlated with both organic and psychological illness attributions, although less so 
with the latter (Moss-Morris et al., 2002).  Without the need to make such a conceptual 
leap, these results echo the findings of a meta-analysis of placebo-controlled treatment 
studies for chronic fatigue syndrome (Cho et al., 2005), where it was found that on 
average, psychological interventions elicited lower placebo responses than somatically-
focused interventions.  The authors speculated that participant illness attributions 
influenced their expectations to benefit from the different types of treatment and thus 
their therapeutic response to placebo interventions.  Here also, it cannot be determined 
whether patients expectations to benefit were influenced more so by personal symptom 
attributions, attributions for improvement, or even preferences for certain types of 
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treatment perhaps based on factors such as aversion or convenience (as suggested by the 
qualitative data analysis).  
Nevertheless, the current results are unique as they represent the first empirical 
findings linking treatment expectations with perceived somatic/ psychological focus of 
treatment in an IBS sample.  They are important results as they clearly suggest that for 
individuals with IBS, one‟s positive expectations to benefit from treatment (and thus 
one‟s ability to benefit from the expectation effect) are related to the perceived somatic, 
and to a lesser extent psychological, focus of the proposed treatment.  The implications 
for the treatment of IBS that seem to follow from these findings are that in order to 
maximize positive expectations of treatment, practitioners should consider the patients‟ 
perspectives on what type of intervention and/ or what type of causal factor (somatic or 
psychological) is worth targeting, and in what degree.   
An interesting result of this study was the discrepancy between the influences of 
somatic attributions versus psychological attributions (be them attributions for the cause 
of symptoms or the improvement of symptoms).  This discrepancy is not unique to an 
IBS sample, as it has also been found in other research, such as the stronger associations 
between somatic attributions and treatment expectations in a mixed illness group (Moss-
Morris et al., 2002), as well as the stronger influence of somatic attributions to treatment 
success in a chronic fatigue sample (Chadler et al., 2003).  Results from a recent study of 
health attributions among laypersons suggest that this discrepancy is not necessarily 
unique to certain illness populations (Shiloh, Peretz, Iss & Kiedan, 2007).  In the Shiloh 
et al. study, four groups of healthy students were asked to estimate the chances of 
recovery of a hypothetical person with an unnamed severe disease on a scale from 0 to 
 141 
100.  Groups were presented with different vignettes that varied by the quality of medical 
care (high/low) or the quality of the person‟s psychosocial resources (both personal and 
social; high/low).  Their ratings of „chance for recovery‟ were considered an indirect 
assessment of recovery attributions.  The same participants were then asked to rate (from 
0 to 100) the relative importance of a) biomedical factors, and b) psychosocial resources 
in effecting the recovery of a different hypothetical person with the same illness.  This 
was considered an explicit measure of participants‟ recovery attributions.  Comparing 
ratings derived from the indirect assessment of recovery attributions across groups, there 
was only a main effect of psychosocial resources, with higher psychosocial resources 
being related to higher ratings of chance for recovery.   In fact, the effect size for the 
influence of psychosocial factors on recovery was 60 times stronger than the effect size 
for biomedical factors.  On the explicit measure of recovery attributions, the importance 
of quality biomedical care was rated as twice as important as the quality of psychosocial 
resources.  This interesting study highlights, among other things, the tendency of people 
to overestimate the influence of medical/organic factors, and underestimate the 
importance of psychosocial factors, when asked explicitly to communicate their 
attributions for improvement.  This tendency may have been at play in the current 
research, as individuals were explicitly asked to rate the perceived somatic/psychological 
foci of their preferred treatment.  Interestingly, when asked to comment freely about 
factors they perceived as contributing to their expectations of benefit, there were a greater 
number of references made to psychological attributions or holistic attributions than to 
medical/organic attributions of illness/ recovery.  
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B. Control Beliefs 
 The control belief variables were also correlated with expectations to benefit from 
treatment across all three samples.  Furthermore, in both the full sample and the 
Experienced sample, Control over symptoms was a significant predictor of treatment 
expectancies when entered with other health belief variables in the second step of the 
regression.  Thus, in this IBS sample, the greater one‟s beliefs about having control over 
one‟s symptoms, and to a lesser extent, control over one‟s health, the higher one‟s 
expectations to benefit from the treatment.  The general link between control beliefs and 
expectations of treatment has previously been demonstrated in a large sample of mixed 
illness groups (Moss-Morris et al., 2002), but this is the first empirical evidence to 
support a link between treatment expectancies and control beliefs in an IBS sample.   
 These results regarding the general influence of control beliefs on expectations of 
treatment fit nicely with theories of expectancy formation (e.g., Olson et al, 1996) if we 
consider variations in control beliefs as constituting a form of change attribution, from 
more internal (I am in control of my symptoms) to less internal (low scores on control 
belief measures).  Olson and colleagues propose that if changes are attributed to internal, 
stable causes, then future positive changes will be expected.  With less personal and 
internal change attributions, expectations of benefit are less certain.  Health psychology 
research has emphasized that better adjustment to chronic illness is related not only to 
possessing more internal causal attributions, but also to having stronger attributions 
regarding the controllability of symptoms (Roesch & Weiner, 2001).  In other words, 
better adjustment has been noted among those who attribute to themselves a greater 
amount of control over their illness.  These results are also in line with findings that 
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greater control beliefs are inversely related to symptom severity in certain chronic 
illnesses (e.g., tinnitus; Sirois, Davis & Morgan, 2006), and that weaker personal control 
over symptoms are associated with less favourable outcomes in IBS samples (Rutter & 
Rutter, 2002).        
 The finding that beliefs of control over symptoms are more strongly related to 
outcome (here expectations of outcome) than are beliefs of control over health in general 
is consistent with both theory and research (Sirois et al., 2006).  Folkman (1984) suggests 
that different types of control beliefs influence cognitive appraisals in different ways.  
General control beliefs may lead someone to consistently perceive ambiguous situations 
as more manageable, but situation-specific control beliefs can be considered as coping 
resources to be drawn on only under certain conditions.  It follows that control over IBS 
symptoms would be more relevant when considering expectations regarding a treatment 
designed to improve IBS symptoms; in this case control over health in general is 
obviously not as specific and not as relevant. 
 It is possible that these findings may not generalize to other illness populations, or 
that the magnitude of the relationships would vary across samples or treatment contexts.  
Moss-Morris and colleagues (2002) suggest that beliefs about personal control may be 
more relevant in situations where treatment choices themselves can be seen as a personal 
decision of how best to manage or control symptoms.  For example, in situations where 
there is no one proscribed treatment (e.g., in IBS), treatment choices themselves can be 
seen as a personal decision of how best to manage or control symptoms.  In contrast, in 
chronic illnesses like HIV or diabetes where treatment is very prescriptive, beliefs about 
treatment effectiveness may be conceptually distinct from beliefs about personal ways of 
 144 
controlling or managing symptoms.  One can also consider how symptom-specific 
control beliefs could overlap or combine with beliefs about self-efficacy to carry out or 
adhere to treatment recommendations (French & Weinman, 2008).  For example, if 
following diet recommendations is an important part of a treatment plan for IBS, then 
one‟s expectations to benefit from the treatment should vary with one‟s sense of their 
ability to manage their symptoms by following the diet recommendations.  References to 
these types of self-efficacy concerns did surface in the qualitative data as statements in 
the emergent category labeled Convenience.  Examples include „Fits better into my 
lifestyle‟ and „I sometimes do not have the time or finances to go through relaxation 
therapy‟ or „It may be too difficult to maintain if it involves strict dietary restrictions.‟  
Following from these findings, it may be desirable in future research to more explicitly 
examine the relationship between treatment expectancies and one‟s level of self-efficacy 
to adhere to specific aspects of the proposed treatment.              
 Although these results may not be as robust in another illness group, this study 
has clearly shown that in this sample of individuals with IBS, control beliefs, particularly 
beliefs of control over symptoms, are important psychosocial variables to consider when 
aiming to strengthen expectations of treatment benefit.   
C. Optimism 
 Optimism is one of two individual difference variables that were identified as 
relevant in both the full sample and the sub-sample of participants who had more 
experience with treatment.  In particular, in the Experienced sample, optimism was found 
to be a moderate predictor of variance in treatment expectancies and to retain its 
significance in the full regression model.  The results were the same, although less robust, 
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in the full sample.  It was found that greater levels of reported optimism were associated 
with greater expectations about benefiting from the proposed treatment.   
This is the first time that optimism has been linked with treatment expectancies in 
an IBS sample.  This result is consistent with research where treatment expectancies have 
been correlated with optimism in cancer patients (Weinfurt et al., 2003) as well as in non-
clinical populations (Hyland, Whalley & Geraghty, 2007).  Furthermore, it corresponds 
with the results from a recent study where levels of optimism were correlated with levels 
of positive placebo responding (Geers et al., 2007).  Thus this finding is an important 
contribution to a growing literature regarding the importance of dispositional optimism 
and its relationship to expectations of treatment. 
The fact that optimism was linked with treatment expectancies while pessimism 
was not is also consistent with empirical research wherein pessimism is only linked to 
negative outcome expectancies (Montgomery et al., 2003) and related to negative placebo 
suggestions (Geers, Helfer, et al., 2005).  Overall, it seems that dispositional optimism is 
relevant in the context of a suggestion for positive outcomes.  It has been suggested that 
optimists are more likely to be persuaded by positively framed suggestions (Geers, 
Helfer, et al., 2005), for example information regarding treatment benefits, as optimism 
itself pertains to relatively stable expectations that good things will happen.  Perhaps 
dispositional optimism can be considered as an information processing bias towards 
information that confirms and strengthens initial positive expectations.  This theory of 
how optimism may affect the magnitude of expectancies is similar to cognitive-
attentional bias theories of how expectations may lead to placebo responses (Sirois, 2001, 
2009; Stewart-Williams, 2004). 
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D. Self-Focused Attention 
 Self-focused attention (SFA) is another individual difference variable 
hypothesized to influence levels of expectation of benefit through its effect on cognitive-
attentional processing.  In the present study, this variable was found to be just as relevant 
as optimism in its association to expectations to benefit from treatment, if not more so.  In 
particular, in addition to displaying a modest correlation and regression coefficient in 
relation to treatment expectancies in the full sample, one‟s level of self-focused attention 
was found to be a fairly robust positive correlate in the Experienced sample, and to 
remain a significant predictor in the full regression model, uniquely accounting for 12% 
of the variance in the criterion.  These findings indicate that those who reported being 
more internally focused also reported greater expectations to benefit from treatment.  
This strong finding needs to be replicated in another IBS sample and in other illness 
groups, as it seems that this is the first finding of a positive correlation between levels of 
self-focused attention and levels of expectations of treatment benefit. 
 Despite its novelty, this finding is consistent with both placebo research and 
theory.  In particular, the Belief-Activation Model of placebo responding posits that 
levels of self-focused attention influence placebo responding as those with higher levels 
of SFA may direct attention away from external information (i.e., placebo suggestions) 
towards more internal sensations and cues, which may contradict externally introduced 
expectations, thus moderating the degree or direction of one‟s expectations regarding the 
intervention (Sirois, 2001, 2009).   In one study of placebo responding (Geers at al., 
2006), it has been demonstrated that greater levels of induced self-focused attention are 
associated with increased placebo responding.  However, this relationship was found only 
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among those in the deceptive placebo group (versus the conditional placebo group).  To 
explain this latter finding, Geers and his colleagues speculated that among those with 
stronger (or more certain) initial placebo expectations (the deceptive placebo group), 
greater SFA guided information processing towards internal stimuli that confirmed these 
initial expectations.   
It is possible that this explanation regarding the results of the „certainty‟ 
manipulation could be used to explain the current differential results regarding self-
focused attention found across groups, in particular that self-focused attention (among 
other variables) displayed a stronger relationship to treatment expectancies in the 
Experienced group than in the full sample or the Inexperienced sub-sample.  In particular, 
it could be that those with previous treatment experience also had „stronger‟ or „more 
certain‟ initial expectations.  If this was the case, then the results of this study mirror 
those from the Geers study; specifically, level of self-focused attention displayed a 
relationship with treatment expectancies, but only among those with more 
certain/stronger initial expectations.   
According to expectancy theory, previous experience is considered to be the most 
effective factor in shaping expectancies, much more effective than other informative 
factors, such as third-party communication (Olson et al., 1996).  One can imagine that 
qualitatively, the „strength‟ or „level of certainty‟ of a specific expectation can vary from 
little more than a guess or hunch (no prior experience), to a moderate level of certainty 
(some prior experience) to the point where an expectation is subjectively equivalent to 
knowledge (extensive prior experience).  With this in mind, we would predict that those 
with previous experience with a similar treatment would likely have developed the most 
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„certain‟ or strongest expectations regarding the benefits of that specific treatment, 
regardless of the „level of benefit‟ that is expected.  Note that the „strength‟ of 
participants‟ treatment expectancies was not measured, but only the level of the expected 
benefit (from no expected benefit to excellent expected benefit).  It may have been useful 
to also have asked participants to rate how certain they felt about achieving that level of 
benefit or „how strong is your expectation to benefit at this level?‟  
Why would the strength of one‟s initial expectations influence whether self-
focused attention has an impact on placebo responding or level of treatment expectation? 
As described above, it has been suggested that stronger initial expectations guide 
information processing to confirm themselves; this, along with greater SFA (induced or 
trait) may lead to even stronger internally-directed expectation-confirmation biases.  
Before exploring this possibility further, it seems timely to discuss the relevance of 
previous treatment experience to current treatment expectancies in this sample. 
E. Previous Experience with Treatment 
 In terms of the relevance of psychosocial variables in the prediction of treatment 
expectancies, it seems that „previous experience with treatment‟ has been found herein to 
be relevant in more than one way.  First is the strong positive correlation between 
Previous satisfaction with preferred treatment and current expectations of treatment, 
along with the fact that this variable uniquely contributed to almost 20% of variance in 
treatment expectancies in the full regression model, among those who reported having 
had previous experience with their preferred treatment. The second way that previous 
experience stands out as potentially quite relevant is that it was found to moderate the 
relationships of TE to two of the psychosocial variables, and by way of the observation 
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that several other relationships that this study has attempted to quantify seem to vary 
based on whether the sample has had more or less previous experience with treatment.  
These findings will be addressed in turn. 
 The strong relationship identified between previous satisfaction and current 
expectations is fully consistent with both theory and empirical literature.  Both 
expectancy and placebo theorists posit that previous personal experience has the strongest 
influence on a person‟s beliefs and thus on their expectations about the outcomes of 
similar experiences (Olson et al., 1996; Price et al., 2008; Stewart-Williams, 2004). 
Quantitative research has confirmed that previous experience is an important correlate of 
outcome expectancies (Montgomery et al., 2003; Montgomery & Bovbjerg, 2003; 
Whalley, Hyland & Kirsch, 2008) and can have a strong and sustained influence on 
placebo responding (Colloca & Benedetti, 2006).  The qualitative findings are similar to 
those found in other studies, wherein past experience is mentioned in a narrative by most 
participants who are asked about expectations to benefit from treatment (Liddle et al., 
2007; Stone et al., 2005).  Together these results suggest that previous experience is an 
important factor to consider if one is interested in maximizing treatment expectancies in a 
therapeutic context.   
 Other than this direct relationship between previous treatment satisfaction and 
current treatment expectations, also of interest and potential relevance is how the 
significance of many relationships in the full sample fall out (are teased apart) when the 
full sample was examined as those with treatment experience versus those without.  Note 
that the experience level of the two groups differed in several ways.  For one, the 
Experienced sample had previous experience with the preferred treatment, while the 
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Inexperienced sample did not have previous experience with either treatment.  Also, the 
Experienced sample reported higher average numbers of current treatments and higher 
average numbers of past treatments.  With respect to the differential results, recall that 
previous treatment experience was shown in regression analyses to moderate the 
relationship between treatment expectancies and both Self-focused attention and Coping 
self-efficacy.  In both cases, a significant positive relationship was found in the 
Experienced group while no relationship was found in the Inexperienced group.  Three 
other variables displayed a significant relationship to treatment expectancies only in the 
Experienced group (Optimism, Acute health problems, and Hope), although regression 
analyses did not confirm a true moderating effect of treatment experience for these 
relationships.  It thus appears that having had previous experience with a similar 
treatment may create a context wherein certain psychosocial variables become more or 
less relevant in their associations with levels of treatment expectancy.  This again 
highlights the importance of considering one‟s previous treatment experiences, yet leaves 
us pondering the explanation.   
 Turning back to theories of expectancy formation suggests a possible explanation.  
In particular, Olson and colleagues (1996) describe how previous experience can shape 
expectations also by influencing „other beliefs.‟  Perhaps among those whose memories 
of a previous similar treatment experience are activated, the beliefs that were influenced 
by/ are associated with that experience are also more strongly activated and thus more 
available to influence current expectations of treatment.  This model also fits with 
theories of illness representations (Leventhal, Meyer & Nerenz, 1980), which posit that 
people have a collection of beliefs (sometimes implicit) about their illness that are formed 
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and later activated in response to stimulus information about the illness (which could 
include practitioner suggestions, proposed treatments, etc).  It has been found that the 
activation of a certain illness representation (e.g., one associated with a particular 
previous treatment) depends on the specificity of the stimulus information that is 
presented (Henderson, Hagger & Orbell, 2007), with very specific illness representations 
being activated by specific stimuli.  Thus, in the current context, it is possible that a 
specific treatment could activate a specific illness representation containing not only 
memories of one‟s previous experience with that treatment, but also the beliefs that were 
influenced by that experience.  Once those associated beliefs are activated, they are 
accessible to influence current beliefs and expectations.   
 There is an alternative, but not incompatible, explanation of why stronger 
associations between psychosocial variables and treatment expectancies are found among 
those with more treatment experience.  Returning to the concept that prior experience 
with a specific treatment can result in „stronger‟ or „more certain‟ expectations about 
being able to benefit from that treatment, it is suggested that the beliefs that may be 
associated with that treatment (e.g., control beliefs, self-efficacy beliefs) may also 
become stronger or come to be held with greater certainty.  In that case, it may be that 
those who „know‟ more about treatments also know more about their ability to control 
and cope with their symptoms in the context of those treatments.  Whereas for the less 
experienced, whose beliefs and expectations may be less certain, the task of rating one‟s 
expectations and beliefs may involve more guess work leading overall to weaker 
relationships between these variables.                
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 It is estimated that approximately 50% of individuals with IBS seek treatment for 
their symptoms (Cremonini & Talley, 2005).  Specifically taking into account the greater 
treatment experience of the Experienced group, it should be noted that there have been 
some studies documenting differences among individuals with IBS who seek treatment 
vs. those who do not.  For example, individuals who seek treatment for IBS have been 
found to make more somatic attributions for their IBS symptoms (Martin & Crane, 2003), 
and to report higher levels of bodily preoccupation (Crane & Martin, 2002, 2004b) higher 
levels of general anxiety and symptom-specific anxiety (Crane & Martin, 2004; Hazlett-
Stevens et al., 2003), as well as lower levels of quality of life and coping resources 
(Ringström, Abrahamsson, Strid & Simrén, 2007) than do non treatment seekers.  
Although these findings should be taken into account when considering the more 
numerous relationships identified herein in the Experienced vs. Inexperienced groups, 
this explanation on its own cannot be used to explain the current results.  For one, having 
less experience with treatment cannot be considered the equivalent of being a „non 
treatment seeker.‟  Furthermore, in the current study, SFA was the only psychosocial 
variable found to differ between these groups.         
F. Interaction of Previous Experience and SFA 
 Returning for a moment to considering the role of SFA, both Geers and 
colleagues (2006) and the Belief-Activation Model suggest that greater levels of SFA 
guide information processing toward internally generated information (e.g., sensations, 
cues) which then influence one‟s expectations, and thus placebo responding.  It is 
important to note that both models discuss how SFA should influence outcome 
expectations at a point in time after the intervention.  However, in the current study, trait 
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SFA was examined (and found to be relevant) at a point prior to intervention, and thus 
would not be guiding information processing towards expectation-confirming or 
disconfirming sensations, per se.    
In this case it is plausible that greater self-focused attention would guide 
information processing towards other internal aspects of the self, (such as beliefs about 
the self or beliefs about treatments) for confirmation or disconfirmation (and thus 
modulation) of externally-derived expectations for the current situation (e.g., “This 
treatment will work for you”).  Indeed it has been shown that greater self-focus increases 
access to self-knowledge (Gibbons, 2006) and according to expectancy theorists, 
accessibility is one of the determinants of the strength of a belief and its corresponding 
expectancy (Olson et al., 1996). With this in mind, it seems reasonable to suggest that 
personal health beliefs may be stronger predictors of treatment outcome beliefs (and 
expectancies) among individuals with higher levels of self-focus relative to individuals 
with lower levels of self-focus.  Consistent with this hypothesis, recall that SFA was the 
only variable (other than the treatment experience variables) on which the Experienced 
and Inexperienced groups differed, with those with previous experience reporting higher 
average levels of SFA.  Thus, it could be that differential levels of SFA can account for 
the fact that among the Inexperienced very few individual difference and health belief 
variables contributed to TE, whereas among the Experienced there were several 
significant variables. 
There may be a third, more inclusive, possible explanation.  Namely, it is 
proposed that in the Experienced sub-sample, a combination of previous experience and 
increased self-focused attention was responsible for the greater number of relevant 
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relationships between psychosocial variables and current treatment expectancies.  As 
described above, it has been proposed that previous experience with a certain treatment 
would create a) stronger initial expectations that may then guide information processing 
towards their confirmation, and b) the activation of treatment-specific associated beliefs 
in one‟s illness representation, and c) more certain treatment-related beliefs and more 
certain associations between those beliefs and treatment expectations.  It may also be, as 
in the Geers et al study, that presumably „stronger‟ or „more certain‟ and more specific 
initial expectations then combine with greater SFA to produce these differential results.  
In other words, among those with previous experience with their preferred treatment, 
their stronger and more specific initial expectations, coupled with greater SFA, led to a 
situation where individuals had more access to, more certainty regarding, and thus 
consulted their related illness and treatment beliefs when asked to explicitly rate their 
level of expectation.  As „strength‟ or „certainty‟ of treatment expectancies were not 
manipulated or assessed in the current study, this model remains only speculative and in 
need of further study.  
G. Current Health 
 Returning to an examination of the relative importance of different psychosocial 
variables in the prediction of treatment expectancies, first we will examine the factors 
that were significant in the Experienced group only, potentially as a result of the action of 
the just-proposed mechanisms.  Current health, measured by totaling the number of acute 
common health problems endorsed by the participant, did show a significant inverse 
relationship with TE in the Experienced sample.  Despite a relatively modest zero-order 
correlation, this was the only health belief variable to remain a significant predictor of TE 
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in the full regression model.  As hypothesized, those who reported experiencing more 
acute health problems in the last six months also reported lower expectations to benefit 
from the current treatment.  These results are consistent with research reporting that one‟s 
relative health stock is positively correlated with expectations regarding treatment 
outcome (Weinfurt et al., 2003).   
H. Self-Efficacy 
Coping self-efficacy was another variable found to be a modest positive correlate 
of TE in the Experienced sample, but not in the other samples.  It was not a significant 
predictor in the regression model, however.  This variable was included to capture an 
aspect of symptom management to complement the measure of symptom severity.  This 
coping self-efficacy scale assesses the belief that one is successfully coping with the day-
to-day aspects of one‟s condition.  Although coping self-efficacy has been previously 
linked to health outcomes in illness populations, such as quality of life (Henderson, 2003) 
and overall functioning (Strahl, Kleinknecht, & Dinnel, 2000) this is the first time that 
this variable has been linked specifically with expectations to benefit from treatment.  
This result fits with expectancy theory in a manner similar to how control beliefs are 
thought to influence expectancies.  In particular, Olson et al. (1996) note that high self-
efficacy implies that success is expected and that success reflects personal capacities; 
thus, individuals with high self-efficacy will attribute positive changes to internal factors 
and will expect future positive changes.  In addition, as described above with reference to 
control beliefs, it may be that confidence about managing one‟s symptoms is related to 
expectations to benefit from treatment by way of treatment adherence self-efficacy 
(French & Weinman, 2008).  For example, if relaxation exercises are a part of the 
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treatment plan and one is confident about engaging in relaxation, then one may report 
higher levels of confidence in being able to cope with the day-to-day aspects of one‟s 
condition (coping self-efficacy) as well as higher levels of expectation to benefit from 
treatment. 
Interestingly, scores on the health self-efficacy scale, which assessed feelings of 
competence and confidence to carry out actions important for maintaining and taking care 
of one‟s health in general, were not related to TE in any sample.  These results confirm 
that self-efficacy regarding one‟s ability to do what needs to be done to be healthy in 
general are distinct from self-efficacy beliefs that are specific to coping with one‟s illness 
(Chesney, Neilands, Chambers, Taylor, & Folkman, 2006), and suggest that the latter 
beliefs are more relevant with regards to expectations regarding specific treatments.  This 
pattern is similar to the one noted above regarding the relatively stronger influence of 
symptom-specific control beliefs versus general health control beliefs on TE.        
I. Hope 
 The final variable found to be positively correlated with expectations of benefit in 
the Experienced sample was Hope.  It did not however, contribute to significant amounts 
of variance in TE when in a model with the other individual difference variables.  The 
finding that higher levels of dispositional hope were correlated with more positive 
treatment expectancies is consistent with one other study where levels of hope were 
correlated with expectancies for positive non-volitional outcomes (Montgomery et al, 
2003).  The relatively weak relationship identified herein between levels of hope and 
levels of positive expectation for treatment suggests that although hope may be somewhat 
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relevant among those with greater self-focused attention and previous treatment 
experience, it is not as relevant as its conceptual cousin, optimism.   
J. Catastrophizing 
Two other variables to be discussed are those for which there was a significant 
correlation with the dependent variable in the full sample only.  One of these is 
„catastrophizing,‟ which was the only other health belief variable to show a significant 
correlation to treatment expectancies in the full sample and to remain a significant 
predictor of TE in the full regression model.  Its relationship with expectations was fairly 
weak, it uniquely contributed to only 3% of the variance; yet this was more than was 
contributed by optimism in the full sample.  The direction of the relationship was 
surprisingly in the opposite direction to what was hypothesized.  It was found that those 
who endorsed more catastrophizing beliefs about their symptoms also reported higher 
levels of TE.  This is the first time that catastrophizing has been linked with treatment 
expectancies, thus the directionality of this relationship cannot be compared with findings 
from other studies.  It was included in the current research because it has been studied in 
samples with gastrointestinal disorders, and found to be related to less favourable health 
outcomes (Drossman, et al., 2000; Rutter & Rutter, 2002). „Catastrophizing‟ is the short 
title used herein for the „catastrophizing interpretation of bodily complaints‟ scale, which 
measured the tendency to interpret physical symptoms and sensations as indicators of 
serious illness.  It could perhaps be argued that this scale assesses a tendency to be 
anxious about one‟s symptoms (i.e., trait symptom anxiety).  If so, this finding may echo 
the mixed findings that have been described regarding the influence of anxiety on 
expectations and placebo responding.     
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K. Patient-Provider Relationship 
Perceived quality of the patient-provider relationship was one context-dependent 
psychosocial variable that was positively correlated with TE in the full sample, but not a 
significant predictor when entered with the context-dependent variables in the full 
regression model.  This factor was not correlated with TE in either of the other samples, 
suggesting that very weak effects in both the Experienced and Inexperienced group may 
have combined additively to result in a weak but statistically significant finding in the full 
sample.  These weak relationships between treatment expectancies and the patient-
provider relationship is likely an artifact of a) the hypothetical nature of the provider, and 
b) efforts to minimize the emotional/ relational aspects of the provider in the treatment 
vignettes.  
The finding that higher levels of perceived quality in the patient-provider 
relationship was related to greater expectations to benefit from treatment is consistent 
with theory in both the placebo (Miller & Kaptchuk, 2008) and expectancy literatures 
(Harris & Rosenthal, 1985).  Empirically, provider interactions have been linked with 
both greater expectations to benefit from treatment (Beach et al., 2006) and greater 
placebo responding (e.g., Colloca et al., 2004; Kaptchuk et al., 2008).  Some authors have 
even suggested that the placebo effect be renamed the „contextual healing‟ effect and 
have emphasized that placebo research should focus its efforts on examining the 
contextual aspects of the therapeutic situation, especially aspects of the relationship 
(Miller & Kaptchuk, 2008).    
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L. Variables Not Related to Treatment Expectancies 
 Before moving on to summarize and discuss the potential implications of the 
significant findings found in the current study, it is important to note that several of the 
psychosocial variables hypothesized to be correlated with levels of treatment expectations 
were not found to be relevant correlates in this sample.  For some of these variables, these 
findings are not a great surprise; in particular, the non-significant relationships of TE with 
Perceptions of health, Health self-efficacy and beliefs of Vulnerability to illness.  Both 
Health self-efficacy and Vulnerability to illness were included in the current study as 
potentially relevant psychosocial variables based on some demonstrated relationships 
with health outcomes.  Neither had been previously associated with placebo responding 
or treatment expectancies themselves.  Perceived levels of general health had been 
previously documented to show a relationship to treatment outcome expectancies in 
studies using different measures of overall health, particularly „relative health stock‟ and 
the Medical Outcome Scale –Short Form 36 (Cheng et al., 2000; Weinfurt et al., 2003).  
Seeing that in this study, treatment expectancies were related to current health using the 
other index (number of acute health problems), suggests that perhaps the three author-
created questions used to measure „perception of health‟ did not accurately capture 
participant‟s overall sense of their general health.      
 The null findings regarding both trait anxiety and motivation are of more interest 
in the context of understanding placebo mechanisms, as both have been linked with 
placebo responding and have been frequently cited as potential mediators of the placebo 
effect.  The finding that trait anxiety was unrelated to treatment expectancies is consistent 
with some studies that have reported no relationships between trait anxiety and treatment 
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expectancies (McCarthy et al., 2003; Montgomery et al., 1998).  It is inconsistent, 
however, with the results of an experimental placebo study with an IBS sample where 
levels of anxiety regarding experimental pain were positively correlated with levels of 
expectation of pain, and where together anxiety and expectation predicted significant 
levels of variance in reported pain (Vase, Robinson, Verne & Price, 2005).  Perhaps these 
differential results are due to a study‟s focus on either trait anxiety (no relationship) vs. 
treatment or symptom-specific anxieties (some relationship).  Another possible 
explanation for these differential results (which may work in conjunction with this first 
suggestion) is the negative or positive valence of the treatment/ intervention.  In the Vase 
et al study (2005), participants were told to expect pain, whereas in the current study 
participants were presented with a potentially beneficial treatment.  Whereas the former 
suggestion may understandably lead to increased anxiety, the latter would likely not.  
Recently, neurobiological findings have revealed that at least in the context of placebo 
hyperalgesia (or nocebo hyperalgesia) where one is told to expect pain, the expectation of 
pain leads to anxiety itself, which then increases pain through neurobiological processes 
of its own.  In particular, anxiety regarding pain leads to increased activation of 
cholecystokinin, a peptide hormone that facilitates pain transmission (Colloca & 
Benedetti, 2007; Enck, Benedetti & Schedlowski, 2008).  These recent findings suggest 
that although anxiety and expectation may work together to influence outcome in 
situations where outcomes are considered adverse, they may not necessarily be correlated 
in situations where the outcomes themselves are not anxiety-producing.     
 The other potentially meaningful null result in the current study is the finding that 
none of the measures of motivation (i.e., Desire for relief, Symptom severity, IBS: 
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Interference with daily activities, or Socially desirable responding) were related to levels 
of expectation to benefit from treatment.  These findings are not necessarily inconsistent 
with placebo research.  In particular, previous research has documented that motivational 
factors, such as desire for relief or desire to please the experimenter, contribute to 
enhanced placebo responding.  In one of these studies, expectations were not directly 
measured, thus the authors could only speculate that the motivational element influenced 
placebo responding through its interaction with outcome expectations.  Specifically it was 
suggested that when goals and expectations are in line there will be greater placebo 
responding as opposed to when goals and expectations are out of line (Geers et al., 2005).  
In three other studies where expectations were measured explicitly, although it was 
reported that both expectancies and desire for relief (as well as their interaction) predicted 
levels of placebo responding, it was not reported whether there was a significant 
relationship between the two variables (Price et al., 2005; Vase et al., 2003; Vase et al., 
2005).   
In the current study it was hypothesized that motivational factors might be related 
to treatment expectancies as these previous studies have not indicated otherwise and this 
hypothesis is in keeping with placebo theories wherein expectations (conscious or 
unconscious) represent the final common pathway in placebo responding (Kirsch, 1985).  
Other researchers, however, have suggested that motivational factors contribute to 
placebo responding directly (Vase et al., 2003).  The contribution of motivational factors 
to placebo responding in earlier studies, combined with the null relationship between 
motivation and treatment expectations in this study, together lend support to the theory 
that such motivation factors work either independently or in concert with expectations to 
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contribute to placebo responding, as opposed to being mediated by expectations.  Recent 
brain imaging studies further support this view; it has been documented that there is 
activation of expectations areas as well as motivation/emotion areas during placebo 
responding (see Price et al., 2008).         
M. Qualitative Findings 
 It is interesting to note that in the narrative responses, it was the context-
dependent factors that were mentioned most frequently.  Specifically, when asked to 
comment on what personal factors may contribute to one‟s own expectations to benefit 
from treatment, a great number of participants gave statements referring to aspects of the 
treatment itself, and how this meshed with their perspectives/experiences/lifestyles.  The 
two most referenced pre-set categories were Treatment experience and Illness 
attributions.  Furthermore, all of the emergent categories were either extensions of these 
themes of previous experience and illness attributions or referred directly to aspects of 
the treatment (side effects, aversion, and convenience) that weren‟t manipulated or 
measured in this study. 
III. Summary and Implications  
This research was designed to identify and quantify the relative contributions of 
various personal psychosocial variables to expectations to benefit from treatment in an 
IBS sample.  In the pursuit of this end, this research has been successful in several ways.  
For one, this research has successfully achieved its specific aims and answered its main 
research questions focused on identifying a parsimonious set of psychosocial variables 
that are associated with treatment expectancies in an IBS sample.  Second, it has both 
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supported and extended the conceptual models that together guided this research in its 
aims.  Importantly, it has provided valuable information that can be used to clinically in 
the treatment of IBS.  And lastly, it has highlighted areas of study that are in need of 
more empirical investigation.   
Consistent with Response Expectancy Model (Kirsch, 1985) and Olson et al., 
(1996) expectancy formation theory, past direct experience was an important context-
dependent variable in this model predicting treatment expectancies.  For one, previous 
experiences with a specific treatment (i.e., previous satisfaction) were directly positively 
associated with current treatment expectancies.  Although Olson et al., outlined that prior 
experience will have an important influences on one‟s beliefs, the current findings 
regarding the moderating effect of prior treatment experience on the relationships of 
various psychosocial variables to treatment expectancies add a unique and important 
piece to our understanding of the role of previous experience in this model.  Both Kirsch 
and Olson et al. gave some consideration to the potential role for attributions in a model 
predicting (treatment) expectations.  The current research has made a contribution by 
providing empirical support for this theorized association, namely by linking treatment 
expectancies to individuals‟ perceptions of the somatic/ psychological focus of their 
treatment.  A strong inspiration for the current research, the Belief Activation Model 
(Sirois, 2001, 2009) suggested that individual difference variables and health belief 
variables have a role to play in influencing one‟s expectations regarding a proposed 
intervention.  The current research has supported and extended this model by a) providing 
empirical support for the associations between TE and self-focused attention and 
optimism, and b) identifying several health belief variables that contribute to treatment 
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expectancies (control beliefs, coping self-efficacy, perceptions of current health).  The 
findings regarding the null relationships of motivation and anxiety to treatment 
expectations may provide support for models of the placebo effect that suggest that these 
variables influence placebo responding without being mediated by expectancies (e.g., 
Price, Finniss & Benedetti, 2008).  Finally, although it is well accepted that contextual 
factors are important variables in a model predicting treatment expectancies and placebo 
responding, the current research has identified some further treatment-specific variables 
reported to influence an individuals‟ positive expectations about treatment (e.g., 
convenience, aversion, side-effects).  This research further contributes to our 
understanding of why placebo research has been unable to identify a consistent placebo 
responder, or to isolate the individual difference or personality traits that can be 
consistently used to predict placebo responsiveness.  In particular, this research highlights 
that the treatment expectations that mediate placebo effects are influenced by a variety of 
individual difference and health belief factors whose individual influences may vary 
considerably according to the impact of important context-dependent psychosocial 
factors.  Truly it seems that expectations effects are influenced by a dynamic interaction 
of person and context.  
In terms of the implications of this research for the treatment of irritable bowel 
syndrome, the current research findings are unique in that they specifically demonstrate 
which psychosocial factors contribute to treatment expectancies in this sample (and their 
relative contributions).  This information can be translated into informing treatment 
providers about psychosocial factors that should be addressed if one‟s goal is to 
maximize the expectation effect in the therapeutic context of treating individuals with 
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IBS.  First these results highlight the importance of assessing patients‟ perceptions of the 
extent to which the proposed treatment targets what are perceived as the somatic causes 
of IBS symptoms.  It has also been proposed herein that it may be relevant to assess and 
understand a patient‟s preference for a more somatically or psychologically focused 
treatment.  These results also highlight the importance of assessing whether a patient has 
had previous experiences with the proposed treatment(s), and if so, assessing how 
successful they perceived the previous treatment to be.    
This research has demonstrated that personal health beliefs do indeed have a role 
in influencing one‟s expectations to benefit from treatment.  Overall, specific health 
beliefs, as opposed to more general health beliefs, seem to be more relevant to TE for 
specific treatments.  The results suggest that control beliefs, particularly beliefs about 
one‟s ability to control and manage one‟s symptoms, are one of the more relevant health 
beliefs to consider.  Other research, guided by Leventhal‟s Common-Sense Model of 
health (CSM; Nerenz & Leventhal, 1983; Meyer, Leventhal & Gutmann, 1985), has 
demonstrated that control beliefs are an important aspect of one‟s illness representation 
that can be ameliorated through intervention, resulting in improved health outcomes 
(Petrie, Cameron, Ellis, Buick & Weinman, 2002).  In the CSM, illness representations 
are related to outcome via changes in people‟s coping actions and efforts.  However, 
accumulating research has suggested that illness representations may be associated with 
outcomes independently of coping strategies (Hagger & Orbell, 2003).  The current 
research findings suggest that certain aspects of one‟s illness representation (e.g., control 
beliefs and attributions) may influence outcomes through their positive influence on 
expectations for treatment benefit.   
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Another important individual difference factor to consider, according the results 
of this study and others (i.e., Geers et al., 2006) is one‟s level of self-focused attention.  
The present research found that among those with more previous treatment experience, 
people with higher levels of self-focused attention also reported greater expectations to 
benefit from treatment.  Thus, contrary to the idea encountered in IBS literature that 
increased bodily preoccupation is a pathological attribute of IBS treatment seekers, the 
current findings suggest that people with more self-focus are more optimistic about their 
ability to benefit from treatment.  It makes sense that with more treatment experience, 
people who are more internally-focused may become more skilled at monitoring their 
IBS symptoms, discriminating them from non-IBS symptoms, and making useful 
connections about how symptoms respond to different aspects of a treatment intervention.  
It follows that such people would then report more confidence in their ability to benefit 
from treatment.  Although it may not always be easy or practical to assess a patient‟s 
level of dispositional self-focused attention, other research studies have shown that 
greater SFA can be induced (e.g., Geers et al., 2006).  In fact, enhancing body/ somatic 
awareness is an increasing popular component of treatment in several areas of healthcare. 
The findings of this research also point to a role for some other health belief 
variables that demonstrated a relationship to treatment expectancies.  In particular, one 
might consider assessing a patient‟s tendency to catastrophize about their bodily 
symptoms, how many acute health problems they are dealing with, as well as the degree 
to which they feel they can cope with the day-to-day aspects of their symptoms.  This 
research suggests that individuals with „stronger‟ initial expectancies (for example due to 
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prior personal experience) and greater levels of self-focused attention may be more in 
touch with these intrinsic health beliefs that can alter their expectations for treatment. 
Another potential implication for the treatment of IBS concerns the treatment 
preferences that were expressed by participants during the pilot study.  Healthcare 
providers should be aware that the majority of participants in the pilot sample expressed a 
preference for a treatment that combined both pharmacological and psychological 
approaches to the management of their IBS symptoms.  This finding was further 
supported by the qualitative data, wherein several participants made reference to a 
preference for a holistic approach to treating their IBS, and/or discussed their symptom 
attributions as having both physical and psychological components.   
The implications for clinical practice that are suggested by these overall findings 
are that it is important to provide patients with opportunities to enhance their sense of 
control over their illness and their symptoms.  For people with IBS, because of the 
elusive etiology of symptoms and the range of treatment approaches that are available, 
being able to make decisions regarding the choice of treatment may be a simple and 
effective strategy to engender enhanced feelings of control.  It is suggested that a clinical 
interview include an exploration of a person‟s understanding of the success or failure of 
previous treatments, attributions for symptom causes and management, preferences for 
different treatment approaches, confidence for day-to-day coping and success with bodily 
awareness.  If available, cognitive-behavioural interventions could be used to address any 
emergent maladaptive beliefs in the service of fostering a strengthened sense of control.        
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IV. Limitations and Suggestions for Future Research 
 The present results add to existing literature by extending our knowledge of which 
psychosocial variables display relationships to treatment expectancies in an IBS sample.  
There are, however, limitations of the present work that should be highlighted.  First, 
several aspects of the design of the study limit the generalizability of these findings.  
Although efforts were made to recruit participants from the community, and to offer 
individuals the opportunity to complete a paper version of the study, the majority of the 
data was collected online and the majority of participants were recruited from the 
„volunteer‟ section of websites that host free online classified ads.  One issue regarding 
this type of sampling method is potential bias introduced as participants had to have 
access to the Internet, be savvy to Internet classifieds sites and also be interested in 
volunteering.  This may have resulted in the generally higher level of education of the 
sample, and may have contributed to the sample being predominantly Caucasian and 
female.  The ratio of female to males in this study (5.7:1) is higher than what would be 
expected if sampling from the general IBS population (where prevalence estimates by 
gender range from 2:1 female predominance to a ratio of 1:1 (Saito, Schoenfeld & Locke, 
2002).  It has been suggested that participants who volunteer to complete an online 
survey may differ in systematic ways from those recruited from patient populations in the 
community (Soetikno, Mrad, Pao & Lenert, 1997).  Evidence from other studies suggests 
that individuals with gastrointestinal disorders that are recruited from the Internet report 
more serious symptomatology and less functionality than those recruited in the 
community (Jones, Bratten & Keefer, 2007).   However, some research on the 
characteristics of participants from Internet studies suggest that such samples are more 
 169 
heterogeneous that their community based counterparts (Krantz & Dalal, 2000), and that 
data collected online are of as good quality as community-collected data (Gosling, 
Vazire, Srivastava & John, 2004).  One advantage of conducting online research with 
illness populations is that it provides an opportunity to reach individuals who may not 
normally be recruited in the community because of limited mobility and other illness 
related restrictions (Sirois, 2003).  
 The use of a cross-sectional design in the context of an Internet survey allowed 
for the recruitment of a large sample of individuals with IBS over a relatively small 
amount of time and with little financial investment.  A limitation of this design, however, 
was that the main dependent variable (expectation to benefit from treatment) was elicited 
using fairly generic hypothetical treatment scenarios.  It is possible that both the 
significance and the magnitudes of the relationships found herein may not generalize to 
an in vivo treatment scenario or to a real-world therapeutic context.  For example, it is 
presumed that the fairly weak relationship between TE and Patient-provider relationship 
may be a function of the hypothetical nature of the provider (and thus the relationship).    
In addition, the cross-sectional nature of the design certainly precludes any conclusions 
regarding causality.  It also may have limited this study‟s ability to identify a relationship 
between TE and the psychosocial variables that are theorized to influence treatment 
outcomes either after the administration of an intervention (e.g., self-focused attention, 
anxiety) or by way of an interaction with TE (e.g., motivational factors).  Future studies 
may wish to explore these relationships in a more naturalistic environment using a 
prospective design, which would allow for further clarification of the relationships and 
relative roles of these variables in a real-life treatment context.  It would certainly be of 
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interest to see whether these more intrinsic psychosocial variables (e.g., health beliefs, 
illness attributions) remain relevant predictors over and above the presumably powerful 
influence of a strong patient-provider relationship. 
 Limiting this investigation to one illness population has allowed for increased 
control over several possibly confounding sources of variance.  It has also allowed for a 
greater understanding of what may be the most relevant psychosocial variables for this 
illness group, potentially contributing to improved management of this syndrome.  
However, it does limit the generalizability of these results to other illness populations. 
It may be that some of the relationships are relevant only in an IBS sample.  For example, 
catastrophizing about bodily complaints has been noted and studied primarily in IBS 
samples (Gomborone et al., 1995; Kolowski et al 2005), and it may be that it is not a 
relevant factor influencing TE in other illness groups.   Furthermore, as suggested above, 
certain variables such as control beliefs may show stronger relationships to TE among 
illness groups where there is more treatment choice or where treatment adherence 
requires more day-to-day personal effort (French & Weinman, 2008).  Additional 
research is needed to ascertain which of these relationships are confirmed in other illness 
samples, both functional and organic.  It may also be of interest to explore these 
relationships in the context of the treatment of an acute illness or injury.  
 It is also important to take into account the fact that the majority of participants in 
the pilot study chose the combined treatment (with both pharmacological and 
psychological aspects), yet this treatment was not offered in the main study.  As such, it 
is possible that participants in the main study may have felt that they were being offered 
the choice between two less-than-ideal treatments, as opposed to the type of treatment 
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they would actually prefer.  This situation could have contributed to low engagement 
during survey completion, jeopardizing the validity of study findings.  Although this is a 
possibility, it should be noted that several efforts were made to increase the credibility 
and acceptability of the treatment vignettes.  For example, each proposed treatment 
contained dietary components (consultation and specific recommendations), as this is 
considered the most important line of treatment for the management of IBS symptoms.  
In addition, each treatment plan involved a thorough assessment of personal triggers for 
IBS symptoms as well as an educational component, and each treatment plan was based 
on actual state-of-the-art treatment approaches.  
 This research also had some methodological limitations.  The main problem that 
arose with methodology was the weak psychometric properties of the original measure of 
illness attributions.  Although the analysis was unable to proceed as planned due to the 
failure of this instrument, perceived somatic/psychological foci of treatment was 
available for use as an approximation of a participant‟s illness attributions.  Additional 
work may be needed to develop and/or validate a sound measure of illness attributions. 
Responses in the qualitative data also highlighted the need to measure a participant‟s 
holistic illness attributions (mind-body interaction), and to a lesser extent, situational 
symptom attributions.  Future work should consider including these aspects of illness 
attributions and assessing their contribution to treatment expectancies.     
 An additional methodological limitation is the failure to measure the „strength‟ of 
one‟s expectation to benefit from treatment.  This research was originally interested in 
how „positive‟ one‟s treatment expectancies were, ranging from no expected benefit to 
excellent expected benefit, as this is how treatment and outcome expectancies are 
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typically measured.  However, it may be advisable for future researchers to include a 
measure of the „certainty‟ or „strength‟ of an expectation, as this aspect of the expectation 
has been proposed to play a role in the extent to which expectancies guide information 
processing (Geers et al., 2006).    
 One further potential limit to the generalizability of some of these findings is that 
the relationships of psychosocial variables to outcome expectancies were only examined 
in the context of suggestions for positive outcomes (i.e., “This treatment will help with 
those symptoms.”)  It has been shown throughout the literature that some relationships 
that stand in the context of positive suggestions may not hold up under conditions 
including negative suggestions (e.g., Geers et al., 2007; Montgomery et al, 2003).  
Further work investigating the correlates of expectations for negative outcomes in an IBS 
sample would likely be clinically relevant, as most treatments (especially 
pharmacological ones) are associated with negative side effects.  Sensitivity to side 
effects could potentially be reduced if contextual and psychosocial correlates of negative 
expectations could be identified and managed.   
V. Conclusion 
 The placebo literature has clearly highlighted the important role that outcome 
expectancies play in enhancing one‟s response to an intervention.  As such, interest has 
been growing in regards to identifying the factors that contribute to or interact with these 
expectations.  The current study was designed to identify, in particular, the salient 
psychosocial variables that are relevant in influencing expectations to benefit from a 
proposed treatment.  This research has been successful in identifying a manageable set of 
psychosocial variables that contribute to positive treatment expectancies in an IBS 
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sample.  In several instances this was the first time these variables had been linked in an 
IBS sample.  Two of the context-specific psychosocial variables identified as relevant in 
this sample included previous satisfaction with similar treatments and the level of 
perceived somatic focus of the treatment.  In addition, control beliefs, self-focused 
attention and optimism were identified as variables intrinsic to the individual that had an 
influence on whether one expected to benefit from treatment.  If the relevance of these 
variables can be confirmed in a naturalistic IBS treatment context, the next steps would 
be to assess whether these important variables can be addressed efficiently in a 
therapeutic context.  This work would ideally lead towards the development and 
implementation of guidelines and interventions designed to target and utilize these 
idiosyncratic beliefs and information-processing biases in an effort to maximize 
expectations of treatment success and therefore the effectiveness of the therapeutic 
intervention. 
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 APPENDICES 
Appendix A. Letter of Information to Site Moderators  
 
I am contacting you to request your assistance with recruiting participants for an on-line 
research study on expectations of treatment for irritable bowel syndrome (IBS). 
 
The purpose of this study is to investigate the personal factors that influence an 
individual‟s expectations of benefiting from treatment.  Previous research has shown that 
expectations regarding treatment play an important role in treatment success, but little is 
known about what individual factors contribute to the magnitude of positive expectations.  
The main study will look closely at the individual factors that may influence treatment 
expectations.  We expect data collection to take approximately 12 months.  Before we 
conduct the main study, a pilot study will be conducted to validate the treatment vignettes 
to be used in the main study.  This pilot study will last approximately three weeks.  
Individuals who participate in the first study would not be eligible to participate in the 
second study.  
 
A link placed on your message board to the following website mylinkhere would be of 
great assistance.  Interested participants would simply click on the link if you agree to 
post it on your board, and then after reading the letter of information they can make an 
informed decision about participating. The survey for the first study takes about 10 
minutes to complete and the survey for the main study takes about 25 minutes to 
complete.  All information provided will be kept confidential.  We will also produce a 
brief on-line report of our findings for anyone interested by June 2009. More information 
about the study is available on our web site.  
 
As an incentive participants will be given a chance to win one of several gift certificates 
from a major on-line bookseller. 
 
This research has been approved by the University of Windsor Research Ethics Board. 
 
If you have any questions or require more information about the study, please contact me 
at (519) 256-2586, or by email at wilso2c@uwindsor.ca. 
 
Please send a reply to this email, regardless of your intent to participate.  Please check 
below your participation interests:   
 
 Agreement to post recruitment message for main study  ____ 
 Agreement to post recruitment message for pilot study   ____ 
 No interest in participating          ____  
 
Thank you for your time and assistance. 
Tobi Wilson, M.A.  
Fushia Sirois, Ph.D. 
Department of Psychology 
University of Windsor 
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Appendix B. Materials for Recruiting via Gastroenterology Clinics 
 
Letter of Recruitment to Gastroenterologists 
 
I am contacting you to request your assistance with recruiting participants for an on-line 
research study on treatment expectations among individuals with irritable bowel 
syndrome (IBS). The purpose of this study is to investigate the relationships between 
individual difference factors (optimism, hope, anxiety, etc), health beliefs (beliefs of 
vulnerability to illness, control over symptoms, health self-efficacy, catastrophizing, etc) 
and treatment expectations among individuals with IBS.  There is a considerable 
literature supporting the link between treatment expectancies and treatment outcomes.  
This study is designed to investigate whether certain psychosocial variables, unique to 
each patient in a treatment situation, influence the strength of a patient‟s expectations of 
treatment.  Should this study be able to identify a parsimonious list of psychosocial 
variables that are correlated to the strength of one‟s treatment expectancies, these 
variables can then become potential targets of assessment and intervention in the service 
of maximizing treatment effectiveness.   
 
Posting our attached recruitment flyer in your clinic would be of great assistance. 
Interested participants would simply go to the website listed on the flyer to access the 
letter of information explaining the study, at which time they can make an informed 
decision about participating.  Should they decide to participate, they would read about 
hypothetical IBS treatment scenarios, rate their expectations of each treatment, and 
complete an online survey containing questionnaires designed to measure various 
individual difference and health belief variables.  The survey takes about 25 minutes to 
complete and all information will be kept confidential.  If preferred, participants can elect 
to complete a paper version of the package.. More information about the study is 
available on our web site.  
 
As an incentive participants will be given a chance to win one of several gift certificates 
from a major on-line book seller. 
 
This research has been approved by the University of Windsor Research Ethics Board.  If 
you have any questions or require more information about the study, please contact me 
by email at wilso2c@uwindsor.ca. 
 
Please send a reply to this email, regardless of your intent to participate.  Please check 
below your participation interests:   
Agreement to post recruitment message for study         ____ 
 No interest in participating          ____  
 
Thank you for your time and assistance, 
Tobi Wilson, M.A. 
Fuschia Sirois, Ph. D.  
Department of Psychology 
University of Windsor 
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Recruitment Flyer for Gastroenterology Clinics 
 
Would these Treatments Work for 
You Too? 
 
 „IBS Treatment Study –Two‟ 
 
The University of Windsor is looking for 
individuals age 16 and above with diagnosed 
irritable bowel syndrome to participate 
anonymously in an online survey study about 
individual‟s thoughts and beliefs about IBS 
treatments.  
 
Your participation would take about 25 minutes, 
and you would be entered into a draw to win one of 
several $20 gift certificates.  Please go to 
mylinkhere.com for more information. 
 
Please note that you may also complete a paper version of the study that 
we will mail to you along with a postage paid return envelope. Go to 
mylinkhere.com for more information. 
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Appendix C. Recruitment Messages 
 
1. Pilot Recruitment Message 
 
Would these IBS Treatments Work for You? 
The University of Windsor „IBS Treatment Study - One‟ is looking for individuals 
age 16 and above with diagnosed IBS to participate in an online survey study about 
individual‟s thoughts and beliefs about IBS treatments.  Your participation would 
take about 10 minutes, and you would be entered into a draw to win one of several 
$20 gift certificate.  Please click on the following link for more information:  
mylinkhere  
 
 
2. Main Study Recruitment Message 
 
Would these IBS Treatments Work for You Too? 
The University of Windsor „IBS Treatment Study –Two‟ is looking for individuals 
age 16 and above with diagnosed IBS to participate in an online survey study about 
individual‟s thoughts and beliefs about IBS treatments.  Your participation would 
take about 25 minutes, and you would be entered into a draw to win one of several 
$20 gift certificates.  Please click on the following link for more information:  
mylinkhere  
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Appendix D. Rome III IBS Criteria  
 
IBS Symptom Questionnaire 
For each question, please „check‟ the number that applies best to you: 
1. In the last 3 months, how often   did 
you have discomfort or pain anywhere 
in your abdomen? 
  ___  0   Never 
  ___  1   Less than one day a month 
  ___  2  One day a month 
  ___  3  Two to three days a month 
  ___  4  One day a week 
  ___  5  More than one day a week 
  ___  6  Everyday 
If you answered ‘never’ to the above questions, please skip remaining questions 
2. For women:  Did this discomfort or 
pain occur only during your menstrual 
bleeding and not at other times? 
  ___  0  No 
  ___  1  Yes 
  ___  2 Does not apply to me because   
                 I have had the change of life 
3. Have you had this discomfort or pain 
6 months or longer? 
  ___  0  No 
  ___  1  Yes 
4. How often did this discomfort or pain 
get better or stop after you had a bowel 
movement? 
  ___  0  Never or rarely 
  ___  1  Sometimes 
  ___  2  Often 
  ___  3  Most of the time 
  ___  4  Always 
5.  When this discomfort or pain started, 
did you have more frequent bowel 
movements? 
   ___  0  Never or rarely 
  ___  1  Sometimes 
  ___  2  Often 
  ___  3  Most of the time 
  ___  4  Always 
6. When this discomfort or pain started, 
did you have less frequent bowel 
movements? 
  ___  0  Never or rarely 
  ___  1  Sometimes 
  ___  2  Often 
  ___  3  Most of the time 
  ___  4  Always 
7.  When this discomfort or pain started, 
were your stools (bowel movements) 
looser? 
  ___  0  Never or rarely 
  ___  1  Sometimes 
  ___  2  Often 
  ___  3  Most of the time 
  ___  4  Always 
8. When this discomfort or pain started, 
how often did you have harder stools? 
  ___  0  Never or rarely 
  ___  1  Sometimes 
  ___  2  Often 
  ___  3  Most of the time 
  ___  4  Always 
9. In the last 3 months, how often did 
you have hard or lumpy stools? 
  ___  0  Never or rarely 
  ___  1  Sometimes 
  ___  2  Often 
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  ___  3  Most of the time 
  ___  4  Always 
10. In the last 3 months, how often did 
you have loose, mushy or watery stools? 
  ___  0  Never or rarely 
  ___  1  Sometimes 
  ___  2  Often 
  ___  3  Most of the time 
  ___  4  Always 
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Appendix E. Rome III Diagnostic Criteria & Scoring Criteria 
 
Diagnostic Criteria 
 
 Recurrent abdominal pain or discomfort at least 3 days/ month in the last 3 months 
associated with two or more of criteria #1 - #3 below: 
 
Pain or discomfort at least 2-3 days / month (Question 1 > 2) 
For women, does pain occur only during menstrual bleeding?  (Question 2 = 0 or 2) 
 
1. Improvement with defecation 
 
Pain or discomfort gets better after BM at least sometimes (Question 4 > 0) 
 
2. Onset associated with a change in frequency of stool. 
 
Onset of pain or discomfort associated with more stools at least sometimes  
        (Question 5 > 0)   OR 
Onset of pain or discomfort associated with fewer stools at least sometimes  
        (Question 6 > 0) 
 
3. Onset associated with a change in form (appearance) of stool. 
 
Onset of pain or discomfort associated with looser stools at least sometimes  
        (Question 7 > 0)   OR 
Onset of pain or discomfort associated with harder stools at least sometimes  
        (Question 8 > 0) 
 Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to 
diagnosis. 
 
(Question 3 = 1) 
 
Criteria for IBS- C:   (Question 9 > 0) and (Question 10 = 0) 
 
Criteria for IBS- D:   (Question 9 = 0) and (Question 10 > 0) 
 
Criteria for IBS- A:   (Question 9 > 0) and (Question 10 > 0) 
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Appendix F. Informed Consent Forms 
 
LETTER OF INFORMATION FOR CONSENT TO PARTICIPATE IN 
RESEARCH 
 
IBS Treatment Study 
Study One 
 
You are asked to participate in a research study conducted by Tobi Wilson, graduate 
student, and Dr. Fuschia Sirois, research supervisor, from the Department of Psychology 
at the University of Windsor.  The results of this research will contribute to Ms. Wilson‟s 
doctoral dissertation.    
 
If you have any questions or concerns about the research, please feel free to contact Dr. 
Fuschia Sirois at 519-253-3000 X 2224. 
 
PURPOSE OF THE STUDY 
 
The purpose of this study is to look at what people with irritable bowel syndrome (IBS) 
think about some of the options that are available for treating IBS.  Specifically, this 
study is interested in people‟s thoughts about whether different treatments will work for 
them.   
 
PROCEDURES 
 
If you volunteer to participate in this study, we would ask you to do the following things:  
First you would be asked to read about some hypothetical treatment options for IBS.  
Then you would be asked to rate how much you thought each treatment would work for 
you, and pick the one you would prefer.  You would also be asked some questions about 
whether you found these treatments credible, and would be given the opportunity to tell 
us your thoughts about these treatment options.   
 
If you volunteer to participate in this study, you would click on the I AGREE button 
below and would be directed to the study webpage to complete the study online.  It would 
take about ten minutes to complete, and you would only be asked to participate once.  A 
similar study will be conducted again in the near future, but you would only be asked to 
participate in this study.   
 
POTENTIAL RISKS AND DISCOMFORTS 
 
Participating in this study may make you feel slightly uncomfortable.  We have tried to 
minimize this risk by making your participation anonymous, and by only asking you to 
provide your opinions. 
 
POTENTIAL BENEFITS TO PARTICIPANTS AND/OR SOCIETY 
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Participating in this study will be of no direct benefit to you. 
 
We think that the results of this study could potentially be of benefit to society.  For 
example, we think that IBS treatments could be improved if we had more knowledge 
about what people with IBS think about different treatment options.   
 
PAYMENT FOR PARTICIPATION 
 
In return for your participation, at the end of the study you will have the option to be 
entered into a draw for one of several gift certificates from a major international 
bookseller.  The value of these gift certificates is 18 USD  (20 CAD, 14 EUR or 10 
GBP).   
 
CONFIDENTIALITY 
 
The information you provide in this study will remain anonymous.  This means that you 
will NOT be asked to provide your name.  If you choose to be contacted by regular mail 
in the case that you win a gift certificate, your address will be stored separately from your 
study information so that your information cannot be linked to you.  All data will be 
stored securely and may only be accessed by the main investigator and faculty supervisor.  
Data will be stored securely for a period of 10 years, as required, at which time it will be 
destroyed.    
 
PARTICIPATION AND WITHDRAWAL 
 
You can choose whether to be in this study or not.  If you volunteer to be in this study, 
you may withdraw at any time without consequences of any kind.  You may also refuse 
to answer any questions you don‟t want to answer and still remain in the study. 
 
The investigators may withdraw you from this research if circumstances arise which 
warrant doing so.  Your information would be withdrawn from the study if you do not 
complete at least 80% of the survey items.  As this study is interested only with 
individuals who have been diagnosed with IBS, your information could be withdrawn if 
you do not currently meet criteria for a diagnosis of IBS. 
 
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE PARTICIPANTS 
 
The results of this study will be available to the participants in May 2007 on the 
following website: http://athena.uwindsor.ca/fsirois 
 
SUBSEQUENT USE OF DATA 
 
This data will not be used in subsequent studies. 
 
RIGHTS OF RESEARCH SUBJECTS 
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You may withdraw your consent to participate at any time and discontinue participation 
without penalty.  If you have questions regarding your rights as a research subject, 
contact: Research Ethics Coordinator, University of Windsor, Windsor, Ontario, CA, 
N9B 3P4; telephone 519-253-3000, ext. 3916; e-mail: lbunn@uwindsor.ca 
 
SIGNATURE OF INVESTIGATOR 
 
These are the terms under which I will conduct research. 
 
Tobi Wilson, M.A. 
Department of Psychology 
University of Windsor 
 
It is recommended that you print out a copy of this letter of information for your 
records.  
 
Pass it on: Feel free to send this page to other people you know with IBS who might be 
interested in completing the survey 
 
Do you wish to continue?  To acknowledge that you have read and understood this 
information and would like to continue with the survey, please click on “I agree.”  
 
 
 
 
 
 
 
LETTER OF INFORMATION FOR CONSENT TO PARTICIPATE IN 
RESEARCH 
 
IBS Treatment Study 
Study Two 
(online version) 
 
You are asked to participate in a research study conducted by Tobi Wilson, graduate 
student, and Dr. Fuschia Sirois, research supervisor, from the Department of Psychology 
at the University of Windsor.  The results of this research will contribute to Ms. Wilson‟s 
doctoral dissertation.    
 
If you have any questions or concerns about the research, please feel free to contact Dr. 
Fuschia Sirois at 519-253-3000 X 4447 or email sirois12@uwindsor.ca. 
 
PURPOSE OF THE STUDY 
 
I AGREE 
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The purpose of this study is to look at what people with irritable bowel syndrome (IBS) 
think about some of the options that are available for treating IBS.  Specifically, this 
study is interested in people‟s thoughts about whether different treatments will work for 
them.  In addition, this study is designed to assess how individual‟s expectations and 
preferences for different treatments vary due to individual‟s unique personal 
characteristics.     
 
PROCEDURES 
 
If you volunteer to participate in this study, we would ask you to do the following things:  
First you would be asked to read about some hypothetical treatment options for IBS.  
Then you would be asked to rate how much you thought each treatment would work for 
you, and pick the one you would prefer.  You would be asked to provide some basic 
demographic information about yourself and your experience of IBS symptoms and 
treatments.  You would then complete a survey that asks questions about your unique 
characteristics.  Finally, you would be given the opportunity to tell us your thoughts 
about these treatment options.   
 
If you volunteer to participate in this study, you would click on the I AGREE button 
below and would be directed to the study webpage to complete the study online.  It would 
take about 25 minutes to complete, and you would only be asked to participate once.  A 
similar study has been conducted not long ago, (IBS Treatment Expectations – Study 
One) and if you participated in that study, we ask that you do not participate in this one.  
 
POTENTIAL RISKS AND DISCOMFORTS 
 
Some people may experience some mild distress when asked to think about their IBS. We 
have tried to minimize this risk by making your participation anonymous, and by only 
asking you to provide your opinions. 
 
POTENTIAL BENEFITS TO PARTICIPANTS AND/OR SOCIETY 
 
Participating in this study will be of no direct benefit to you. 
 
We think that the results of this study could potentially be of benefit to society.  For 
example, we think that IBS treatments could be improved if we had more knowledge 
about what people with IBS think about different treatment options, and what individual 
factors affect these expectations. 
 
PAYMENT FOR PARTICIPATION 
 
In return for your participation, you will have the option to be entered into a draw for one 
of several gift certificates from a major international bookseller.  The value of these gift 
certificates is 18 USD  (20 CAD, 14 EUR or 10 GBP).   
 
CONFIDENTIALITY 
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The information you provide in this study will remain anonymous.  This means that you 
will NOT be asked to provide your name.  If you choose to be contacted by regular mail 
in the case that you win a gift certificate, your address will be stored separately from your 
study information so that your information can be linked to you. All data will be stored 
securely and may only be accessed by the main investigator and faculty supervisor.  Data 
will be stored securely for a period of 10 years, as required, at which time it will be 
destroyed. 
 
PARTICIPATION AND WITHDRAWAL 
 
You can choose whether to be in this study or not.  If you volunteer to be in this study, 
you may withdraw at any time without consequences of any kind.  You may also refuse 
to answer any questions you don‟t want to answer and still remain in the study. 
 
The investigators may withdraw you from this research if circumstances arise which 
warrant doing so.  Your information would be withdrawn from the study if you do not 
complete at least 80% of the survey items.  As this study is interested only with 
individuals who have been diagnosed with IBS, your information could be withdrawn if 
you do not currently meet criteria for a diagnosis of IBS. 
 
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE PARTICIPANTS 
 
The results of this study will be available to the participants in June 2009 on the 
following website: http://athena.uwindsor.ca/fsirois 
 
SUBSEQUENT USE OF DATA 
 
The data for this study may be used in subsequent research on treatment expectations. By 
completing and submitting the survey package you agree that this data can be used in 
subsequent studies. 
  
RIGHTS OF RESEARCH SUBJECTS 
 
You may withdraw your consent to participate at any time and discontinue participation 
without penalty.  If you have questions regarding your rights as a research subject, 
contact: Research Ethics Coordinator, University of Windsor, Windsor, Ontario, CA, 
N9B 3P4; telephone 519-253-3000, ext. 3916; e-mail: lbunn@uwindsor.ca 
 
SIGNATURE OF INVESTIGATOR 
 
These are the terms under which I will conduct research. 
 
Tobi Wilson, M.A. 
Department of Psychology 
University of Windsor 
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It is recommended that you print out a copy of this letter of information for your 
records.  
 
Pass it on: Feel free to send this page to other people you know with IBS who might be 
interested in completing the survey 
 
Do you wish to continue?  To acknowledge that you have read and understood this 
information and would like to continue with the survey, please click on “I agree.”  
 
 
 
I AGREE 
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CONSENT TO PARTICIPATE IN RESEARCH 
 
IBS Treatment Study 
Study Two 
(Paper version) 
 
You are asked to participate in a research study conducted by Tobi Wilson, graduate 
student, and Dr. Fuschia Sirois, research supervisor, from the Department of Psychology 
at the University of Windsor.  The results of this research will contribute to Ms. Wilson‟s 
doctoral dissertation.    
 
If you have any questions or concerns about the research, please feel free to contact Dr. 
Fuschia Sirois at 519-253-3000 X 4447 or email sirois12@uwindsor.ca. 
 
PURPOSE OF THE STUDY 
 
The purpose of this study is to look at what people with irritable bowel syndrome (IBS) 
think about some of the options that are available for treating IBS.  Specifically, this 
study is interested in people‟s thoughts about whether different treatments will work for 
them.  In addition, this study is designed to assess how individual‟s expectations and 
preferences for different treatments vary due to individual‟s unique personal 
characteristics.     
 
PROCEDURES 
 
If you volunteer to participate in this study, we would ask you to do the following things: 
First you would be asked to read about some hypothetical treatment options for IBS.  
Then you would be asked to rate how much you thought each treatment would work for 
you, and pick the one you would prefer.  You would be asked to provide some basic 
demographic information about yourself and your experience of IBS symptoms and 
treatments.  You would then complete a survey that asks questions about your unique 
characteristics.  Finally, you would be given the opportunity to tell us your thoughts 
about these treatment options. 
 
If you volunteer to participate in this study, it would take about 25 minutes to complete, 
and you would only be asked to participate once.  You would then be asked to seal the 
completed study materials (consent form and survey package) in the postage-paid 
envelope provided, and place the package in the mail. A similar study has been conducted 
not long ago, (IBS Treatment Expectations – Study One) and if you participated in that 
study, we ask that you do not participate in this one. 
 
POTENTIAL RISKS AND DISCOMFORTS 
 
Some people may experience some mild distress when asked to think about their IBS.  
We have tried to minimize this risk by making your participation anonymous, and by 
only asking you to provide your opinions. 
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POTENTIAL BENEFITS TO PARTICIPANTS AND/OR SOCIETY 
 
Participating in this study will be of no direct benefit to you. 
 
We think that the results of this study could potentially be of benefit to society.  For 
example, we think that IBS treatments could be improved if we had more knowledge 
about what people with IBS think about different treatment options, and what individual 
factors affect these expectations. 
 
PAYMENT FOR PARTICIPATION 
 
In return for your participation, when you return your package by mail, you will be 
entered into a draw for one of several gift certificates from a major international 
bookseller.  The value of these gift certificates is 20 CAD (18 USD, 14 EUR or 10 GBP).     
 
CONFIDENTIALITY 
 
The information you provide in this study will remain anonymous.  This means that you 
will NOT be asked to provide your name.  If you choose to be contacted by regular mail 
in the case that you win a gift certificate, your address will be stored separately from your 
study information so that your information cannot be linked to you.  All data will be 
stored securely and may only be accessed by the main investigator and faculty supervisor.  
Data will be stored securely for a period of 10 years, as required, at which time it will be 
destroyed.    
 
PARTICIPATION AND WITHDRAWAL 
 
You can choose whether to be in this study or not.  If you volunteer to be in this study, 
you may withdraw at any time without consequences of any kind.  You may also refuse 
to answer any questions you don‟t want to answer and still remain in the study. 
 
The investigators may withdraw you from this research if circumstances arise which 
warrant doing so.  Your information would be withdrawn from the study if you do not 
complete at least 80% of the survey items.  As this study is interested only with 
individuals who have been diagnosed with IBS, your information could be withdrawn if 
you do not currently meet criteria for a diagnosis of IBS. 
 
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE PARTICIPANTS 
 
The results of this study will be available to the participants in June, 2009 on the 
following website: http://athena.uwindsor.ca/fsirois 
 
SUBSEQUENT USE OF DATA 
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The data for this study may be used in subsequent research on treatment expectations. By 
completing and submitting the survey package you agree that this data can be used in 
subsequent studies. 
 
RIGHTS OF RESEARCH SUBJECTS 
 
You may withdraw your consent to participate at any time and discontinue participation 
without penalty.  If you have questions regarding your rights as a research subject, 
contact: Research Ethics Coordinator, University of Windsor, Windsor, Ontario, CA, 
N9B 3P4; telephone 519-253-3000, ext. 3916; e-mail: lbunn@uwindsor.ca 
 
SIGNATURE OF RESEARCH SUBJECT/LEGAL REPRESENTATIVE 
 
I understand the information provided for the study IBS Treatment Study - Two as 
described herein.  My questions have been answered to my satisfaction, and I agree to 
participate in this study.  I have been given a copy of this form. 
 
____________________________________   ________________ 
 Signature             Date  
 
SIGNATURE OF INVESTIGATOR 
 
These are the terms under which I will conduct research. 
 
 
_______________________________________ 
Tobi Wilson, M.A. 
 
Department of Psychology 
University of Windsor 
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Appendix G. Demographic & Background Questions 
 
We would like to know a little bit about you.  Please fill in the information below. 
 
Age: _____________ 
Date of Birth:  Day _____  Month ______ Year _______ 
Recruited by:  ___ IBS website ___ Research website    ___ Other 
Ethnicity:  (check one) 
 Asian  ___ 
 Black  ___ 
 East Indian ___ 
 Hispanic  ___ 
 Mixed  ___ 
 Native  ___ 
 White  ___ 
Employment Status: (check one) 
 Employed Full-time ___ 
 Employed Part-time ___ 
 Unemployed  ___ 
 Disabled   ___ 
 Retied   ___ 
 Student   ___ 
Education (check one) 
 Some high school     ___ 
 High school graduate   ___ 
 Some college/ university   ___ 
 College / university graduate  ___ 
 Graduate / professional school ___ 
Marital Status: (check one) 
 Never married   ___ 
 Married/ Common law  ___ 
 Separated / Divorced  ___ 
 Widowed    ___ 
 
About your IBS: 
Diagnosed IBS?     Yes ___  No ___    By:     Physician  _____   Self ___ 
Have you ever been misdiagnosed? Yes ___    No ___  
Time since diagnosis (years) ________ 
Time experiencing symptoms (years) ________ 
IBS subtype?   
 Constipation predominant  ___  Alternating subtype  ___ 
 Diarrhea predominant  ___ Unknown   ___ 
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Appendix H. Letter of Explanation 
 
EXPLANATION OF THE STUDY 
IBS Treatment Study - One 
 
 Research has found that a person‟s beliefs about a treatment can have an 
important effect on his or her response to that treatment.  For example, if someone 
believes that a treatment will be of benefit, he/she is more likely to actually benefit from 
that treatment than is someone with less positive beliefs.  There has been a lot of interest 
in this relationship between beliefs and health outcomes.  So far, however, very little is 
known about what how someone‟s personal characteristics may influence one‟s beliefs 
about treatment.  This study was designed to be followed by a larger study that will look 
at how strongly one‟s personality and thoughts about health influence one‟s beliefs about 
treatment.  For example, the larger study may find that, on average, those with higher 
levels of anxiety show less positive beliefs about treatment.  Or maybe people who think 
of themselves as generally pretty healthy (despite having an illness) have more positive 
beliefs about treatment, compared to people who think of themselves as generally 
unhealthy. 
Before doing the larger study, we had to make sure that the hypothetical treatment 
scenarios that we had written were credible.  Also, we wanted to check that not everyone 
had the same beliefs about these treatments, as we want to know whether certain personal 
characteristics or thoughts strengthen or weaken someone‟s beliefs about treatment.     
In order to make sure that the treatment scenarios were reasonable, we conducted 
this small study that you have just participated in.  This study will provide some 
important information that we will use in the larger study.  For example, this study was 
interested in your thoughts about the different treatment options.  Based on the reactions 
of all participants in this small study, we will be able to figure out if these treatment 
scenarios are OK or if they need to be changed.   This study may also provide some 
important information about IBS treatment.  For example, we were also interested in your 
comments about the treatments and your beliefs about whether the treatments would be a 
benefit to you.  Knowing what types of treatments people prefer, and whether these 
preferences are related to their history of treatment, their diagnosis, or the severity of 
their symptoms, can be potentially useful information for those health care providers that 
want to offer the best IBS treatment to their patients.   
 
 Thank you so much for participating in this research.  We greatly appreciate your 
time and effort! 
 
Tobi Wilson, M.A. 
Fuschia Sirois, Ph. D 
Department of Psychology, University of Windsor 
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EXPLANATION OF THE STUDY 
IBS Treatment Study - Two 
 
 Research has found that a person‟s expectations about a treatment can have an 
important effect on his or her response to that treatment.  For instance, if an individual 
expects that a treatment will be of great benefit, he/she is more likely to actually benefit 
from that treatment than is an individual with less positive expectations.  Although this 
finding has been well established, very little is known about what sort of personal 
characteristics may influence one‟s expectations of treatment.  This study was designed 
to investigate how strongly one‟s personality and beliefs influence one‟s treatment 
expectations.  For example, we may find that, on average, those with higher levels of 
anxiety show less positive treatment expectations.  Perhaps people who think of 
themselves as generally pretty healthy (despite having a particular illness) have more 
positive expectations about the outcomes of treatment.  The questionnaires you have just 
completed are designed to measure certain aspects of your personality (e.g., level of 
hope, optimism, anxiety, motivation), as well as aspects of your beliefs about health and 
illness (e.g., your general health, sense of control over your symptoms, belief in your own 
ability to manage your illness).  Your responses will help us to figure out whether on 
average, certain personality traits or beliefs are strongly related to treatment expectations.  
With this information, we can develop ways to boost people‟s expectations about their 
treatment.  For example, if it turns out that anxiety really interferes with treatment 
expectations, then we will encourage treatment providers to assess a person‟s anxiety and 
address it, in order to help that person get the most out of treatment.   
 
 Thank you so much for participating in this research.  We greatly appreciate your 
time and effort! 
 
Tobi Wilson, M.A. 
Fuschia Sirois, Ph. D 
Department of Psychology 
University of Windsor 
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Appendix I. Treatment Vignettes 
 
Please read the following treatment vignettes and imagine that you are participating in 
this scenario.   
 
(Note that this treatment scenario is hypothetical; your participation in the 
current study will not involve participating in any treatments).   
 
Please imagine that these treatment scenarios would occur free of charge and at a location 
convenient for you. 
 
In this treatment scenario, first you would be invited into a local clinic… 
 
An interview will be conducted by a gastroenterologist (IBS specialist) to 
assess: 
 
a) Your IBS symptomotology (severity, IBS subtype, history of symptoms and 
treatment, and how much your IBS gets in way of your life);  
 
b) Potential contributors (dietary habits, personal trigger factors, stress 
management knowledge and behaviours); 
 
c) Other health concerns; and 
 
d) Differential diagnosis (Your family history of health problems, and symptoms 
associated with organic diseases will be assessed via interview to ensure that a 
diagnosis of IBS is appropriate for you.  
 
If necessary you will be referred for physical tests to aid in this differential 
diagnosis or asked to track potential  contributors in a daily diary for the 
period of one week.  This supplemental information will be reviewed in a 
follow-up clinical interview.   
 
If you do not meet diagnostic criteria for IBS, you will no longer be eligible to 
participate in this treatment scenario.  You would be provided with an external 
follow-up referral if indicated.   
 
Based on the information provided in the interview(s), you will be assigned to 
one of three treatment options:   
 
a) Treatment A 
o You would receive a dietary consult, and be provided with specific 
dietary recommendations as well as other suggestions regarding 
lifestyle factors known to affect global symptom reporting in 
individuals with IBS 
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o You would be prescribed a pharmaceutical drug, specific to your IBS 
subtype (IBS-D or IBS C/A) that is designed to provide global IBS 
symptom improvement  
o  Both drugs have been shown in clinical trials to improve global 
 symptom reports in both men and women, as compared to 
 placebo treatments. 
o  Specifically, both drugs have been shown to significantly 
 improve pain/discomfort, abnormal bowel habits, and bloating. 
o  After extensive clinical testing, neither drug has been 
 associated with serious health consequences 
o Both drugs are associated with mild-moderate side-effects in some 
people. 
o  The most common side-effect for the IBS-D drug is  constipation 
(in about 15% of participants).  For the IBS-C/A  drug, the most 
common side-effect is diarrhea (in about 10% of  participants) 
o  Other, less common side effects associated with these drugs 
 include headache, abdominal pain, nausea or flatulence. 
o If prescribed the IBS-D drug, you would take the drug three times a 
day in tablet form.  If prescribed the IBS-C/A drug, you would take the 
drug twice a day, in tablet form. 
o Once per week, for eight weeks, you would be asked to visit the local 
clinic to talk with the gastroenterologist for 20 minutes about your IBS 
symptoms and any side-effects.  
 
 
b) Treatment B 
o You would first receive a dietary consult, and be provided with 
specific dietary recommendations as well as other suggestions 
regarding lifestyle factors known to affect global symptom reporting in 
individuals with IBS. 
o You will then be prescribed a short course of individual therapy with a 
professional, designed to provide global IBS symptom improvement.  
o The therapy will involve cognitive-behavioural therapy for IBS 
combined with guided relaxation. 
o  This type of treatment has been shown in clinical trials to 
 improve global symptom reports in both men and women, as 
 compared to placebo treatments. 
o  This treatment has been found to improve bowel symptoms 
 and quality of life significantly for IBS sufferers. 
o  The cognitive-behavioural component involves the  identification 
of environmental triggers and the modification of  self-defeating 
patterns of thought and behaviour underlying  IBS symptoms. 
o  The relaxation component uses guided imagery to promote 
 relaxation, reduce pain and regulate bowel function.  
o Neither component has been associated with serious side-effects 
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o You would be asked to attend a 50-minute therapy session once per 
week and to complete approximately one hour of homework per week 
o You would meet with the professional for therapy at the local clinic for 
8 weeks. 
 
c) Treatment C 
o You would first receive a dietary consult, and be provided with 
specific dietary recommendations as well as other suggestions 
regarding lifestyle factors known to affect global symptom reporting in 
individuals with IBS. 
o You will then be prescribed a short course of individual therapy with a 
professional, as well as a pharmaceutical drug, both designed to 
provide global IBS symptom improvement.  
o Both types of treatment have been shown in clinical trials to contribute 
to global symptoms improvements in both men and women 
o In this treatment, you will prescribed the same drug as above (specific 
to your IBS subtype), except that the dose will be reduced to 50% of 
the dose for the above treatment  
o In this treatment, you will be prescribed a 6 - week course of therapy, 
and will only receive the cognitive-behavioural component of the 
therapy  
o The cognitive-behavioural component involves the identification of 
environmental triggers and the modification of self-defeating patterns 
of thought and behaviour underlying IBS symptoms 
o The drug treatment has been associated with mild-moderate side-
effects (described above) 
o The cognitive-behavioural therapy has not been associated with any 
side-effects 
o You would be asked to attend a 40 – minute therapy session once per 
week for 6 weeks, and to complete approximately one hour of 
homework per week 
o Once per week, for 8 weeks, you would talk with the 
gastroenterologist for 10 minutes about your IBS symptoms and any 
side-effects.  
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Appendix J. Expectancy Rating Scales  
 
Think back to the treatments in the vignettes.  We are 
interested in how much you think each treatment would work 
for you and your IBS symptoms, if you were in the 
hypothetical treatment situation.     
 
This is no right or wrong answer; we are just interested in 
your opinion.   
  
Think about the treatment that offered a drug specific to 
your IBS subtype.   
 
How much do you expect that this treatment would work for 
you and your symptoms of IBS? 
 
On the line below, please show how much you expect this 
treatment to work, by making a mark along the line 
somewhere between „No Expected Benefit‟ and „Excellent 
Expected Benefit.‟ 
 
No               Excellent 
Expected                Expected 
Benefit                     Benefit 
_____________________________________________________________________________ 
0   25   50   75      100 
 
 
 
 
Think about the treatment that offered both cognitive-
behavioural therapy and guided relaxation.  
 
How much do you expect that this treatment would work for 
you and your symptoms of IBS? 
 
On the line below, please show how much you expect this 
treatment to work, by making a mark along the line 
somewhere between „No Expected Benefit‟ and „Excellent 
Expected Benefit.‟ 
 
No               Excellent 
Expected                Expected 
Benefit                  Benefit 
_____________________________________________________________________________ 
0   25   50   75     10 
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Appendix K. Treatment Credibility Questions 
 
Think back again to the treatments in the vignettes.  We are also interested in how 
credible you think each treatment description was. 
There is no right or wrong answer; we are just interested in your opinion.   
  
Think about the treatment that offered a drug specific to your IBS subtype.   
 
How credible is this treatment for IBS? 
 
On the line below, please show how much you thought this specific treatment was 
credible for IBS, by making a mark along the line somewhere between „Not At All 
Credible‟ and „Completely Credible.‟ 
 
Not                
At All                  Completely 
Credible               Credible 
_____________________________________________________________________ 
0   2.5  5   7.5                  11 
 
Think about the treatment that offered both cognitive-behavioural therapy and guided 
relaxation. 
How credible is this treatment for IBS? 
 
 
Not                
At All                     Completely 
Credible              Credible 
_______________________________________________________________________ 
0   2.5   5   7.5         11 
 
 
 
Think about the treatment that offered a drug specific to your IBS subtype as well as 
cognitive-behavioural therapy.   
 
How credible is this treatment for IBS? 
 
 
Not                
At All               Completely 
Credible              Credible 
_______________________________________________________________________ 
0   2.5   5   7.5         11 
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Appendix L. The Private Self- Consciousness Scale 
 
Please indicate how much each of these statements describes 
you, by checking the appropriate box.   
 
 
Not at all 
like me 
Kind of 
like me 
Much 
like me 
A lot 
like me 
I‟m always trying to figure myself out. 
    
I think about myself a lot. 
    
I often daydream about myself. 
    
I generally pay attention to my inner 
feelings. 
    
I‟m constantly thinking about my reasons 
for doing things. 
    
I sometimes step back (in my own mind) 
in order to examine myself from a 
distance. 
    
I‟m quick to notice changes in my mood. 
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Appendix M. Trait Anxiety Measures 
 
Anxious Arousal subscale of the Mood and Anxiety Symptoms Questionnaire 
 
Below is a list of feelings, sensations, problems and experiences 
that people sometimes have.  Read each item and then mark the 
appropriate choice in the space next to that item.  Use the 
choice that best describes how much you have feel or experience 
things this way generally.    
 
 
Not at 
all 
A 
Little 
Bit 
Moderatel
y 
Quite a 
Bit 
Extremel
y 
Startled 
Easily 
     
Faint      
Numbness or 
tingling in 
my body 
     
Pain in my 
chest 
     
Hot or cold 
spells 
     
Dizzy or 
lightheaded 
     
Short of 
breath 
     
Unable to 
relax 
     
Like I was 
choking 
     
A very dry 
mouth 
     
Afraid I 
was going 
to die 
     
Heart 
racing or 
pounding 
     
Trembling 
or shaking 
     
Need to 
urinate 
frequently 
     
Trouble 
swallowing 
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Cold or 
sweaty 
hands 
     
Penn State Worry Questionnaire 
 
Enter the number that best describes how typical or characteristic each item is of you: 
 
1    2  3   4  5 
Not at all typical   Somewhat typical   Very Typical 
 
1. If I do not have enough time to do everything,  
I do not worry about it.     ____ 
2. My worries overwhelm me.     ____ 
3. I do not tend to worry about things.    ____ 
4. Many situations make me worry.    ____ 
5. I know I should not worry about things,  
 but I just cannot help it.     ____ 
6. When I am under pressure I worry a lot.   ____ 
7. I am always worrying about something.   ____ 
8. I find it easy to dismiss worrisome thoughts.   ____ 
9. As soon as I finish one task, I start to worry  
 about everything else I have to do.   ____ 
10. I never worry about anything.    ____ 
11. When there is nothing more I can do about a concern,   
  I do not worry about it anymore.   ____ 
12. I have been a worrier all my life.    ____ 
13. I notice that I have been worrying about things.  ____ 
14. Once I start worrying, I cannot stop.    ____ 
15. I worry all the time.      ____ 
16. I worry about projects until they are all done.  ____ 
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Appendix N. The Life Orientation Scale – Revised 
 
Please indicate how much you agree with each of the 
statements below by checking the appropriate box.  Try to 
be as honest and accurate as your can, and try not to let 
your answer to one question influence your answer to other 
questions.  There are no right or wrong answers.   
 
 Strongly 
Disagree 
Disagree Agree Strongly 
Agree 
In uncertain times, I 
usually expect the 
best  
    
It‟s easy for me to 
relax 
    
If something can go 
wrong for me, it will 
    
I‟m always optimistic 
about my future 
    
I enjoy my friends a 
lot 
    
It‟s important for me 
to keep busy 
    
I hardly ever expect 
things to go my way 
    
I don‟t get upset too 
easily 
    
I rarely count on good 
things happening to me 
    
Overall, I expect more 
good things to happen 
than bad 
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Appendix O. The Adult Hope Scale 
 
Directions:  Read each tem carefully.  Using the scale 
shown below, please select the number that best 
describes YOU and put that number in the blank 
provided. 
 
1. = Definitely False 
2. = Mostly False 
3. = Somewhat False 
4. = Slightly False 
5. = Slightly True 
6. = Somewhat True 
7. = Mostly True 
8. = Definitely True 
 
___ 1. I can think of many ways to get out of a jam. 
___ 2.  I energetically pursue my goals. 
___ 3.  I feel tired most of the time. 
___ 4. There are lots of ways around any problem. 
___ 5. I am easily downed in an argument. 
___ 6. I can think of many ways to get the things in 
life that are important to me.   
___ 7. I worry about my health. 
___ 8. Even when others get discouraged, I know I can 
find a way to solve the problem. 
___ 9. My past experiences have prepared me well for 
my future. 
___ 10. I‟ve been pretty successful in life. 
___ 11. I usually find myself worrying about 
something. 
___ 12. I meet the goals that I set for myself.   
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Appendix P. Perception of Health items 
 
These questions are about how healthy you perceive your 
self to be.  Please read each question and indicate your 
response by checking the appropriate box.  There are no 
right or answers; we are interested in your opinion. 
 
 
Very 
Poor 
Poor Average Good Excellent 
Compared to other 
people your age, how 
would you rate your 
health? 
     
Compared to other 
people with IBS, how 
would you rate your 
health? 
     
In general, how would 
you rate your health? 
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Appendix Q. Brief Health History Checklist 
 
This section deals with health issues you have experienced that 
are either temporary or over a short period of time (acute).  
 
 
ACUTE HEALTH PROBLEMS:   
 
Please indicate which ones you are currently experiencing, or can 
remember experiencing within the past six months. – please check 
all that apply 
 
 
Back problems  Insomnia  Allergies 
 
Sprains or muscle 
strains 
 Infections  
Skin 
problems/r
ashes 
 
Headache  Flu, cold or fever  
Reproducti
ve/ 
menstrual 
problems 
 Acute digestive 
problems 
(constipation, 
heartburn, etc.) 
 Dental problems  
Other 
acute 
health 
problems 
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Appendix R. Control Beliefs Inventory  
 
The following statements concern the different ideas that people have about their health. 
Some of these statements refer to your general state of health and others refer to specific 
times when you are experiencing illness symptoms. Please read each statement carefully 
and answer according to how much you agree with each statement by circling a number  
from 1 to 6.  Please answer according to the following scale: 
 
 
1 2 3 4 5 6 
STRONGLY 
DISAGREE 
DISAGREE MILDLY 
DISAGREE 
MILDLY 
AGREE 
AGREE STRONGLY 
AGREE 
Control Over Health Items 
1. My health depends on how I take care of myself. 
2. It is my own actions that determine how healthy I am. 
3. People who take care of themselves stay healthy. 
4. How soon I recover from an illness depends on how I look after myself. 
5. My current state of health is a reflection of how I look after myself. 
6. If I make the effort, I can manage my illness. 
Control Over Symptoms Items 
7. If I do the right things I can make my symptoms more manageable. 
8. If I make the effort, I can manage my symptoms. 
9. There are things that I can do to make my symptoms easier to deal with. 
10. I believe that I can do more to control my symptoms 
11. I can take control of my health by managing my day-to-day symptoms. 
Health Self-Efficacy Items 
12. Even though there are things I can do to improve my health, I don‟t feel that I can do 
them. 
13. I am able to meet the challenge of following a healthy routine 
14. When facing a health problem, I often feel overwhelmed about what to do. 
15. I am certain that with effort I can improve my health. 
16. I am confident that I could deal with any unexpected health problems. 
17. When it comes to my health, I often feel unable to do what I know should be done. 
18. I am confident in my ability to make the right decisions about my health. 
19. Regardless of circumstances, there are things I can do to improve my health.  
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Appendix S. Coping Self-Efficacy Scale 
 
Please indicate how well you feel you have been dealing with the different 
aspects of your condition in general by checking a box for each question. 
 
 Strongly 
Disagree 
Disagree Neither 
Agree nor 
Disagree 
Agree Strongly 
Agree 
a) I am successfully 
coping with the 
symptoms of my 
condition 
     
     
b) I am successfully 
coping with the 
day to day 
problems that 
living with my 
condition creates 
     
     
c) I am successfully 
coping with the 
emotional aspects 
of my condition 
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Appendix T. Resistance to Illness Subscale 
 
Please read each of the following statements carefully and indicate how true is statement 
is for you by checking the appropriate box.    
 
 
Definitely 
False 
Mostly 
False 
Don’t 
Know 
Mostly 
True 
Definitely 
True 
I seem to get sick a little 
easier than other people 
     
Most people get sick a little 
easier than I do 
     
My body seems to resist 
illness very well 
     
When there is something 
going around I usually catch it 
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Appendix U. Catastrophizing Interpretation of Bodily Complaints Subscale 
 
 
Completely 
Wrong 
Mostly 
Wrong 
Mostly 
Right 
Completely 
Right 
A suddenly appearing joint pain 
can be a sign of a beginning 
paralysis 
    
I‟m healthy when I don‟t have any 
bodily sensations 
    
My doctor or I must be capable of 
finding an explanation for all my 
bodily complaints. 
    
When suffering from constipation, 
one should consult an expert 
immediately to be certain that one 
doesn‟t have intestinal cancer. 
    
Bodily complaints are always a 
sign of disease. 
    
Red blotches on the skin are a 
threatening sign of skin cancer 
    
When suffering from joint pain, 
one should take good care of 
oneself. 
    
When one sweats a lot, it can be 
due to an overburdened heart. 
    
The most common reason for 
discomfort is a serious illness. 
    
If a doctor refers me for further 
examinations, then he is 
convinced that there is a serious 
problem. 
    
Only persons who do not exert 
themselves physically stay healthy 
in the long run. 
    
A healthy body doesn‟t cause 
complaints. 
    
A tingling sensation in the legs 
can be a serious sign of a nerve 
disorder. 
    
The most serious diseases develop 
unnoticed and then break out at 
some time or other. 
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Appendix V. Treatment Experience Questions 
 
Think about the treatment that offered a drug specific to 
your IBS subtype.   
 
Do you have experience with this type of treatment? ___ Yes    ___  No (Check One) 
If Yes, Please rate how successful that treatment was for you (by making a mark on the line 
below): 
0           10 
__________________________________________________________________________ 
Not at all         Completely 
Successful         Successful 
 
 
 
 
 
 
 
Think about the treatment that offered both cognitive-
behavioural therapy and guided relaxation. 
 
Do you have experience with this type of treatment? ___ Yes    ___  No (Check One) 
If Yes, Please rate how successful that treatment was for you (by making a mark on the line 
below): 
0           10 
__________________________________________________________________________ 
Not at all         Completely 
Successful         Successful 
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This section deals with your current and past IBS treatment 
experiences, as well as how successful they were for 
helping with your symptoms.  
 
Please check off any treatments that you are CURRENTLY 
using to treat your symptoms of IBS.  For treatment that 
you are using, rate your satisfaction with this treatment 
by checking the appropriate box.  
   
YES 
 
   
very 
dissatisfied 
dissatisfied 
mildly 
dissatisfied 
mildly 
satisfied 
satisfied 
very 
satisfied 
 
Diet Changes 
      
 Relaxation 
Training 
      
 Biofeedback 
Training 
      
 Laxatives / 
Antidiarrheals 
      
 Herbal / Mineral 
/Vitamin 
Supplements 
      
 
Probiotics 
      
 
Acupuncture 
      
 
Antispasmotics 
      
 Serotonin 
Agonists/ 
Antagonists 
      
 
Hypnotherapy 
      
 
Psychotherapy 
      
 
Antidepressants 
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Please check off any treatments that you have used in the 
PAST to treat your symptoms of IBS.  For treatment(s) that 
you have used, rate your satisfaction with this treatment 
by checking the appropriate box.  
 
YES 
 
   
very 
dissatisfied 
dissatisfied 
mildly 
dissatisfied 
mildly 
satisfied 
satisfied 
very 
satisfied 
 
Diet Changes 
      
 Relaxation 
Training 
      
 Biofeedback 
Training 
      
 Laxatives / 
Antidiarrheals 
      
 Herbal / Mineral 
/Vitamin 
Supplements 
      
 
Probiotics 
      
 
Acupuncture 
      
 
Antispasmotics 
      
 Serotonin 
Agonists/ 
Antagonists 
      
 
Hypnotherapy 
      
 
Psychotherapy 
      
 
Antidepressants 
      
 
 
 
 
 
Please indicate below if you have been treated by a 
gastroenterologist before, as well as your satisfaction 
with this treatment. 
 
YES 
 
   
not satisfied 
mildly 
satisfied 
moderately 
satisfied 
very much 
satisfied 
extremely 
satisfied 
 Treated by 
Gastroenterologist  
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Appendix W. Symptom Attribution Questions 
 
Listed below are symptoms you may or may not have ever experienced.  Below each 
symptom are three possible reasons for this symptom.  For each reason, please indicate 
how much the reason might explain your symptom, by making a mark along the line 
beside the reason.  Please mark every item for each symptom.   
 
If I had trouble sleeping, I would probably think that is because: 
       Very 
    Not true   Much 
    At all   True 
Some kind of pain or physical 
discomfort is keeping me awake                           0_______________________________10 
  
I'm not tired or I had too much coffee                   0_______________________________10 
I'm worrying too much or I must be  
nervous about something                                       0_______________________________10 
 
If I were constipated or irregular, I would probably think that it is because: 
       Very 
    Not true   Much 
    At all   True 
There is not enough fruit or fiber  
in my diet                                  0_______________________________10 
  
Nervous tension is keeping me from        
being regular                                 0_______________________________10 
 
There is something wrong with my 
Bowels or intestines                                              0_______________________________10 
 
 
If I were sweating a lot, I would probably think that it is because: 
       Very 
    Not true   Much 
    At all   True 
 
I must have a fever or infection                             0_______________________________10 
                              
I‟m too anxious or nervous                                   0_______________________________10 
 
The room is too warm, I‟m  
Overdressed or working too hard                          0_______________________________10  
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If I had abdominal pain or discomfort, I would probably think that it was because: 
       Very 
    Not true   Much 
    At all   True 
 
I‟ve worried myself sick                               0_______________________________10 
 
I have the flu or stomach irritation                 0_______________________________10 
 
I‟ve had something to eat  
that did not agree with                                    0_______________________________10 
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Appendix X. Perception of Treatment Focus Rating Scales 
 
Think back to the treatment that you said you would hypothetically prefer.   
 
While thinking about the treatment that you chose, consider how true the following 
statements are. 
 
This is no right or wrong answer; we are just interested in your opinion.   
 
 
“This treatment targets the physical causes of IBS.” 
 
On the line below, please show how much you feel this statement is true, by making a 
mark along the line somewhere between „Not at All True‟ to „Very Much True.‟ 
 
 
Not at          Very 
All          Much 
True          True 
 ______________________________________________________________ 
0   2.5  5  7.5       10 
 
 
 
“This treatment targets the psychological causes of IBS.” 
 
On the line below, please show how much you feel this statement is true, by making a 
mark along the line somewhere between „Not at All True‟ to „Very Much True.‟ 
 
Not at          Very 
All          Much 
True          True 
 ______________________________________________________________ 
0   2.5  5  7.5       10 
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Think back to the other treatment that was offered, the one you did not choose as your 
preferred treatment.   
 
While thinking about the treatment that you did not choose as preferred, consider how 
true the following statements are. 
This is no right or wrong answer; we are just interested in your opinion.   
 
 
“This treatment targets the physical causes of IBS.” 
 
On the line below, please show how much you feel this statement is true, by making a 
mark along the line somewhere between „Not at All True‟ to „Very Much True.‟ 
 
 
Not at          Very 
All          Much 
True          True 
 ______________________________________________________________ 
0   2.5  5  7.5       10 
 
 
 
“This treatment targets the psychological causes of IBS.” 
 
On the line below, please show how much you feel this statement is true, by making a 
mark along the line somewhere between „Not at All True‟ to „Very Much True.‟ 
 
 
Not at          Very 
All          Much 
True          True 
 ______________________________________________________________ 
0   2.5  5  7.5       10 
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Appendix Y. Current IBS Symptom Severity Scale 
 
Current Symptoms Questionnaire 
 
For each question, please „check‟ the number that best 
describes your symptoms over this past week.  Please answer 
all questions.   
 
1. ABDOMINAL PAIN 
          
    No symptoms 1 2 3 4 5 6 7 8 Extremely 
severe 
          
2. CONSTIPATION         
         
    No symptoms 1 2 3 4 5 6 7 8 Extremely 
severe 
          
3. DIARRHEA          
          
    No symptoms 1 2 3 4 5 6 7 8 Extremely 
severe 
          
4. INCOMPLETE EVACUATION AFTER A BOWEL MOVEMENT 
          
    No symptoms 1 2 3 4 5 6 7 8 Extremely 
severe 
          
5. BLOATING         
          
    No symptoms 1 2 3 4 5 6 7 8 Extremely 
severe 
          
6. FLATULENCE         
         
    No symptoms 1 2 3 4 5 6 7 8 Extremely 
severe 
          
7. URGENCY WHEN NEEDING A BOWEL MOVEMENT  
          
    No symptoms 1 2 3 4 5 6 7 8 Extremely 
severe 
 
To what extent has IBS affected your daily activities? (check one): 
 
Not at all A little Somewhat A lot 
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Appendix Z. The Social Desirability Scale -17 
 
Below you will find a list of statements.  Please read each 
statement carefully and decide if this statement describes 
you or not.  It if describes you, check the “true”; if not, 
check the word “false.” 
 
 TRUE FALSE 
I sometimes litter   
I always admit my mistakes openly and 
face the potential negative consequences 
  
In traffic I am always polite and 
considerate of others 
  
I sometimes only help because I expect 
something in return 
  
I always accept others‟ opinions, even 
when they don‟t agree with my own 
  
I take out my bad moods on others now 
and then 
  
There has been an occasion when I took 
advantage of someone else 
  
In conversations I always listen 
attentively and let others finish their 
sentences 
  
I never hesitate to help someone in case 
of emergency 
  
When I have made a promise, I keep it – 
no ifs, ands or buts 
  
I occasionally speak badly of others 
behind their back 
  
I would never live off other people   
I always stay friendly and courteous 
with other people, even when I am 
stressed out 
  
During arguments I always stay objective 
and matter-of-fact 
  
There has been at least one occasion 
when I failed to return an item I 
borrowed 
  
I always eat a healthy diet   
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Appendix AA.  Modified Patient Reactions Assessment 
 
Please think back to the treatment vignettes that you read.  Imagine that you were actually 
involved in the treatment scenario, having a clinical interview with a gastroenterologist 
who later referred you to a particular treatment.  Imagine yourself interacting with the 
treatment provider.  Please keep this in mind while reading the following statements and 
indicate your level of agreement (hypothetically) by checking the appropriate box. 
 
 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
I understand the treatment 
side-effects 
     
I have been told what the 
treatment would do 
     
I understand the treatment plan 
for me 
     
I have a good idea about the 
changes to expect in my health 
     
The treatment procedure has 
been clearly explained 
     
It is difficult to get conflicting 
information straightened out 
     
I have difficulty asking about 
something I don‟t understand 
     
It is hard for me to tell about 
new symptoms 
     
It is difficult asking the 
provider questions 
     
The provider is warm and 
caring towards me 
     
The provider makes me 
comfortable discussing 
personal issues 
     
This person really respects me      
I sometimes feel insulted when 
talking to this person 
     
The provider doesn‟t seem 
interested in me as a person 
     
It is hard for me to ask how 
treatment is going 
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Appendix AB.  Qualitative Data Coding Manual 
 
Pre-set categories 
 
Self-focused attention. 
Definition: a tendency to tendency to focus on attending to inner thoughts, 
feelings and sensations. 
Examples:  I‟m always checking in with what is going on in my body.  
I pay a lot of attention to whether I‟m feeling stressed. 
Anxiety.  
Definition: a tendency towards feeling apprehensive about situations and 
potentialities, accompanied by worries, negative affect and 
physiological feelings of anxiety. 
Examples:  I‟ve always been a worrier. 
When I get to feeling anxious… 
Optimism/ Pessimism. 
Definition:  a tendency to expect good things will happen; a tendency to expect 
bad things will happen. 
Example:  I tend to look on the bright side. 
   If something bad could happen, it usually will. 
Hope. 
Definition:  a cognitive set based on reciprocally derived sense of successful 
agency (goal-directed determination) and pathways (ways to meet 
goals). 
Example:  Any mention of the word „hope.‟ 
Current Health: Perception of health. 
Definition: beliefs about one‟s general level of overall health 
Examples:  I‟m pretty healthy overall. 
  My health is not what I‟d call good. 
Current Health: Acute health problems. 
Definition: current health problems other than IBS 
Example:  Any mention of any other health condition.  
Control Beliefs: Health. 
Definition: a belief that one generally knows how to manage their health. 
Example: It‟s up to me to get healthy. 
Control Beliefs: Symptoms. 
Definition: a belief that one can manage their symptoms of IBS 
Example: I‟ve always been aware of how I affect my IBS symptoms… 
Health self-efficacy. 
Definition: a belief that one has the ability to be healthy, to reduce 
symptomatology, to recover from illness, etc. 
Example: I can do what it takes to get control of my health. 
Vulnerability to illness. 
Definition: a belief that one is more susceptible to illness or poor health 
Example: If it‟s going around, I‟ll catch it for sure. 
Catastrophizing.  
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Definition: a belief that bodily sensations and symptoms are indicative of a 
serious illness or problem. 
Example: I tend to get really worried when my body feels differently. 
Treatment experience: Previous experience with similar treatment. 
Definition: having tried or been offered a similar in the past. 
Example:  I‟ve tried therapy for my IBS and it did nothing. 
Treatment experience: Number of treatments attempted. 
Definition: having tried any number of treatments in the past. 
Example:   I‟ve tried so many treatments already…. 
Illness attributions: Somatic. 
Definition: a perception that one‟s symptoms are caused by organic factors or that 
the treatment is targeting the somatic aspects of one‟s symptoms. 
Example: The drug treatment really gets at the root of my problem 
Illness attributions: Psychological. 
Definition: a perception that one‟s symptoms are caused by psychological factors 
or that the treatment is targeting the psychological aspects of one‟s 
symptoms. 
Example: I know that stress really affects my IBS symptoms… 
Motivation: Desire for relief. 
Definition: a state of wanting to see relief 
Example:  I have to see some sort of improvement! 
Motivation: Symptom severity. 
Definition: a state of varying severity of symptoms 
Example: My symptoms aren‟t so bad these days anyways 
Motivation: Socially desirable responding. 
Definition: a tendency to present oneself in the most favourable light 
Example: I always adhere to all treatment recommendations 
Patient-provider relationship. 
Definition: any aspect of the provider that is salient to the patient 
Example: If my doctor recommends it, I trust him 
 
Emergent Categories 
 
Aversion. 
 Definition: a preference against / dislike of something 
 Examples: I prefer to treat my symptoms without drugs. 
   I don‟t do for that therapy stuff 
Side effects. 
 Definition: undesirable consequences of a therapeutic agent 
 Example: It sounds like the side effects would be as bad as my symptoms 
Illness attributions: Holistic. 
Definition: a perception that one‟s symptoms are caused by a combination of 
somatic and psychological factors or that the treatment is targeting the somatic 
and psychological aspects of one‟s symptoms. 
 Example: I really think one needs to address the mind and the body together 
Illness attributions: Situational. 
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Definition: a perception that one‟s symptoms are caused by factors that are neither 
somatic nor psychological factors. 
 Example: My IBS is due to my poor lifestyle  
Convenience. 
Definition: a perception that a treatment may or may not be best due to lifestyle, 
personality, financial, or social factors 
 Example: I don‟t have the time to do relaxation 
   Weekly therapy would be too expensive for me 
Treatment experience: Vicarious. 
 Definition: having known someone who has tried something similar in the past 
 Example: Therapy has done very little to help my mom with her symptoms 
Treatment experience: Inexperience. 
 Definition: having not tried something in the past 
 Example: I haven‟t yet tried that approach…  
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Appendix AC.  Testing for Moderation 
 
1. Summary of Hierarchical Regression Analysis to Test Moderation of Self-focused 
Attention to Treatment Expectancies
a
 by Treatment Experience (N = 227) 
Variable B SE B  R
2
 R2 
Step 1 
Experience 
Self-focused attention 
 
.08 
.01 
 
.06 
.01 
 
.08 
.12 
.02  
Step 2 
Experience 
Self-focused attention  
Experience*Self-focused attention 
 
.76 
.00 
.04 
 
.24 
.01 
.01 
 
.76** 
.03 
.77** 
.06** .04** 
a
Transformed. Adjusted R
2 
after step 1 = .01, after step 2 = .04.  
*p < .05. **p < .01.  
 
 
2. Summary of Hierarchical Regression Analysis to Test Moderation of Optimism to 
Treatment Expectancies
a
 by Treatment Experience (N = 227) 
Variable B SE B  R
2
 R2 
Step 1 
Experience 
Optimism 
 
.05 
.05 
 
.06 
.02 
 
.05 
.18** 
.04*  
Step 2 
Experience 
Optimism 
Experience*Optimism 
 
.40 
.03 
.05 
 
.26 
.02 
.03 
 
.41 
.10 
.38 
.05* .01 
a
Transformed. Adjusted R
2 
after step 1 = .03, after step 2 = .03.  
*p < .05. **p < .01.  
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3. Summary of Hierarchical Regression Analysis to Test Moderation of Hope to 
Treatment Expectancies
a
 by Treatment Experience (N = 227) 
Variable B SE B  R
2
 R2 
Step 1 
Experience 
Hope 
 
.06 
.00 
 
.06 
.00 
 
.06 
.01 
.01  
Step 2 
Experience 
Hope 
Experience*Hope 
 
.61 
.00 
.01 
 
.31 
.00 
.01 
 
.63 
.02 
.59 
.03 .01 
a
Transformed. Adjusted R
2 
after step 1 = .03, after step 2 = .03.  
 
 
4. Summary of Hierarchical Regression Analysis to Test Moderation of Acute Health 
Problems to Treatment Expectancies
a
 by Treatment Experience (N = 227) 
Variable B SE B  R
2
 R2 
Step 1 
Experience 
Acute health problems 
 
.05 
.02 
 
.06 
.01 
 
.06 
.09 
.01  
Step 2 
Experience 
Acute health problems 
Experience*Acute health problems 
 
.05 
.00 
.04 
 
.06 
.02 
.02 
 
.05 
.01 
.16 
.03 .01 
a
Transformed. Adjusted R
2 
after step 1 = .00, after step 2 = .01.  
*p < .05. **p < .01.  
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5. Summary of Hierarchical Regression Analysis to Test Moderation of Coping self-
efficacy to Treatment Expectancies
a
 by Treatment Experience (N = 227) 
Variable B SE B  R
2
 R2 
Step 1 
Experience 
Coping self-efficacy 
 
.08 
.03 
 
.06 
.01 
 
.08 
.16* 
.03*  
Step 2 
Experience 
Coping self-efficacy  
Experience* Coping self-efficacy 
 
.84 
.01 
.08 
 
.21 
.01 
.02 
 
.87** 
.04 
.88** 
.09** .06** 
a
Transformed. Adjusted R
2 
after step 1 = .02, after step 2 = .08.  
*p < .05. **p < .01.  
 
 
6. Summary of Hierarchical Regression Analysis to Test Moderation of Control over 
Symptoms
a
 to Treatment Expectancies
a
 by Treatment Experience (N = 227) 
Variable B SE B  R
2
 R2 
Step 1 
Experience 
Control over symptoms 
 
.05 
.14 
 
.06 
.03 
 
.05 
.30** 
.10**  
Step 2 
Experience 
Control over symptoms  
Experience* Control over symptoms 
 
.05 
.09 
.12 
 
.06 
.04 
.06 
 
.05 
.20* 
.16 
.11** .02 
a
Transformed. Adjusted R
2 
after step 1 = .09, after step 2 = .10.  
*p < .05. **p < .01.  
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7. Summary of Hierarchical Regression Analysis to Test Moderation of Perceived 
Somatic Focus of Treatment
a
 to Treatment Expectancies
a
 by Treatment Experience (N = 
227) 
Variable B SE B  R
2
 R2 
Step 1 
Experience 
Perceived somatic focus of tx 
 
.08 
.37 
 
.06 
.05 
 
.08 
.48** 
.23**  
Step 2 
Experience 
Perceived somatic focus of tx  
Experience* Perceived somatic focus of tx 
 
.22 
.41 
.08 
 
.18 
.06 
.09 
 
.23 
.52** 
.16 
.23** .00 
a
Transformed. Adjusted R
2 
after step 1 = .22, after step 2 = .22.  
**p < .01.  
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